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ABBREVIATIONS
AEV antrectomy with reconstruction after Herfarth, combined with 
vagotomy
Cl confidence interval
DPV duodenal resection with plasty after Helwing, combined with 
vagotomy
DPWU duodenal posterior wall ulcer
DU duodenal ulcer
ЕГГ endoscopic injection therapy
GU gastric ulcer
H. pylori Helicobacter pylori
NSAID non-steroidal anti-inflammatory drug
OGD oesophagogastroduodenoscopy
PU peptic ulcer
PUH peptic ulcer haemorrhage
UGIH upper gastrointestinal haemorrhage
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1. INTRODUCTION
PU is a very common medical condition. Every tenth person suffers from DU or 
GU at some time during their lives (Johnson, 1994). The key role of H. pylori 
and NSAIDs in PU development has been recognized worldwide. A continuous 
and dramatic decrease in hospital admissions (Kurata and Corboy, 1988) and 
elective surgery (Penston et al., 1993; Paimela et al., 1991) for PU during recent 
decades has been repeatedly reported from different regions. However, emer­
gency admissions and surgery for the complications of PU have not changed 
much (Kurata and Corboy, 1988; Bloom et al., 1990; Paimela et al., 1991).
Acute haemorrhage is the most common complication of PU. The lifetime 
prevalence of haemorrhage in PU patients has been estimated to be 15-20% 
(Vaira et al., 1997). The incidence of PUH has been reported to be between 25- 
65 per 100,000 population per year (Panos and Walt, 1993; Fraser et al., 1997; 
van Leerdam and Tytgat, 2002). The incidence rates of PUH are significantly 
higher in the elderly, and time trends show a continuous increase in the pro­
portion of the elderly (Bloom et al., 1990). The most important risk factor for 
the development of ulcer bleeding is NSAID use (Kuyvenhoven et al., 1999).
According to the unpublished annual reports of the Bureau of Medical 
Statistics at the Ministry of Social Affairs of Estonia, PUH has redoubled in 
incidence during the last 20 years, a phenomenon not observed in the developed 
world. Changes in the natural course of the disease, more extensive use of 
ulcerogenic drugs, altering treatment tactics, as well as socio-economic stress 
may have contributed to the change. The reasons for such a major increase have 
not been assessed yet. Epidemiological studies that could cast light on the 
causes of the change have not been performed and thus the present-day epide­
miological pattern of PUH in Estonia has been unclear until now.
The prognosis of PUH is determined by a number of patient-, ulcer- and 
treatment-related factors (Holman et al., 1990; Rockall et al., 1995; Turner et 
al., 1991), the so-called prognostic factors. Age over 60 years, hypovolaemia, 
haemoglobin less than 80 g/1, a severe concomitant disease and further bleeding 
are the main prognostic factors. All these should be considered during the cour­
se of treatment to obtain the best possible results. Therefore, the identification 
and assessment of the clinical relevance of the prognostic factors and, subse­
quently, their application is an essential aspect of the studies directed to im­
prove the outcome of PUH.
The most important advances in the management of gastrointestinal bleeding 
were the introduction of blood transfusion, the development of safe surgical 
treatment, the advent of endoscopic diagnosing and improvements in anaesthe- 
siological support. More recently, endoscopic treatment of bleeding ulcers and 
of ulcers that have bled has enabled to reduce the frequency of rebleeding and 
thus to diminish surgical intervention and mortality (Cook et al., 1992; Gralnek 
et al., 1998; Ohmann et al., 2000).
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While the significance of the latter is established, the precise role of surgery, 
the indications for it and the methods to be used have not yet been clarified in 
the published literature. Though the overall trend shows a decline in the surgical 
management of PUH (Williams et al., 1993; Asaki, 2000; Schwesinger et al.,
2001), there is still discussion as to whether more aggressive or less aggressive 
surgical management is called for. Specific problems in choosing the best 
operative method, depending on the location of the ulcer, are rarely discussed in 
the literature. Giant ulcers situated in the posterior wall of the duodenum tend to 
bleed massively and repeatedly and are complicated to be managed operatively.
Overall hospital mortality rate has been reported to vary in a broad range, 
between 0-14% worldwide (Asaki, 2000; Dertinger et al., 1996). However, it 
should not exceed 5% nowadays (Zittel et al., 2000). The ways of lowering 
hospital mortality are widely discussed in the literature currently.
If the patient survives, the further goal is to prevent ulcer relapse and sub­
sequent ulcer complications in long term by applying proper medical therapy or 
definitive operative treatment. However, researchers have largely neglected the 
long-term results of PUH.
PU, its complications and gastroduodenal surgery have been studied for 
more than 70 years at the Clinic of Surgery of Tartu University (Linkberg, 
1930; Rulli, 1939; Sarv, 1968; Sibul and Truve, 1968; Petlem and Peetsalu, 
1973; Truve et al., 1973; Peetsalu et al., 1990; Vardja et al., 1996; Peetsalu et 
al., 1998; Sillakivi et al., 2000). The present study, focusing on PUH covers the 
epidemiology, prognostic factors, short-term and long-term results of the 
treatment as well as certain aspects of the surgical treatment of PUH patients 
that have not been studied so far in Estonia.
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2. REVIEW OF THE LITERATURE
2.1. Peptic ulcer disease
PU attracts continuously the attention of physicians and researchers worldwide. 
Some 10% of the population will be affected by PU at some time during their 
lives (Bemersen et al., 1990). The ratio of DU to GU has been estimated to be 
between 1:1 to 4:1. The establishment of an ulcer is a multifactorial process, an 
outcome of imbalance between aggressive (ulcerogenic) and defence mecha­
nisms. Although acid is required for ulcer formation, and suppression of acid 
aids in healing and prevention of ulcers, acid alone does not generally cause 
ulcer disease. The two primary risk factors for ulcer disease are H. pylori (NIH 
Consensus Conference, 1994) and NSAID use (Singh and Triadafilopoulos, 
1999; Frezza et al., 2001). The natural course of PU is characterised by nume­
rous episodes of spontaneous healing, frequent relapses and occasional compli­
cations, e.g. haemorrhage, perforation and obstruction. Haemorrhage is the most 
common complication of PU. However, less than 1% of PU patients suffer from 
PUH each year (van Leerdam and Tytgat, 2002)
2.2. Upper gastrointestinal haemorrhage
UGIH is a potentially life-threatening syndrome that may be induced by a 
number of different disease conditions. The essence of UGIH is release of 
whole blood into the lumen of the upper gastrointestinal tract.
The incidence of UGIH is estimated at 48 to 150 per 100,000 population per 
year (Rockall et al., 1995; Cutler and Mendeloff, 1981; Skok, 1998).
Approximately half of UGIH episodes are accounted for by DU and GU 
(Jensen, 1999; Skok, 1998). Acute gastroduodenal mucosal lesions, esophageal 
varices, esophagitis and Mallory-Weiss tear are responsible for one-third of the 
episodes (Sanderson et al., 1990; Wara, 1987; Skok, 1998). Besides, there is a 
variety of other causes of UGIH including marginal ulcer, Dieulafoy’s lesion, 
benign and malignant tumors, vascular ectasia, angiomas, diverticula, bleeding 
after surgical or endoscopic procedures, radiation induced gastritis, foreign bo­
dies, haemobilia (Rollhauser and Fleischer, 1997; Skok, 1998; Marek, 2001). 
These minor causes of bleeding have an incidence of about 10% and no lesions 
can be detected by endoscopy in up to 10% of the patients (Sanderson et al.,
1990).
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2.3. Peptic ulcer haemorrhage
2.3.1. Pathophysiology
Ulcers bleed when the ulcerating process erodes into a blood vessel, either a 
vein or an artery at the base of the lesion. In most cases the bleeding artery is 
small ranging from 0.1 to 1.8 mm with a mean of 0.7 mm (Swain et al., 1986). 
The size of the eroded artery is probably an important determinant of the pattern 
and outcome of ulcer haemorrhage. A larger artery is evidently related to a 
poorer outcome. It has been reported that severe bleeding is more common from 
ulcers located in the posterior wall of the duodenal bulb or high in the lesser 
curvature of the stomach. These sites are anatomically close to the gastroduo­
denal and the left gastric arteries (Shafi et al., 1999) which are the largest 
arteries related to the duodenum and the stomach.
Ulcer bleeding ceases spontaneously in at least 80% of patients without 
specific intervention (Mondardini et al., 1998). Vasoconstriction and formation 
of a platelet plug together with a fibrin clot stops bleeding and prevents further 
haemorrhage (Johnston, 1984; Swain, 1990). Gastric acid and pepsin may dis­
turb the process of a normal coagulation cascade (Patchett et al., 1989; Vree- 
burg et al., 2001). An arteritis often present in the bleeding vessel can explain 
why normal mechanisms of clotting do not always prevent rebleeding (Shafi et 
al., 1999).
2.3.2. Epidemiology 
Incidence and patient profile
A continuous decrease in hospital admissions and surgery (Kurata and Corboy, 
1988; Penston and Wormsley, 1993; Paimela et al., 1991; Schwesinger et al.,
2001) for PU during recent decades has been repeatedly reported from different 
regions. However, emergency admissions for PU complications lack such a 
trend (Kurata and Corboy, 1988; Bloom et al., 1990). PUH is estimated to have 
an incidence of 25-65 per 100,000 population per year (Panos and Walt, 1993; 
van Leerdam and Tytgat, 2002; Laporte et al., 1991). DU predominates in most 
series of PUH. In on study the incidence of PUH for men was higher than for 
women, 59 and 45 per 100,000 per year, respectively. The incidence rate was 
significantly higher in the elderly, being 6.5 for those <40 years of age and 
more than 120 for those >60 years of age per 100,000 per year (Ohmann et al.,
1992). The admission rates for PUH increase among the elderly (Higham et al.,
2002) and the time trends show a continuous increase in the proportion of the 
elderly (Bloom et al., 1990).
This tendency could be related to the consumption of NSAIDs (McCarthy,
1991). On the other hand, it has been supposed that in the light of new moda­
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lities of medical treatment and vanishing elective ulcer surgery, the prophylactic 
role of the latter has greatly diminished, and subsequently, ulcer complications 
start appearing at an older age (Paimela et al., 1995).
The absence of signs of PU in a high proportion of patients with PU compli­
cations has been reported. In one study bleeding was the first sign of PU in 52% 
of cases (Holvoet et al., 1991). Asymptomatic ulcers present a major problem, 
as no preventive measures can be applied against life-threatening ulcer comp­
lications. It has been found that in older people ulcer symptoms can be vaguely 
expressed and NSAID use is often noted in such cases (Katz, 1991).
Death rates of PUH have been estimated to be 1.6-3.9 per 100,000 popu­
lation (Cutler and Mendeloff, 1981; Paimela et al., 1995).
Predisposing factors
The role of a bacterium, H. pylori, in the pathogenesis of PU is widely known. 
It has been repeatedly demonstrated that eradication of H. pylori dramatically 
alters the natural history of PU by significantly lowering the rate of ulcer 
recurrence. Recent studies have shown that eradicating this micro-organism in 
PU patients markedly (18-fold) lowered the rate of PUH (Powell et al., 1994). 
Besides, eradication of H. pylori infection after an episode of PUH results in a 
significant reduction of both ulcer recurrence and bleeding relapses in long term 
(Labenz and Börsch, 1994; Graham et al., 1993). This suggests a similarity 
between the pathogenesis of bleeding ulcer and that of noncomplicated ulcer. 
However, the prevalence of H. pylori in PUH patients, 40-90%, seems to be 
lower compared with cases of noncomplicated ulcer, 90-100% (Vaira et al.,
1997). This fact indicates that factors other than H. pylori can result in bleeding 
PU.
Studies have shown an extremely high prevalence of H. pylori infection, 73- 
87%, among the population of Estonia in three regions; the prevalence is as 
high as 68-83% even in those bom in 1955-1970 (Vorobjova et al., 1994; Maa­
roos, 1995). Comparable data from the Western countries show significantly 
lower H. pylori infection rates among those bom in recent decades, ranging 
between 10-20% (EUROGAST Study Group, 1993). However, the relationship 
between H. pylori and PUH has not been studied in Estonia yet.
NSAIDs are clearly another important factor. Both aspirin and non-aspirin 
NSAIDs are among the most commonly used medications. It is well known that 
NSAID use is related to adverse gastrointestinal side effects. These drugs are 
associated with a high risk of developing GU, but not related to DU formation. 
However, these drugs can induce bleeding from both locations. Several studies 
have shown that PUH is closely related to previous NSAID use (Wilcox et al., 
1994; Rodriguez and Jick, 1994; Holvoet et al., 1991; Chamberlain, 1993; Shafi 
et al., 1999; Mellemkjaer et al., 2002). It has been found that these drugs may 
be more important in causing haemorrhage from GU compared with DU
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(Rodriguez and Jick, 1994; Wilcox et al., 1994). Savage et a l, 1993, have 
reported an increased relative risk of 5.1 for haemorrhage and perforation in 
association with NSAIDs. NSAID use was the strongest independent risk factor 
for haemorrhage caused by PU (relative risk, 8.4), while the relative risk 
associated with H. pylori infection was 1.5 (Kuyvenhoven et a l, 1999). The risk 
has been found to be higher in case of both H. pylori infection and NSAID use, 
which shows a synergism between the two in causing PUH (Huang et a l, 
2002). However, the absolute individual risk of the development of PUH in 
NSAED users has been estimated as low. The risk of developing a serious ulcer 
complication is in the range of 1.3-2% for a population of NSAID users per 
year of use (Graham, 1996). The number of cases induced in the whole popu­
lation becomes important in view of the widespread use of NSAIDs (Langman 
et a l, 1991). Studies show the use of these drugs in 35% to 89% of cases prior 
to PUH (Holman et al., 1990; Kuyvenhoven et al., 1999; Lanas et a l, 1992). 
Concern has been expressed about the high prevalence of over-the-counter 
NSAID use in patients with haemorrhage (Wilcox et al., 1994). There is a diffe­
rence between different NSAIDs in terms of the risk of provoking ulcer 
haemorrhage. Azapropazone and piroxicam had relative risks higher than 10, 
while ibuprofen had the lowest risk, 3, in a study by Rodriguez and Jick, 1994. 
The authors also found that the risk was the highest for the current users, lower 
for the recent users and the lowest with the past use of these drugs. The risk is 
also dose-related (Rodriguez et al., 1994), though low-dose aspirin too is 
associated with ulcer bleeding (Stack et al., 2002; Loke et al., 2003). Irregular 
use of NSAIDs, compared with non-use, is related to a significantly higher, 5.5- 
fold, risk of PUH than the 1.9-fold risk in daily users (Imhof et al., 1997). No 
risk reduction has been found to be associated with the use of oral enteric- 
coated, oral slow-release or rectal formulations of the drugs (Mellemkjaer et al.,
2002). NSAID consumption is increasing, especially in the elderly (Glise, 1990; 
Leivonen and Kivilaakso, 1991), while women use these drugs more often than 
men (McCarthy, 1991; Savage et al., 1993). The elderly are more prone to take 
them due to cardiovascular disease and disorders of the locomotor system. 
Daily users of NSAIDs who bleed are suggested to have fewer PU symptoms 
prior to the onset of bleeding compared with nonusers who bleed (Klein et al., 
1993). NSAID users infected with H. pylori have an almost redoubled risk of 
bleeding PU in comparison with uninfected NSAID users (Hawkey, 2000). It 
has been found that bleeding DU patients with neither H. pylori infection nor 
NSAID use are extremely rare (only 2%), which suggests that the pathogenesis 
of bleeding DU is similar to that of non-complicated DU disease (Gisbert et al., 
2001).
Although it was reported recently that the use of NSAIDs was lower in 
Estonia than in developed countries (Kiivet et al., 1992), the use of these drugs 
has not been studied in Estonian PUH patients.
The previous history of PU or PUH is strongly associated with the risk of 
haemorrhage (Laporte et al., 1991; Weil et al., 2000). The proportion of patients
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bleeding from PU tends to increase with the length of individual ulcer history. 
Within 10 years of the diagnosis approximately 15% of ulcers have bled, while 
after 20 years the proportion affected is 20-40% (Dobrilla et al., 1993). If a PU 
patient has already suffered from ulcer haemorrhage, the risk of a second 
bleeding is 15% within three years and it might be as high as 50% in ten years 
(Penston and Wormsley, 1992).
Besides, oral anticoagulants and corticosteroids, heart failure, diabetes, 
current smoking (Weil et al., 2000), immoderate alcohol consumption (Ander­
sen et al., 2000) and blood group 0 (Kuyvenhoven et al., 1999) have been found 
to enhance the risk of PUH. The incidence of UGIH is stated to be higher in 
socioeconomically deprived areas (Dallai and Palmer, 2001).
2.4. Diagnosis
PUH patients usually present with melaena and/or haematemesis. Bleeding may 
vary in intensity from a minor episode to a severe exsanguinating haemorrhage.
The primary goal of diagnosing is to assess whether bleeding is directly life- 
threatening and to establish the source of bleeding. Several approaches can be 
used to determine the cause of bleeding: endoscopy (OGD), barium x-ray stu­
dies, selective angiography, and radionuclide scanning. OGD has been the 
“golden standard” of diagnosing UGIH since the first Consensus Development 
Conference on Gastrointestinal Endoscopy and Its Role in Upper Gastrointes­
tinal Bleeding held in 1980. It was stated there that OGD is the most sensitive 
and specific method to identify the causative lesions and their location in most 
UGIH patients (Pitcher, 1990). The diagnostic yield of OGD is up to 99% in 
UGIH patients (Dertinger et al., 1996). The complication rate of OGD is low, 
2.8%, including hypoxia, hypotension, arrhythmias, bleeding and perforation 
(Marek, 2001). Today, every patient with UGIH should undergo OGD. Ac­
cording to current consensus opinion, OGD should be performed within the first 
24 hours but not necessarily as an emergency procedure. Prospective controlled 
trials have shown that urgent diagnostic endoscopy does not influence mortality 
(Panos and Walt, 1993). However, early OGD is of benefit in high-risk patients 
who should be subjected to endoscopy after stabilizing their condition (Spiegel 
et al., 2001).
In 1974 Forrest et al. first described the status of ulcer at endoscopy in pa­
tients with PUH. They divided the lesions into those actively bleeding, lesions 
with an evidence of recent bleeding, and lesions without an evidence of blee­
ding (Forrest, 1974). The Forrest classification of the type of ulcer haemorrhage 
at endoscopy has been modified to meet the needs and widely accepted due to 
its prognostic relevance, ability to predict rebleeding (Kohler and Riemann, 
1991; van Leerdam et al., 2000).
19
2.5. Prognostic factors for mortality
Various factors have been suggested as predictive for the adverse outcome of 
PUH. Both clinical and endoscopic prognostic factors have been suggested to 
predict the outcome.
2.5.1. Clinical factors
There are several clinical prognostic factors that have been suggested to be 
predictive for an adverse outcome of haemorrhage. These can be grouped into 
factors indicating large initial bleeding and those not associated with the amount 
of initial bleeding.
Among the factors reflecting large initial bleeding, red haematemesis, 
anaemia with haemoglobin less than 80-100 g/1 and haemodynamic shock carry 
a high risk of mortality (Clason et al., 1986; Holman et al., 1990; Katschinski et 
al., 1994; Dallai and Palmer, 2001). Other factors are patient-related and not 
indicative of a large bleeding. Most authors agree that age over 60 years (Clason 
et al., 1986; Peterson, 1990) and severe concomitant disease (Turner et al., 
1991; Rockall et al., 1995) enhance the risk to patient life.
Further, distinction between ceased bleeding, continued bleeding and re­
bleeding is of vital importance in terms of outcome. Continued bleeding and 
rebleeding are closely associated with patient mortality (Turner et al., 1991; 
Katschinski et al., 1994) and rebleeding is the most important prognostic factor 
(Katschinski et al., 1994) increasing mortality 10-fold (Dallai and Palmer, 
2001).
Mortality was twofold higher in patients taking NSAIDs according to one 
study. Other studies have failed to demonstrate a significant difference in out­
come between NSAID users and non-users (Peterson, 1990). However, recent 
NSAID use has been found to predispose bleeding ulcer patients to in-hospital 
recurrent bleeding (Godil et al., 2000).
The above mentioned clinical factors can be very helpful in grading patients 
into low- and high-risk groups. The prognostic importance of these factors is 
even more powerful when combined with endoscopic risk factors.
2.5.2. Endoscopic factors
Endoscopic factors predictive of rebleeding and hence of a poorer outcome 
include ulcer size >2 cm (Hsu et al., 1996) and ulcer location within proximity 
to large arteries — high gastric minor curvature ulcer (Brüllet et al., 1996) and 
DPWU (Swain etal., 1986).
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A major contribution to the prediction of further haemorrhage has been 
achieved with the definition of the features of the ulcer seen at endoscopy. The 
appearance of an ulcer at endoscopy, according to the Forrest classification, is 
closely related to prognosis (Table. 1).
Table 1. Forrest classification, endoscopic features, prevalence, rebleeding rate and 
mortality (Kolkmann and Meuwissen, 1996; Johnston, 1990; Shafi et al., 1999)*
Forrest type Endoscopic feature Prevalence (%) Rebleeding (%) Mortality (%)
la Spurting bleeding 18 85-100 11
lb Oozing bleeding 40-55
Ila Visible vessel 17 18-51 11
lib Adherent clot 17 18-24 7
lie Pigmented spot 20 10 3
III Clean ulcer base 42 0-5 2
* In case the patients were not provided endoscopic therapy
Scoring systems have been developed to predict the risk of death combining 
clinical and endoscopic prognostic factors. These systems might be useful in 
developing treatment protocols. High-risk patients would benefit from a more 
intensive therapy and low-risk patients could be discharged early or treated on 
an outpatient basis (Rockall et al., 1996).
2.6. Treatment
Management of PUH should be carried out in hospital. In selected low-risk 
cases out-patient treatment has been recommended (Rockall et al., 1996).
The primary goals of therapeutic modalities for treating PUH are resuscita­
tion, control of active bleeding, prevention of rebleeding and, ultimately, pre­
vention of ulcer recurrence and subsequent bleeding in long term.
Bleeding from PU will stop spontaneously in about 80-85% of patients 
(Mondardini et al., 1998; Zittel et al., 2000).
Current management of patients with PUH requires a multidisciplinary ap­
proach with a skilled endoscopist, experienced surgeon, gastroenterologist and 
nurses. In many cases the support of anaesthesiologists and of an intensive care 
unit are needed. Twenty-four-hour blood transfusion and laboratory service is 
essential.
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2.6.1. Resuscitation
Crucial to the safe management of patients with PUH is continuous monitoring 
of the patient’s clinical condition and prompt fluid transfusion aimed at nor­
malization of the circulatory status. Although prospective randomized studies 
are lacking (Duggan, 2001), blood transfusion to maintain haemoglobin be­
tween 70 to 90 g/1 seems sufficient (Jiranek and Kozarek, 1996). Excess trans­
fusion may reduce the physiological hypercoagulable state of PUH patients, 
probably as a result of the citrate contained in stored blood (Henriksson and 
Svensson, 1991). A state of shock may require more aggressive transfusion.
2.6.2. Medical therapy
After initial haemostasis has been achieved, a potent and maintained acid in­
hibition may generate optimal conditions for clotting and thus prevent re­
bleeding (Lanas et al., 1995; Vreeburg et al., 2001). However, randomized 
controlled trials performed with H2 blockers using various doses, or with 
Omeprazole have shown a reduction in rebleeding rates and surgery but not in 
mortality (Kolkmann and Meuwissen, 1996; Selby et al., 2000; Zed et al.,
2001). The vasoconstrictors Vasopressin and Somatostatin as well as the 
antifibrinolytic drug Tranexamic acid have been found to produce no benefit in 
terms of stopping bleeding or preventing recurrence (Villanueva and Balanzo, 
1997; Kubba et al., 2001). Therefore, available pharmacological therapy alone 
cannot be recommended as a treatment of choice for an acute bleeding episode 
of PU. However, two randomized trials demonstrate that as compared with a 
placebo or cimetidine, an intravenous proton pump inhibitor can significantly 
reduce rebleeding from PU after successful endoscopic haemostasis (Cash,
2002). Besides, it is reasonable to promote the beginning of ulcer healing from 
the start (Zittel et al., 2000; Kubba et al., 2001).
There is increasing evidence that eradication of H. pylori can actually “cure” 
PU (Rauws and Tytgat, 1990; Laine et al., 1998) and thereby avoid possible 
subsequent PUH (Macri et al., 1998). Prospective randomised studies show that 
eradication of H. pylori infection after an episode of PUH result in a significant 
reduction of both ulcer recurrence and bleeding relapse compared to con­
ventional antisecretory treatment (Graham et al., 1993; Jaspersen et al., 1995). 
This evidence suggests that the only definitive medical therapy for prevention 
of recurrent PUH in long term is eradication of H. pylori.
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2.6.3. Endoscopic therapy
In recent years it has become possible besides observing bleeding ulcers 
visually, to attempt cessation of bleeding or to prevent possible rebleeding by 
intervention at the time of endoscopy.
Endoscopic hemostatic therapy should be used only in patients who have 
persistent bleeding or a high risk of recurrent bleeding (Bown, 1991). In the 
case of a clean ulcer base (Forrest Ш) endoscopic therapy is not indicated.
Randomized controlled trials in patients with PUH and a nonbleeding visible 
vessel have found endoscopic therapy superior to traditional medical and sur­
gical treatment in terms of lowering rebleeding rates and reducing the need for 
blood transfusion and emergency operations (Gralnek et al., 1998). A meta­
analysis of clinical trials showed that endoscopic therapy also reduces hospital 
mortality (Cook et al., 1992). Various methods of endoscopic therapy: injection, 
thermocoagulation and Nd:YAG laser therapy have shown similar results in 
randomized controlled trials in terms of initial haemostasis, rebleeding, surgery, 
transfusion, and mortality (Lee and Leung, 1997). Yet for economic and prac­
tical reasons, injection therapy seems to be superior (Qvist et al., 1994; Lee and 
Leung, 1997). Applying endoscopic pure ethanol injection therapy in a total of 
1603 cases, Asaki and colleagues from five other institutions report excellent 
results. They achieved successful initial haemostasis in 99.2% of PUH patients. 
The rebleeding rate was 9.3% and most of these cases were retreated using 
endoscopic therapy. Only 1.9% of the patients needed emergency operation 
(Asaki, 2000). Systematic second-look endoscopy with retreatment significantly 
reduces the risk of recurrent bleeding, but it does not substantially reduce the 
risk of salvage surgery or mortality (Marmo et al., 2003). With respect to the 
cost, endoscopic therapy is considerably less expensive than emergency surgery 
for patients with PUH, while patients prefer it to surgery as an initial or 
subsequent treatment for the emergency control of bleeding (Jensen, 1999).
However, there exist limitations to endoscopic therapy. In some cases the 
technique is initially ineffective, in others rebleeding occurs even after 
haemostasis has been achieved. The most common reason for the failure of 
endoscopic haemostasis is inadequate access to the lesion due to massive 
bleeding or extensive scarring. Presence of shock on admission as well as 
arterial bleeding at endoscopy (Ishikawa et al., 1994), DPWU (Thomopoulos et 
al., 2001), large ulcer (Church and Palmer, 2003), visible vessel larger than 2 
mm in diameter and concomitant disease (Nishiaki et al., 2000) make an un­
successful outcome more likely. Hypotension and ulcer size larger than 2 cm 
have been found to be predictive of the failure of endoscopic retreatment (Lau 
et al., 1999). In such patients surgery could be a better option than endoscopic 
retreatment (van Lanschot et al., 2002).
The ineffectiveness of three attempts of endoscopic therapy should be con­
sidered an indication for surgery (Ishikawa et al., 1994).
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2.6.4. Surgical treatment
Despite the availability of more specific and effective medical treatment, some 
patients with PUH require surgical treatment (Donahue, 2000). The annual 
incidence of operations performed due to PUH has been reported to be between 
2.8 to 10 per 100,000 population (Mäkelä et al., 1992; Gustavsson et al., 1988). 
While elective ulcer surgery has decreased dramatically all over the world 
(Paimela et al., 1987; Fallahzedah, 1993; Schwesinger et al., 2001), there is yet 
no uniform understanding of the role of surgery in treating PUH in the pub­
lished literature. It is still discussed whether more aggressive or less aggressive 
surgical management is called for (Imhof et al., 2003). Centres with both ag­
gressive surgical policy and conservative approach have reported excellent 
results. Bender et al., not relying on endoscopic therapy, operated on 66 of 159 
patients (42%) according to a strict protocol with no mortality but 17% 
complication rate (Bender et al., 1994).
Indications
Most authors find endoscopic therapy as the method of choice for controlling 
active bleeding as well as for reducing the risk of rebleeding and hence the need 
for operative management (Sacks et al., 1990; Cook et al., 1992). Time trends 
of operations for PUH are on decline (Williams et al., 1993; Asaki, 2000; 
Schwesinger et al., 2001). Therefore, it is justified to state that it will be in­
creasingly difficult to train surgeons to perform emergency surgery for bleeding 
ulcers and to maintain these skills, because fewer and fewer such operations are 
being performed (Jensen, 1999).
Surgery is needed in about 5-10% of PUH cases nowadays (Qvist et al., 
1994; Zittel et al., 2000). Emergency surgery is indicated in cases of (1) severe 
haemorrhage unresponsive to initial resuscitative measures; (2) failure of 
endoscopic and medical therapy to control persistent or recurrent bleeding and 
(3) a coexisting second indication for operation, such as perforation, obstruction 
or suspected malignancy (Stabile and Stamos, 2000). In the past decades, some 
centres advocated early elective surgery in patients with a high risk of re­
bleeding (Mueller et al., 1994). This approach reduced mortality to below 10%, 
while it was previously 25% in these patients (Zittel et al., 2000). However, the 
need for early elective surgery is disappearing due to the fact that repeated 
endoscopic treatment in the case of rebleeding has been found to be highly 
effective reducing the need for surgical treatment without increasing the risk of 
death (Asaki, 2000; Lau et al., 1999).
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Methods
The type of emergency surgery to be undertaken is controversial. The type and 
severity of the pathology, the condition of the patient, the subjective bias and 
surgical experience of the operator influence the choice of operation. In recent 
years more and more surgeons prefer nondefinitive methods like oversewing or 
ulcer excision alone (Ohmann, 2000), referring to them as easier and safer 
(Zittel et al., 2000) and relying upon subsequent medical therapy (Röher et al., 
1996; Gilliam et al., 2003). Others advocate definitive approach, vagotomy and 
pyloroplasty or partial gastrectomy, whenever the patient's condition and sur­
gical expertise enable to perform them (Herrington and Davidson, 1987; Stabile 
and Stamos, 2000). A randomized study compared nondefmitive surgery and 
definitive surgery showing no significant difference in mortality. However, 10% 
of nondefinitively operated patients died of fatal rebleeding, while none of the 
definitively operated patients did (Poxon et al., 1991). Nondefinitive operations 
resulted in a significantly higher rebleeding rate, 23% versus 3% for definitive 
operations, and mortality, 23% versus 14% (no significant difference), respec­
tively (Kubba et al., 1996). Rebleeding rates can be lowered if oversewing of 
the ulcer is combined with the ligation of the gastroduodenal and right gastro­
epiploic arteries (Millat et al., 1993). Postgastrectomy and postvagotomy 
syndromes have been pointed out as a drawback of definitive operations (Zitell 
et al., 2000; Johnson and Chir, 2000).
Common operations for DU haemorrhage include:
1. Truncal vagotomy / proximal gastric vagotomy and pyloroplasty with 
excision of the ulcer / oversewing of the ulcer;
2. Truncal vagotomy and antrectomy with excision of the ulcer;
3. Proximal gastric vagotomy with excision of the ulcer / oversewing of the 
ulcer.
Common operations for bleeding GU include:
1. Oversewing / excision of the ulcer
2. Wedge resection of the stomach
3. Distal gastrectomy
4. Truncal vagotomy with pyloroplasty and excision / oversewing of the GU
5. Truncal vagotomy and antrectomy with excision of the prepyloric ulcer 
(Stabile and Stamos, 2000; Donahue, 2000)
Laparoscopic suturing of actively bleeding DU via duodenotomy has been 
successively performed in a series of six patients (Martin et al., 1998).
2.6.5. Giant duodenal posterior wall ulcers
Bleeding DPWU represent a specific problem and are dealt with separately in 
many studies. Being close to the anatomical position of the largest artery, which 
is related to the duodenum, gastroduodenal artery, they are often the source of
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severe bleeding (Swain 1990). Deep and large DU with a diameter of >2 cm, 
known as giant ulcer (Collen et al., 1994; Simeone et al., 1999), is more likely 
to erode into the large artery. Both giant ulcer (Hunt and McIntyre, 1990; Hsu et 
al., 1996) and DPWU (Swain et al., 1986) are factors predictive of rebleeding 
and hence of a poorer outcome. It has been found that a posterior location of 
DU is a poor prognostic factor not only because these ulcers have a strong 
tendency to bleed but also because these ulcers are associated with aged and 
high-risk patients (Millat et al., 2000).
One of the factors adversely affecting the results of endoscopic therapy is a 
posterior location of DU. DPWU makes an unsuccessful outcome more likely 
due to rebleeding (Kolkmann and Meuwissen, 1996) and a higher need for 
emergency surgery compared with anteriorly located ulcer (Thomopoulos et al., 
2001). Mortality rate has been found to be higher for DPWU, 4%, than for 
anterior wall ulcers, 0.9% (Branicki et al., 1990). Therefore, patients with 
bleeding DPWU are regarded as high-risk patients. Early elective operation 
after primary endoscopic treatment and stabilizing of the patients is advocated 
in this situation (Mönig et al., 2002).
The choice of the operation method is complicated in the case of bleeding 
DPWU often penetrating into the pancreas and scarring the duodenum circum- 
ferentially to lead to stenosis (Chang et al., 1998). In these cases oversewing of 
the ulcer base combined with vagotomy (Gostout et al., 1992), or gastric re­
section according to Billroth II (Hunt and McIntyre, 1990; Wu et al., 2002) is 
often performed. However, oversewing of the bleeding duodenal poterior wall 
ulcer may result in excess mortality due to the high rate of recurrent bleeding 
(17-23%) in these ulcers (Hunt and McIntyre, 1990; Kubba et al., 1996). 
Weinberg's procedure, which combines vagotomy and the oversewing of the 
vessel with the ligation of the gastroduodenal and gastroepiploic arteries, has 
revealed an effect superior to that of vagotomy and oversewing alone in terms 
of rebleeding (Millat et al., 1993). Billroth II gastric resections, on the other 
hand, may cause duodenal stump leak as major morbidity with a rate of up to 
22% (Millat et al., 1993). Trying to avoid this, complex methods with manage­
ment of the duodenal stump in the case of DPWU have been introduced, in­
cluding omentoplasty and duodenostomy (Wu et al., 2002). Complicated 
handling of bleeding penetrating DPWU has led some surgeons to perform 
extreme, even anecdotal, operations: oversewing of the bleeding ulcer base 
together with Billroth П resection with Nissen duodenojejunostomy, Tomoda 
valve construction and Braun enteroenterostomy (Meissner, 1994). Technically 
relatively simple ulcer exteriorising operations — DPV, described by Helwing 
(Figure 1, publ. VI), and AEV, described by Herfarth (Figure 2, publ. VI) — 
enable to have a good control of bleeding and simultaneously to solve the 
problem of stenosis (Helwing and Heymann, 1978; Herfarth et al., 1977). The 
possible hazards of rebleeding, typical of oversewing, as well as duodenal 
leakage and pancreatitis, often present in Billroth II resection, are avoided with 
the use of these methods. A similar approach of leaving the ulcer base out of the
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lumen, i.e. exteriorizing the ulcer in the case of giant DPWU, has been re­
commended also elsewhere (Herrington and Davidson, 1987).
2.7. Short-term outcome
In the late 80-ies and early 90-ies, it was often stated that mortality rates of 10% 
for UGIH and PUH had remained on the same level for decades despite the 
advances in diagnosing, resuscitation, surgery and medical therapy (Gilbert, 
1990; Holman et al., 1990; Henriksson and Svensson, 1991). This phenomenon 
was related to the growing proportion of the elderly among haemorrhage 
patients (Gilbert, 1990). Yet already then had some units achieved mortality 
rates as low as 3-4% (Gostout etal., 1992; Sanderson et al., 1990).
While the mortality of PUH should not exceed 5% nowadays (Zittel et al., 
2000), overall mortality in some centres could be as high as 14% with a 
mortality of 56% for operatively treated and 10% for conservatively treated 
patients (Dertinger et al., 1996).
2.8. Long-term results
When a patient is discharged from hospital it is essential that the next goal is to 
prevent further ulcer relapse and subsequent recurrence of ulcer bleeding in 
long term, thus increasing survival. While short-term results of PUH have been 
extensively dealt with in the literature, the long-term outcome of the patients, in 
contrast, has been insufficiently studied. To prevent recurrent bleeding in long 
term, various models of treatment have been discussed: maintenance therapy 
with acid blockers, H. pylori eradication, and definitive ulcer surgery.
In a follow-up study 530 PUH patients were treated conservatively with H2- 
blockers until ulcer healing, while they did not receive either maintenance the­
rapy or H. pylori eradication thereafter. Over a median follow-up of 36 months 
as many as 169 (32%) of them developed another ulcer complication: bleeding 
(166 cases) and perforation (3 cases). DU with a previous history of bleeding 
was the main risk factor for late recurrent haemorrhage (Ng et al., 1996). The 
authors conclude that in such patients, if H. pylori is negative, maintenance H2- 
blocker therapy or definitive acid-reducing surgery should be seriously consi­
dered to reduce complications in long term. In H. pylori positive patients eradi­
cation is indicated.
Maintenance therapy with H2-blockers significantly reduced recurrent 
haemorrhage from DU during 1-year follow-up (Jensen et al., 1994).
Labenz and Börsch compared the natural course of PU and the course after 
H. pylori eradication. They found that the 1-year ulcer relapse rate decreased 
from 65% to 2%, and the 2-year relapse rate decreased from 87% to 5% after
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H. pylori treatment. Moreover, the 2-year rate of ulcer complications decreased 
from 34% to 0.4% after eradication (Labenz and Börsch, 1996). Thus H. pylori 
eradication can actually cure PU and prevent ulcer bleeding and rebleeding.
Mueller et al. analysed the results of 48 months follow-up in definitively 
operated and in conservatively treated (H2-blockers on demand at home) pa­
tients. The cumulative 5-year PU rebleeding rate was 6% for surgically treated 
versus 13% for conservatively treated patients. The difference was not statis­
tically significant (Mueller et al., 1994).
The long-term prognosis for patients who present with PUH is poor, how­
ever, most deaths are a consequence of a comorbid disease but not of recurrent 
ulcer bleeding. Hudson et al. compared previous PUH patients, aged over 60 
years, to matched controls in terms of mortality and causes of death during a 
mean follow-up of 34 months. The 29% mortality rate for the patients was 
significantly higher than the 12% rate for the controls. The increased mortality 
was predominantly due to a variety of smoking related diseases rather than 
recurrent PU complications. Only 1.2% of previous PUH patients died of ulcer 
bleeding. Unfortunately, the rate of rebleeding was not studied in this series. It 
is worth mentioning that in as many as 1% of the PUH patients gastric cancer, 
which was not diagnosed during initial admission, was found during follow-up 
(Hudson et al., 1995).
In another study of 121 PUH patients, 25% died mainly of cardiovascular 
and pulmonary disease during a median follow-up of 36 months. While 9% of 
the patients suffered another PUH episode during the period under study, no 
deaths could be attributed to PU complications (Kubba et al., 1997).
Rorbaek-Madsen et al. found that the cumulative survival rate of GU 
bleeding patients in an 8-year study was significantly reduced in comparison 
with the expected survival rate of a matched background population. Excess 
mortality was not related to ulcer disease, but was mainly due to cardiovascular 
disorders and non-gastric malignancy (Rorbaek-Madsen et al., 1994).
A comparative study of long-term survival of a general population cohort 
and PUH patients showed that PUH patients carry a twofold higher risk of 
death. Nine percent of the deaths in PUH patients and 3% of the deaths in 
general population were caused by UGIH in long term (Ruigomez et al., 2000).
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3. AIMS OF THE STUDY
The aims of the present study were:
1. To characterize the epidemiological pattern of PU related UGIH in Tartu 
county covering incidence, patient population structure, predisposing factors, 
H. pylori infection rate, location of the ulcer and mortality (pubis. I-IV).
2. To determine the prognostic factors for short-term adverse outcome of PUH 
(publ. IV).
3. To assess changes in the treatment tactics of PUH in recent years. To 
evaluate the role of endoscopic therapy and surgical treatment in PUH pa­
tients and their impact on short-term outcome (publ. VII).
4. To assess long-term results in conservatively treated and operatively ma­
naged PUH patients (publ. V).
5. To establish in terms of long-term outcome the operative methods of 
Helwing and Herfarth, proposed for bleeding giant posterior wall ulcers of 
the duodenum (publ. VI).
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4. PATIENTS AND METHODS
The thesis is based on seven separately designed studies covering different 
aspects of PUH. These were carried out from 1992 to 2001 at the Clinic of 
Surgery of Tartu University Clinics. The main characteristics of the studies are 
presented in Table 2.
Table 2. The characteristics of the seven studies constituting the thesis.
Study type Study
site
Study
period
No of patients 
(male/female)
Goals of the study Publication 
(publication No)
1. Retrospective TUC* 1979-1981
1989-1991
206(148/58) 
401 (274/127)
Epidemiology of 
UGIH and PUH
Acta et
Commentationes 
Universitatis 
Tartuensis (I)
2. Retrospective TUC 1979-1993 635 Incidence changes 
of PUH
Eesti Arst (II)
3. Prospective TUC 1992-1994 263 (159/104) Epidemiology of 
UGIH and PUH
Ann Chir Gynaecol 
(III)
4. Prospective TUC 1992-1993 144(94/50) 1. Epidemiology of 
PUH
2. Prognostic 
factors for PUH
Scand J
Gastroenterol (IV)
5. Prospective TUC 1992-1997 163 (112/51) Long-term results of 
operated and 
conservatively 
treated PUH 
patients
European Journal of 
Trauma and 
Emergency Surgery
(V)
6. Prospective TUC 1984-2001 16(13/3) Long-term results of 
ulcer exteriorising 
operations
Am J Surg (VI)
7. Prospective/ 
retrospective
TUC 1992-1993
1999-2000
212 (148/64) 
177 (135/42)
Role of ЕГТ and 
surgery in PUH
Eesti Arst (VII)
* Tartu University Clinics
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4.1. Patients
Altogether data of 1270 patients were collected and studied. The study groups 
are partly overlapping because a patient could enter different studies at a time 
(Table 2.).
In a retrospective pilot study (publ. I) the data of endoscopic findings for all 
UGIH patients treated at the Clinic of Surgery of Tartu University Clinics du­
ring 1979-81 and 1989-91 were included. A total of 206 patients passed endo­
scopy during 1979-81 and 401 during 1989-91. The sources of haemorrhage 
and the patients' characteristics for the two periods were compared.
In a retrospective study (publ. П) with a defined area (Tartu county) data 
from all case histories of patients with PU complications, either haemorrhage or 
perforation, were included in an epidemiological analysis for a 15-year period 
(1979-93). The evaluation of incidence was based on the population data 
obtained from the Statistics Bureau of Tartu County.
The third study (publ. ПГ) was a prospective defined-area unselected epide­
miological study comparing UGIH epidemiology in a province of Central Fin­
land and in Tartu county. The data of 298 consecutive patients from Central 
Finland and 263 from Tartu county were collected during a two-year period 
(1.8.1992-31.7.1994).
The data of 144 PUH patients, >15 years of age, were assessed in a pro­
spective unselected defined-area (Tartu county) study (publ. IV) over two years 
(1.1.1992-31.12.1993) in order to assess the epidemiology and the mortality 
risk factors of PUH.
The fifth study (publ. V) was designed as a prospective non-randomised 
study of the long-term results of PUH. Included were all 163 patients who had 
suffered from PUH during 2.5 years (1.1.1992-30.6.1994) and had survived 
hospital treatment. Of the patients 61 had been operated (all definitive opera­
tions) and 102 had been treated conservatively, with a 4-6 week H2-blocker 
therapy course, and received intermittent H2-blocker treatment on demand 
thereafter. In a mean time of 17 months (12-31 months) 47 operatively treated 
and 86 conservatively treated patients passed a follow-up examination with 
endoscopy, the results of which were graded according to a modified Visick 
scale.
During 1984-93, sixteen patients with giant, penetrating posterior wall 
duodenal ulcers with haemorrhage were operated according to the methods, 
described by Herfarth and Helwing, at the Clinic of Surgery of Tartu University 
Clinics (publ. VI). Of the patients 4 died due to the reasons not related to PUH 
and two were lost for follow-up. Ten patients passed long-term follow-up 
examination with endoscopy during the years 2000-2001. The results of the 
assessment of quality of life were graded according to a modified Visick scale.
In the seventh study (publ. VII) the prospective data of 212 PUH patients, 
treated at the Clinic of Surgery of Tartu University Clinics in 1992-1993, and
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the retrospective data of 177 PUH patients treated in 1999-2000, were gathered. 
The periods were compared in terms of patient structure characteristics, 
treatment tactics and treatment results.
4.2. Methods
4.2.1. Data
The data for the first study (publ. I) were obtained from endoscopy record cards. 
The primary data for the analysis of the case histories for the second study 
(publ. П) were obtained from the computerised database of Tartu University 
Clinics.
For the third (publ. ПГ) and fourth (publ. IV) studies, the data were gathered 
prospectively. Clinical data, the results of laboratory analyses, as well as the 
findings of endoscopy, operation and autopsy were obtained from case histories. 
For the fifth (publ. V) study the data were collected prospectively.
For the sixth study (publ. VI) the primary data of the operated patients were 
obtained from the computerised database of Tartu University Clinics. Then case 
histories were studied for the identification of patients operated according to the 
methods of Herfarth and Helwing.
Data on mortality and causes of death for the follow-up periods in the fifth 
and sixth studies (pubis. V, VI) were obtained from the Registry Office of the 
Tartu County Government.
For the seventh study (publ. VII) the data for the comparison of the two 
periods, 1992-1993 and 1999-2000, were obtained from case histories.
4.2.2. Patient questionnaire
All patients participating in the prospective studies were questioned according 
to a standard questionnaire (pubis. 1П, IV), which consisted of items about 
previous PUH and/or UGIH, history and symptoms of PU, other major diseases, 
smoking habits, alcohol consumption and NSAID use.
4.2.3. Area of study
The epidemiological studies reflect the situation in a defined area, the town of 
Tartu and Tartu county, further referred to as Tartu county.
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4.2.4. Incidence
Incidence rates were calculated as new cases per 100,000 population per year 
(pubis. П, Ш, IV).
4.2.5. Endoscopic diagnosing and follow-up examination
In all patients the source of bleeding had been diagnosed by means of OGD 
(except for one case of X-ray diagnosis in study П1). In the fourth study (publ. 
IV) two biopsy specimens were obtained during OGD both from the gastric ant­
rum and corpus for evaluation of H. pylori infection. In the long-term follow-up 
studies (pubis. V, VI) examination of the patients, including endoscopic exami­
nation, was performed in outpatient conditions. The presence or absence of 
ulcer recurrence was determined.
4.2.6. Definitions: ulcer location, operations and mortality
The ulcers were classified in accordance with location into DU, pyloric ulcer, 
prepyloric ulcer and GU in the fourth study (publ. IV). In the other epide­
miological studies the ulcers were classified into GU and DU, while DU 
comprised duodenal bulb ulcers, pyloric and prepyloric ulcers.
Nondefinitive operations include ulcer suturation or excision. Definitive 
operations include partial gastrectomies and/or operations with vagotomy. 
Mortality was estimated as death rate in patients during hospital treatment.
4.2.7. Endoscopic therapy
In the seventh study (publ. VII) the role of the endoscopic treatment of PUH 
was assessed. ЕГГ was the method of choice in endoscopic treatment. Injection 
therapy with absolute alcohol, epinephrine (1:10,000) or their combination was 
used.
4.2.8. H. pylori infection
In the fourth study (publ. IV) H. pylori infection rate was estimated. In 120 
PUH cases two gastric mucosal biopsy samples were taken from the antrum and 
two from the corpus, stained according to Giemsa and investigated micro­
scopically for the presence of H. pylori infection.
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4.2.9. Visick scale
The quality of life in the long-term follow-up studies (pubis. V, VI) was graded 
according to a modified Visick scale (Vardja T, 1996). The Visick scale 
estimates were the following: Visick I — excellent: no symptoms; Visick II — 
good: mild, no disturbing symptoms interfering with normal life or work; 
Visick III — satisfactory: mild or moderate symptoms causing a certain degree 
of discomfort or disability; Visick IV — poor: severe symptoms or recurrent 
ulcer on endoscopy.
4.2.10. Operation methods
The fifth study (publ. V) discusses the long-term results in patients operated for 
PUH. In all cases definitive operations with ulcer removal, either partial 
gastrectomies or operations with vagotomy, were performed.
Two ulcer exteriorising operation methods for giant DPWU penetrating into 
the pancreas, complicated with haemorrhage, are described and assessed for 
long-term outcome in the sixth study (publ. VI).
Duodenal resection with plasty after Helwing
DPV is presented in Figure 1, publ. VI. Kocher maneuver is performed to 
mobilize the duodenum. The front wall of the duodenum is opened by two 
semicircular incisions. In case of bleeding the ulcer base is oversewn. The 
duodenum is resected so that the penetrating base of the ulcer remains in the 
pancreas. The posterior wall is sutured in a one-row manner, shifting the gastric 
end over the ulcer base. The sutures pass through all layers of the posterior wall 
of the gastric end to the distal edge of the giant ulcer and the posterior wall of 
the duodenal end. Thus the ulcer base is left out of the duodenal lumen, i.e. is 
exteriorised. The front wall is sutured in an ordinary two-row manner. Further, 
vagotomy is performed.
Antrectomy with reconstruction after Herfarth
AEV is presented in Figure 2, publ. VI. Kocher maneuver is performed to 
mobilize the duodenum. After dissecting the lower part of the stomach, 
antrectomy is performed. Current bleeding is stopped by oversewing the vessel. 
The stump of the stomach is closed leaving an opening for the anastomosis on 
the side of the larger curvature. Then the back wall is sutured in one row, all 
layers of the stomach to the distal edge of the ulcer together with the duodenal 
wall. This exteriorises (leaves out of the lumen) the ulcer base. The gastric 
stump and the front wall of the anastomosis is sutured in an ordinary two-layer 
manner. Truncal vagotomy is performed additionally.
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4.2.11. Statistical methods
The data were analysed by StatView® Student for the Macintosh. The medians 
with 95% confidence intervals (Cl) were calculated for age. The absolute 
numbers were compared with chi-square test. Continuity correction was applied 
to approximate the chi-square test where necessary. The level of significance 
was set at 0.05 throughout the study.
35
5. RESULTS
The results are divided into five main sections. Epidemiology of UGIH and 
PUH in Tartu county is discussed in the first section (pubis. I-IV). The second 
section deals with the prognostic factors of PUH (publ. IV). In the third part the 
role of endoscopic therapy and surgical treatment in PUH patients is assessed 
(publ. VII). Long-term results in conservatively and surgically treated PUH 
patients are evaluated in the fourth part (publ. V). The fifth section presents two 
surgical methods, DPV after Helwing and AEV after Herfarth, for management 
of bleeding giant DPWU penetrating into the pancreas. The long-term results in 
the patients operated with the use of these mehods are reported (publ. VI).
5.1. Epidemiology
5.1.1. Upper gastrointestinal haemorrhage
The overall incidence of UGIH was 98.6 per 100,000 adults (>15 years of age) 
per year in 1992-1994 in Tartu county. The incidence by age groups is shown 
in Table 2, publ. Ш. The total male to female ratio was between 2.5:1 (1979— 
1981) to 1.5:1 (1992-1994) during the periods studied. The mean age of the 
patients was 58.8 years. The proportion of the patients >60 years of age was 
49% (129/263), while it was 35% for men (56/159) and 70% for women 
(73/104).
Of the patients 47% (108/231) had taken NSAIDs prior to bleeding. The 
elderly had taken these drugs significantly more often than the young and the 
women more often than the men (Table 3, publ. 1П).
The cause related distribution of UGIH in 1979-81 and in 1992-94 is 
depicted in Figure 1. PU was responsible for more than half of all UGIH cases. 
In 1979-81 its share was 52% and in 1992-94 it was 55%. Acute gastric muco­
sal lesions, Mallory-Weiss tear, oesophageal varices, malignancies and 
oesophagitis accounted approximately for 30% of UGIH cases. The share of 
malignancies decreased from 11% to 3%. No other significant change took 
place during the 15 study years. The diagnostic yield of endoscopy for UGIH 
was more than 90% in all studies.
The mortality rate of UGIH was 10% (26/263).
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DU — duodenal ulcer
GU — gastric ulcer
AGL — acute gastric mucosal lesions
MW — Mallory-Weiss tear
EV — oesophageal varices
MAL — malignancies 
E — oesophagitis 
OTH — other 
NL — no lesion revealed
Figure 1. Causes of upper gastrointestinal haemorrhage.
5.1.2. Peptic ulcer haemorrhage
The time trends of the overall incidence of PUH are depicted in Figure, publ. П. 
The incidence was between 18 and 28 (mean 23) per 100,000 population per 
year for the years 1979-1990. For 1991-93 there occurred a sharp increase in 
PUH incidence which was between 33 to 48 (mean 40).
During 1992-94 there were no cases of PUH in male patients aged <20 and 
in female patients aged <30 years. The older age groups had a considerably 
higher relative risk of developing PUH than the younger ones. The incidence 
rate was 12 for those aged 20-29 and more than 10-fold higher, over 135, for 
those >70 years of age. For men the relative risk was more than two times 
higher than for women (Table I, publ. IV).
As to the sources of PUH, gastric ulcer had the highest overall incidence, 26, 
followed by duodenal ulcer, 22 per 100,000 per year. Duodenal ulcer had a 
higher incidence for men followed by gastric ulcer, while it was vice versa for 
women. The incidence of PUH according to the location of ulcer is shown in 
Table 3.
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Table 3. Incidence per 100,000 per year of peptic ulcer haemorrhage by ulcer location 
and sex.
Men Women Total
Gastric ulcer 33 20 26
Duodenal ulcer 39 9 22
Prepyloric ulcer 5 6 6
Pyloric ulcer 4 0 2
There was male preponderance among the PUH patients. The male to female 
ratio was roughly 2:1. The overall median age of the patients was 59 years (95% 
Cl, 56-62), for males 54 (95% Cl, 50-58) and for females 67 (95% Cl, 63-71). 
The elderly, >60 years of age, accounted for 49% of all PUH patients, while 
72% of the women and 37% of the men were over 60 years of age.
Duodenal ulcer haemorrhage was more common in men and gastric ulcer 
haemorrhage in women (Table III, publ. IV).
In as many as 27% of the PUH patients, ulcer was asymptomatic prior to 
haemorrhage. There was no difference between the sexes, age groups or the 
causes of bleeding in terms of the rate of asymptomatic ulcers.
Active bleeding (Forrest I) was present in 10% of the PUH patients at 
endoscopy. In 55% stigmata of recent bleeding (Forrest П) and in 35% an ulcer 
without stigmata of bleeding (Forrest III) were found.
Of the PUH patients 8% died in the prospective defined-area study during 
1992-1993. The overall mortality rate in Tartu county was 3.7 per 100,000 
inhabitants. Patients aged >65 years accounted for 75% of the deaths.
5.1.3. Predisposing factors
Of the patients 18% (25/140) had suffered from previous PUH and 45% 
(63/140) had an established PU diagnosis prior to haemorrhage.
H. pylori infection was common in PUH patients, 89% (107/120) of the 
PUH patients were infected. It was present in 100% (14/14) of the prepyloric 
ulcer patients, in 93% (43/46) of the DU patients and in 81% (43/53) of the GU 
patients. The differences were not significant.
Nearly half of the PUH patients, 45% (62/137), had used NSAIDs at least 48 
hours before the onset of bleeding. Half of them had been on regular NSAID 
treatment for more than one week, the others had used these drugs episodically. 
NSAID use by patients with different ulcer locations is presented in Table 4. 
NSAID use together with alcohol consumption and smoking habits by sex and 
age is shown in Table П, publ. IV.
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Table 4. NSAID use by patients with haemorrhage from gastric ulcer, duodenal ulcer 
and prepyloric ulcer
Gastric ulcer 
No (%)
Duodenal ulcer
No (%)
Prepyloric ulcer
No (%)
Regular NSAID use 16(26) 7(14) 6(43)
Episodical NSAID use 17 (27) 11 (21) 2(14)
No NSAID use 29 (47) 34 (65) 6(43)
Total 62 (100) 52(100) 14 (100)
5.2. Prognostic factors
Sixteen factors related to PUH patients were analysed for enhancing the risk of 
mortality. The prognosis was the poorest in patients suffering from major 
cardiac disease as a concomitant disease, in patients with rebleeding during 
treatment and in patients admitted with systolic blood pressure less than 100 
mmHg. Mortality was 30% or higher for these patients. Age >65 years and 
haemoglobin level lower than 80 g/1 on admission were both significantly 
related to the adverse prognosis. The other factors did not have a significant 
impact on mortality, however, the haematemesis versus no haematemesis and 
ongoing bleeding during OGD (Forrest I) were close to significant (Table IV, 
publ. IV).
5.3. Treatment and short-term outcome
The data of all PUH patients treated during 1992-1993 (period I) and 1999- 
2000 (period II) were evaluated in terms of changes in patient profile, treatment 
tactics and the results of short-term outcome. No significant change had taken 
place in the patient population. Neither sex or age distribution, ulcer location 
nor the type of haemorrhage (Forrest) had changed during the seven-year period 
(Table 5).
However, ЕГГ was markedly more often used in period II. ЕГТ was used in 
32% (45/139) of all Forrest I and II patients in period I and in 70% (89/127) in 
period II. Patients with ongoing bleeding at endoscopy received ЕГТ in 54% of 
the cases and patients with stigmata of recent bleeding in 28% of the cases in 
period I, while the respective rates were 83% and 66% in period II.
Surgical treatment decreased from 40% (85/212) to 6% (11/177) during the 
seven-year period (p=0.0001). Mortality rate was 7% (14/2121) in period I and 
2% (4/177) in period II (p=0.042).
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Table 5. Characteristics of peptic ulcer haemorrhage patients during 1992-1993 
(period I) and 1999-2000 (period II).
Period I 
No of patients (%)
Period II 
No of patients (%) P
Number of patients 212 177 NS**
Men 148 (70) 135 (76) NS
Women 64 (30) 42 (24)
Mean age 56 57
Men 53 54
Women 66 68
Patients aged >65 71 (34) 72 (41) NS
Men 34 (23) 46 (34) 0.038
Women 37 (58) 26 (62) NS
Ulcer location
DU 113 (53) 103 (58) NS
GU 97 (46) 68 (38) NS
MU* 2(1) 6(3) NS
Ulcer location in men
DU 89 (60) 86 (64) NS
GU 57 (39) 44 (33) NS
MU 2(1) 5(4) NS
Ulcer location in women
DU 24 (38) 17(41) NS
GU 40 (63) 24 (57) NS
MU 0 1(2) NS
Type of haemorrhage
Forrest I 24 (12) 30 (17) NS
Forrest II 115 (56) 97 (55) NS
Forrest III 67 (33) 50 (28) NS
No information 6 (-) 0
* MU — marginal ulcer
** NS — difference statistically not significant
5.4. Long-term results in conservatively and 
operatively treated peptic ulcer haemorrhage patients
Eleven percent of both the conservatively treated patients (11/102) and 
operatively treated patients (7/61) died during two years after hospital treatment 
for PUH. No death was related to PU complications. The causes of death are 
listed in Table 6.
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Table 6. Causes of death after hospital treatment for PUH during two-year follow-up.
Cause of death_________________ Nr
Cardiovascular disease 9
Malignancy 5
Cerebrovascular disease 2
Liver failure 1
Accident 1
The treatment had provided excellent (no complaints) and good (minor 
complaints) results in 79% (37/47) of the operatively treated and in 40% (34/86) 
of the conservatively treated PUH patients. Poor results (recurrent ulcer and/or 
severe complaints) had been obtained in 13% (6/47) of the operated and in 49% 
(42/86) of the conservatively treated patients, while 6% (3/47) and 16% (14/86), 
respectively, had suffered another PUH episode during the follow-up period 
(Table 7).
Table 7. Long-term results in operatively and conservatively treated PUH patients.
Long term results Operative 
treatment 
N %
Conservative
treatment
N %
Chi square 
P
Visick I 22 47 17 20 0.0021
Visick II 15 32 17 20 0.1756
Visick III 4 9 10 12 0.7915
Visick IV 6 13 42 49 0.0001
— Bleeding recurrence 3 6 14 16 0.1731
— No bleeding recurrence 3 6 28 33 0.0014
5.5. Long-term results in patients treated surgically 
for giant duodenal posterior wall ulcers complicated 
with haemorrhage
Sixteen patients were operated due to bleeding giant DPWU using DPV after 
Helwing (Figure 1, publ. VI) and AEV after Herfarth (Figure 2, publ. VI), du­
ring 1984-93. Of the patients 10 had presented with stenosis of the pyloro- 
duodenal region.
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Follow-up was performed in 2000 and 2001. Two patients were lost for 
follow-up and 4 had died during the years that had passed from the operation. 
Analysis of the death certificates of the latter revealed that they died due to 
reasons not related to their operation or PU.
Of the ten patients assessed for long-term results 7-16 years (mean 11 years) 
after operation, nine completed a questionnaire of subjective health quality 
according to Visick and passed endoscopy. One patient agreed with a telephone 
interview only. The results of the investigation show that long-term results were 
excellent or good in 90% (9/10) of the cases according to the Visick scale. In 
one patient the long-term result was assessed as satisfactory. Endoscopy re­
vealed no cases of ulcer recurrence. The anastomoses after DPV and AEV were 
sufficiently wide in all cases.
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6. DISCUSSION
6.1. Epidemiology
6.1.1. Upper gastrointestinal haemorrhage
The overall incidence of UGIH was 98.6 per 100,000 adults per year during the 
period of 1992—1994 in Tartu county. The incidence rate seems to be medium, 
considering the range of incidence rates from 48 to 150 as reported from else­
where (Rockall et al., 1995; Skok, 1998; Cutler and Mendeloff, 1981). The 
incidence showed a substantial increase with age. The incidence of UGIH for 
men in comparison with women was more than twofold in all age groups except 
in those >70 years of age. A similar pattern has been reported in a study from 
the United Kingdom (Rockall et al., 1995). The preponderance of male over 
female UGIH patients is a world-wide phenomenon.
Several studies report ageing trends in UGIH patients during recent decades 
(Gilbert, 1990). Indeed, the proportion of the elderly was high in Tartu county. 
Half of the patients were >60 years of age there. However, there was a pro­
nounced discrepancy between the sexes, 35% of the men and 70% of the 
women were aged >60. The overall proportion of the elderly has been reported 
to be close to that, 47% (Skok, 1998), in some regions and even higher, 63% in 
others (Figure 2, publ. 1П). According to demographic data, persons >60 years 
of age account for 18% in Tartu county.
The incidence rates of UGIH were notably lower for younger women than 
for men but showed a more pronounced increase with age and almost equalized 
in the older age groups. This indicates that there exist also factors other than 
H. pylori contributing to age and sex related discrepancies. One of these is the 
circumstance that certain causes of haemorrhage are observed mostly in 
younger men (Mallory — Weiss tear which is mostly related to alcohol abuse), 
whereas others are more likely to occur in older women (GU). It has also been 
found that elderly women consume more NSAIDs than men (Savage et al.,
1993), which places them at a higher risk of NSAID related lesions, particularly 
of GU. NSAID use prior to haemorrhage was frequent. Nearly half of the 
patients had received NSAIDs, while the elderly and the women had used them 
significantly more often than younger patients and men. The same observation 
has been made elsewhere as well (Savage et al., 1993).
OGD is the main diagnostic tool in UGIH. In more than 90% of cases the 
source of haemorrhage can be established at endoscopy. In our study the main 
cause of UGIH was PU accounting for more than half of the total number of 
cases, followed by acute gastric mucosal lesions, Mallory-Weiss tear and 
oesophageal varices. The distribution of the causes of UGIH was close to that 
reported from some other centres (Wara, 1987; Henriksson and Svensson, 1991; 
Skok, 1998) and had not changed significantly in Tartu county during the 15
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years under study. However, lately there have been reports of a relative decrease 
in incidence of PU as the cause of UGIH. The current frequency of PUH may 
be as low as 25-29% followed by portal hypertension as the cause of UGIH 
with a frequency of 19%. Such a decrease in PUH may reflect changes in the 
incidence of H. pylori infection as well as the use of novel NSAIDs (Marek, 
2001).
The mortality rate of UGIH was 9.9% in Tartu. Mortality rates are mostly 
reported to be around 10% (Clason et al., 1986; Katschinski et al., 1994; Skok,
1998). Several specialized units have achieved rates as low as 3.7-4.8% 
(Sanderson et al., 1990; Holman et al., 1990).
6.1.2. Peptic ulcer haemorrhage
Our data from Tartu county from 1979 to 1993 showed a sharp, nearly 2-fold 
increase in the incidence of PUH since 1991. Unpublished data from the same 
area show continuing increase in PUH incidence up to 55 per 100,000 per year 
in 1998. Furthermore, according to the unpublished data of the Bureau of 
Medical Statistics at the Ministry of Social Affairs of Estonia the incidence rate 
of PUH in Estonia has a tendency to increase. The incidence of PUH was 40 
cases per year per 100,000 population in 1993, rose up to 56 in 1999 and 
reached a peak with 77 cases in 2001. The incidence rates were on a medium 
level more than 10 years ago and achieved high levels at the beginning of the 
90-ies in comparison with to the range of 25-58 per 100,000 per year as 
estimated by other researchers (Panos and Walt, 1993; Cutler and Mendeloff, 
1981). By now the incidence rate of PUH in Estonia seems to have exceeded the 
highest levels ever reported. It should be emphasized that the other important 
PU complication, ulcer perforation, has the same dramatic increasing pattern of 
the incidence rate (Sillakivi et al., 2002).
Our opinion is that such an increase could be of multi-factorial origin. Sharp 
changes in social and economic conditions, low use of anti-ulcer drugs, de­
clining elective ulcer surgery, smoking habits, increasing alcohol abuse, in­
creasing NSAID use and high H. pylori infection rate among the Estonian 
population may have produced the dramatic increase in PU complications, 
particularly PUH.
The role of rapidly changing social and economic conditions cannot be unde­
restimated. After the regaining of independence in 1991 dramatic changes have 
taken place in Estonia with a major decline in economy and an increase in 
unemployment from 0.6% in 1990 to 10% in 1996 (Statistical Yearbook of 
Estonia 1999).
Low use of antiulcer drugs in the first half of the 90-ies in Estonia has been 
reported recently. The use of these drugs was at least 4 times lower among the
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Estonian population compared with the inhabitants of Stockholm county in 
terms of defined daily doses per 100,000 population (Kiivet et al., 1998).
Prevalence of smoking is high in Estonia. In a stratified random sample of 
2086 adults, 30-59 years of age, 58% of the men and 26% of the women 
smoked (Pâma et al., 2002).
The role of the high prevalence of H. pylori infection in Estonia is discussed 
below in the section “Predisposing factors”.
Haemorrhage has been found to disproportionately affect the elderly (Bloom 
et al., 1990). Indeed, the incidence rate of PUH rose significantly with age in 
our study, being 10-fold higher for patients aged >70 (over 135 per 100,000 per 
year) compared with those aged 20-39 (11.5 per 100,000 per year). The inci­
dence was higher for men in all age groups. The same age and sex related 
differences have been noted in a German study (Ohman et al., 1992) and in a 
US study (Cutler and Mendeloff, 1981). In women growth in incidence rate 
with age was steady, while in men there appeared a sharp 6-fold increase in the 
rate in the age group 40-49 in comparison with younger patients in Tartu 
county (Table I, publ. IV). In the German study the incidence rate showed more 
uniform growth. Compared with our study, the overall incidence rate was twice 
lower for patients aged <50, equalized for those aged 50-79 and was twice 
higher for those aged >80. The US study shows a very high incidence (242 per 
100,000 per year) in patients over 65 years of age in comparison with the 
corresponding rate in Tartu county.
In our study GU haemorrhage had the highest overall incidence, followed by 
DU and prepyloric ulcer. However, DU incidence was higher in men, while GU 
prevailed in women and the incidence of DU was low, close to that of pre­
pyloric ulcer. Several studies have found that GU is a more frequent cause of 
PUH than DU (Wilcox et al., 1994; Ohmann et al., 1992), whereas others report 
the contrary (Rockall et al., 1995).
The distribution of PUH patients (Figure 1, publ IV) reveals a predominance 
of younger men and elderly women: 37% of the men and 72% of the women 
were aged >60. Several studies demonstrate a high proportion of the elderly 
among PUH patients. In studies from the United Kingdom 81% (Holman et a i, 
1990) and 74% (Rockall et al., 1995) of the patients were aged >60, in an 
Australian study their share was 69% (Turner et al., 1991). In Tartu county the 
proportion of patients aged >60, 49%, was lower compared with that in the 
above mentioned studies. This difference can be partly explained by the lower 
proportion of the elderly in the whole population of Estonia. The other possible 
contributing factor is the high H. pylori infection rate among the inhabitants of 
Estonia.
Mortality rates of PUH vary widely, from 3% (Gostout et al., 1992) to 
16.9% (Clason et al., 1986). Though not close to the lowest rates, the 8.3% 
mortality in Tartu county is comparable to rates observed in most centres. Some 
authors have reported lower mortality rate, relating it to specialized unit
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management, strict protocol (Sanderson et al., 1990), aggressive approach 
(Bender et al., 1994) and restrictive blood transfusion policy (Henriksson and 
Svensson, 1991).
6.1.3. Predisposing factors
The role of H. pylori in PU development has been recently established. It has 
been shown that eradication of this bacterium reduces both ulcer recurrence and 
bleeding relapses in long term (Labenz and Borsch, 1994; Graham et al., 1993). 
It is suggested that H. pylori infection rate depends on the socioeconomic level. 
According to the United Nations “Human Development Report 1994”, Estonia 
ranked behind developed countries with respect to the level of socioeconomic 
development. This could be the reason why H. pylori infection is more common 
in Estonia than in the Western countries, affecting 73-87% of the population in 
3 regions studied (Maaroos, 1995). Even younger people from cohorts bom in 
1955-70 had an infection rate as high as 68-83% (Maaroos, 1995; Vorobjova et 
al., 1994) and schoolchildren aged 9-15 had an infection rate of 56% (Vorob­
jova et al., 2000). Comparable data from the Western countries show signifi­
cantly lower H. pylori infection rates among those bom in recent decades, 
ranging between 10-20% (EUROGAST Study Group, 1993). The high H. py­
lori infection rate might result in the high prevalence of PU disease, account for 
the subsequent high incidence rate of PUH and be the reason for the higher 
PUH incidence among the younger population found in our study.
H. pylori infection was frequently (89%) observed in the gastric mucosa of 
PUH patients. Its presence was slightly higher in prepyloric and DU patients 
than in GU patients.
The recently reported somewhat lower NSAID consumption among the 
population of Estonia compared with that of developed countries (Kiivet et al.,
1992) may have an impact on age distribution as these drugs are more often 
used by the elderly. This could explain the lower incidence rate of PUH among 
the elderly compared with that in other countries (Cutler and Mendeloff, 1981; 
Ohmann et al., 1992).
NSAID use has been established to carry enhanced risk for PU genesis as 
well as for PUH development. Studies show the use of these drugs in 35% to 
89% of cases (Holman et al., 1990; Lanas et al., 1992). According to our study, 
45% of the patients had used NSAIDs before the onset of bleeding. Regular 
NSAID treatment prior to PUH was significantly more often observed in the 
elderly. In women the use of these drugs was considerably more frequent than 
in men.
NSAIDs seem to be more related to prepyloric ulcers and GU than to DU 
(Holvoet et al., 1991; Glise, 1990). Our study confirms this finding: the 
proportion of regular NSAID users among the patients with prepyloric ulcer
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(43%) was slightly higher than among the GU patients (26%) and significantly 
higher than among the DU patients (14%).
In one-fourth of the patients from Tartu county haemorrhage developed from 
asymptomatic ulcers. Asymptomatic ulcers present a major problem, as no pre­
ventive measures can be applied against life-threatening ulcer complications. It 
has been found that in older people ulcer symptoms can be vaguely expressed 
and NSA© use is often present in such cases (Katz, 1991). The presence of 
ulcer symptoms was not related to NSAID use in a previous study (Holvoet et 
al., 1991). According to our study ulcer symptoms before bleeding were related 
neither to age, sex, diagnosis nor NSAID use.
Of the other possible predisposing factors for ulcer haemorrhage, smoking 
was significantly more frequent in men than in women in our study. 60% of the 
men and 15% of the women were smokers. The figures are close to those 
reported for the Estonian population (Pâma et al., 2002).
6.2. Prognostic factors
In our patients mortality was associated with higher age, shock, haemoglobin 
level <80 g/1, major cardiac disease and recurrent bleeding. These risk factors 
coincide with those established by other researchers (Holman et al., 1990; 
Rockall et al., 1995; Turner et al., 1991; Zittel et al., 2000).
6.3. Treatment and short-term outcome
Medical therapy and surgery have limitations in treating PUH. Since its advent, 
endoscopic therapy of PUH has shown high effectiveness and has therefore 
spread rapidly. Furthermore, randomized controlled trials showed the benefits 
of endoscopic therapy in terms of lowering rebleeding, surgery, transfusion, and 
mortality (Lee and Leung, 1997). By now endoscopic therapy is the first choice 
and surgery is considered a selective therapeutic option, only to be applied if 
endoscopic haemostasis fails (Lanschot et al., 2002). With respect to the cost, 
endoscopic therapy has been found to be considerably less expensive than 
emergency surgery for patients with PUH and patients prefer it, as initial or 
subsequent treatment for the emergency control of bleeding, to surgery (Jensen,
1999).
Our study focused on changes in treatment at the Clinic of Surgery of Tartu 
University Clinics during the last years. The two periods, 1992-1993 and 1999— 
2000, that were compared did not differ either in the structure of the patient 
population, ulcer location or the type of haemorrhage according to Forrest.
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However, treatment tactics changed considerably during the 7 years under 
consideration. While ЕГГ was used in 22% of the patients in period I, it was 
applied in more than half of the patients in period П. In period II, ЕГГ was more 
often used both in the actively bleeding patients (Forrest I) and in those who 
showed endoscopic signs of recent bleeding (Forrest II).
In about 80-85%  of PUH cases bleeding stops spontaneously (Zittel et al.,
2000). However, studies have shown that approximately half of patients with 
PUH suffer from recurrent bleeding without endoscopic treatment. In the case 
of Forrest I type haemorrhage, 88% of patients either bleed unceasingly or 
develop a new episode of bleeding. In Forrest II patients bleeding recurs in 43% 
of cases. In Forrest III type rebleeding occurs very seldom, in 3% of patients 
(Jensen, 1990). Therefore endoscopic therapy should be used in patients with 
ongoing bleeding or in those with high risk of recurrent bleeding (a visible 
vessel or a clot in the ulcer base). Endoscopic therapy is not indicated if the 
ulcer base is clean.
ЕГГ is considered technically simple, effective and safe (Asaki 2000). The 
possible complications include perforation and onset of uncontrollable bleeding, 
which are relatively rare, with an incidence of 0.9% (Pitcher, 1990). No comp­
lications occurred in our patients.
Based on the meta-analysis of the studies performed in the 80-ies, Sacks 
found that endoscopic therapy reduces significantly the rate of rebleeding, the 
need for emergency surgery and mortality (Sacks et al., 1990). Bleeding recurs 
in up to 20% of PUH patients after endoscopic therapy (Kolkman et al., 1996). 
In these cases repeated endoscopic treatment is indicated due to its high, 75% 
efficiency (Lau et al., 1999). Surgical hemostasis should be used only in case 
endoscopic and medical therapies fail (Swain, 1995). It has been found that 
surgery is needed in only 5-6%  of PUH patients (Ohmann et al., 2000). Asaki 
and colleagues from six Japanese centres got even better results employing ЕГГ 
with absolute alcohol in 1603 patients with PUH. Only 149 developed recurrent 
bleeding, which was stopped by repeated ЕГГ in most cases. In 31 cases (2%) 
emergency surgery was needed to stop bleeding. Ten of the 1603 patients 
enrolled died (Asaki, 2000).
Our material shows a significant decline in surgery, from 40% to 6%, during 
the seven-year study period, the diminished need for so-called early elective 
surgery being largely responsible for it. Early elective surgery was, until quite 
recently, used in PUH patients at high rebleeding risk, who had not been 
subjected to endoscopic therapy. The operation was performed in an elective 
setting shortly after the condition of the patient was stabilised.
The mortality of the studied PUH patients decreased from 7% to 2% during 
the period considered. Our opinion is that the significant fall in the need for 
surgical therapy and the decrease in mortality are related to the more extensive 
use of ЕГГ in the late part of the studied period. Some authors claim that 
mortality from PUH is around 10% and that it has not declined during recent 
decades (Iambrenghi et al., 1995). However, in many departments a lower than
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5% mortality of PUH patients was achieved even at the end of 80-ies (Holman 
et al., 1990). Although there exist centres reporting death rates of 14% 
(Dertinger et al., 1996), the standpoint that they should not exceed 5% nowar- 
days (Zittel et al., 2000) seems to be justified.
The more extensive use of endoscopic therapy as the treatment of first 
choice has enabled to diminish the need for surgical treatment as well as the 
mortality of PUH patients at the Clinic of Surgery of Tartu University Clinics.
6.4. Long-term results in conservatively and 
operatively treated peptic ulcer haemorrhage patients
The surgeon dealing with PUH is faced with multiple tasks among which 
stabilising the patient’s condition and reducing the risk of recurrent bleeding in 
an attempt to diminish mortality are the initial ones. The further goal is to pre­
vent ulcer relapse and subsequent ulcer complications in long term by applying 
medical therapy or definitive operative treatment. However, long-term results of 
PUH have been rarely assessed in the literature.
In our case control study further ulcer haemorrhage occurred in 16% of the 
conservatively treated and in 6% of the operatively treated patients during the 
two-year follow-up period. However, the difference was not statistically signi­
ficant. Intermittent therapy with H2 blockers after conservative hospital treat­
ment resulted in nearly 50% of recurrence of ulcer bleeding, ulcer relapse or 
severe symptoms and 40% of excellent and good results. In a similar study 13% 
of the patients on intermittent H2 blocker therapy rebled during a mean follow- 
up of 48 months (M ueller et al., 1994). The latter study reports the 6% late 
complication rate of PU in definitively operated patients. In a Hong Kong study 
(Ng et al., 1996) the risk of a further ulcer complication, both haemorrhage and 
perforation, has been found to be as high as 32% over a median follow-up 
period of 36 months. The patients were treated with H2 blockers until ulcer 
healing and received no maintenance therapy thereafter.
These unsatisfactory results indicate that intermittent therapy after PUH fails 
to control PU and further haemorrhage in long term, and should not be 
advocated for patients. Ranitidine administered in a maintenance regimen has 
revealed the capacity to reduce both DU relapse and further ulcer bleeding 
(Jensen et al., 1994). However, lifelong maintenance therapy for all ulcer 
haemorrhage patients is expensive. The recent advent of drugs for H. pylori 
eradication has expanded the possibilities of treating PU. The first long-term 
results of the use of these drugs after complications appear to be promising 
(Jaspersen et al., 1995; Labenz et al., 1996). Some authors claim that definitive 
ulcer surgery should be avoided in PUH patients (Röher et al., 1996) and that 
the mere undersewing of the bleeding vessel and its branches should be per­
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formed (Kolkman et al., 1996). We are of the opinion that when operative 
treatment is indicated, definitive procedures with ulcer removal should not be 
abandoned, as they provide an instant and complete control of the bleeding site 
as well as yield good long-term results. In our study excellent and good long­
term outcome was achieved in 80% of the patients. Surgical treatment with 
vagotomy has been found to be superior to therapy with H2 blockers also in 
terms of abdominal complaints and dyspepsia in patients with PU. It produces a 
level of complaints almost identical to that seen in the community population 
(Lindsetmo et al., 1998). Definitive operative treatment is also a safe procedure. 
No hospital deaths resulted from early elective operation in our patients. The 
two patients who died had undergone emergency operation.
Patients surviving an episode of PUH carry a two-fold higher risk of death 
compared with the general population in long term (Ruigomez et al., 2000). 
However, although the long-term prognosis for patients discharged from 
hospital after treatment due to PUH is poor, most deaths cannot be attributed to 
recurrent ulcer bleeding (Kubba et al., 1997; Hudson et al., 1995). In our study 
altogether 18 patients died within two years after hospital treatment due to 
reasons unrelated to PUH. Deaths resulted mainly from cardiovascular disease 
(9/18) and malignancies of various locations (5/18). Among the latter cases one 
patient had been diagnosed with praepyloric ulcer during hospital treatment but 
died of gastric cancer. Obviously, cancer diagnosis had been previously missed.
6.5. Long-term results in patients treated surgically 
for giant duodenal posterior wall ulcers complicated 
with haemorrhage
Giant DPWU penetrating into the pancreas are often the cause of severe 
hemorrhage, primarily owing to the erosion of a. gastroduodenalis (Swain, 
1990). In such cases the choice of the operative method is complicated, parti­
cularly when ulcer hemorrhage is accompanied with stenosis of the pyloro- 
duodenal zone.
The results of our investigation demonstrate that in these cases, excellent or 
good long-term results without ulcer recurrence can be obtained in 90% of cases 
with the application of DPV or AEV. An earlier study of 15 patients by 
Helwing and Heymann yielded good results in all cases 8-24 months after ope­
ration (Helwing and Heymann, 1978). Our results confirm good outcome for the 
first time for a much longer period, on average 11 years after operation.
In our opinion, the important determinant accounting for the achievement of 
such good long-term results with the use of Helwing's method is the focus on 
the salvaging resection of the pyloroduodenal region together with form and 
function preserving plasty after H olle 's concept (Holle and Hart, 1967; Holle,
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1977). H olle‘s pyloroplasty, though not widely used, showed good long-term 
results in our earlier study (Vardja et al., 1996) and has also been recommended 
recently by other researchers (Donahue, 2000). According to Holle‘s concept, 
DPWU is excised. This is feasible in the case of relatively small ulcers. How­
ever, in the case of giant ulcers penetrating into the pancreas, there arise 
technical problems. DPV, which uses the exteriorizing of the ulcer base, enables 
to skip possible hazards and is technically simpler compared with ulcer exci­
sion. At the same time, stenosis from scarring around the ulcer, which, ac­
cording to our present study is frequent, can be simultaneously excised.
Our data show that DPV in the case of a bleeding giant DPWU can prevent 
several postoperative complications that may develop with the use of other 
widely used operative techniques.
Some authors have recommended, in DPWU hemorrhage, the oversewing of 
the bleeding vessel, with or without pyloroplasty, combined with vagotomy 
(Mills, 1991; Gostout et al., 1992; Mönig et al., 2002). However, a significant 
drawback of oversewing is occurrence of early recurrent hemorrhage in up to 
17-23% of operated patients (Hunt and McIntyre, 1990; Kubba et al., 1996), 
with high mortality (Kubba et al., 1996; Kuttila et al., 1991).
Bumm and Siewert recommend to combine the oversewing of the bleeding 
vessel in the ulcer base, through duodenotomy, with the extraluminal ligation of
a. gastroduodenalis, a. gastroepiploica dextra and a. pancreatoduodenal is 
(Bumm and Sievert, 1998). Although postoperative mortality in this case has 
been reported as 3-6% , long-term results obtained with this method are not 
available. Besides, one should also take into account that the mere ligation of 
the bleeding vessel, or the oversewing of the ulcer does not eliminate stenosis 
due to giant ulcer.
As an alternative, Billroth П gastric resection is performed in giant DU 
(Hunt and McIntyre, 1990). However, we consider that Billroth II gastric re­
section is less appropriate than Billroth I type resection because of the possi­
bility of duodenal leakage following the atypical closure of the duodenal stump, 
as well as a significantly more frequent occurrence of postgastrectomy synd­
romes. Therefore, AEV with Billroth I reconstruction after Herfarth should be 
recommended, where the base of the giant penetrating ulcer is not excised but 
exteriorized (Herfarth et al., 1977), together with truncal vagotomy. Herrington 
and Davidson have also suggested a similar method (Herrington and Davidson, 
1987). Our earlier study of long-term outcome on average 8 years after ope­
ration shows that truncal vagotomy with antrectomy in DU patients yields 
excellent and good results without ulcer recurrence in 98% of cases (Vardja et 
al., 1996).
Recent studies have shown that H. pylori eradication results in low recurrent 
bleeding in cases of conservatively treated PUH (Graham et al., 1993; Labenz 
and Börch, 1994). These findings have encouraged some authors to question 
performance of operations with vagotomy in DU hemorrhage (Ohmann et al., 
2000; Zittel et al., 2000). W ould it be right to resort to minimal surgery i.e. to
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attack only the bleeding vessel without vagotomy and to rely on H. pylori 
eradication? However, as Millat et al. have pointed out, the prevalence of H. 
pylori in bleeding PU is not well defined and has been assessed to be lower than 
in uncomplicated ulcers (Millat et al., 2000). The success of H. pylori treatment 
has been reported to be 55-80%  (Maaroos et al., 2001; Vaira et al., 1997). 
Besides, development of giant DU has been associated with the use of NSAIDs 
(Collen et al., 1994), representing one of the main risk factors for PUH 
(Santander et al., 1996). Moreover, NSAID induced ulcer hemorrhage can 
develop without H. pylori infection. Therefore, we agree with the viewpoint of 
Stabile and Stamos that until now no data support the efficacy of an operation 
for bleeding DU that does not include vagotomy (Stabile and Stamos, 2000). 
Our good long-term results from recent and present studies also serve as an 
argument for the use of vagotomy.
Surgical expertise in PU is on the way of disappearance, because elective 
surgery is rarely needed (Johnson and Chir, 2000) and conservative treatment is 
prevailing in ulcer hemorrhage. If surgical treatment of bleeding giant DPWU, 
penetrating into the pancreas, is indicated, we recommend the use of DPV after 
Helwing or AEV after Herfarth, combined with vagotomy, which yielded good 
long-term results in the present study.
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7. CONCLUSIONS
1. Peptic ulcer haemorrhage is the most common cause of upper gastro­
intestinal haemorrhage, being responsible for more than half of haemorrhage 
cases in Tartu county, Estonia. W omen with peptic ulcer haemorrhage are 
older, have consumed NSAIDs in most cases (64%) and suffer mostly from 
gastric ulcer haemorrhage, while men are younger, have consumed less 
NSAIDs (36%) and are mostly prone to duodenal ulcer bleeding.
A considerable, nearly 2-fold rise in peptic ulcer haemorrhage has taken 
place in Tartu county since 1991. The incidence of peptic ulcer haemorrhage 
is high in Tartu county, Estonia, in comparison with that in developed 
countries owing to the higher incidence rate among the younger population. 
The incidence rate is lower in the elderly compared with reports from 
developed countries.
The prevalence of H. pylori infection was 89% in peptic ulcer 
haemorrhage patients.
2. The main prognostic factors for an adverse outcome of peptic ulcer 
haemorrhage included major concomitant cardiac disease, rebleeding during 
treatment, systolic blood pressure less than 100 mmHg on admission, age 
>65 years and haemoglobin lower than 80 g/1 on admission.
3. The more extensive use of endoscopic injection therapy in peptic ulcer 
patients has enabled to diminish the need for surgical treatment as well as the 
mortality.
4. Intermittent H2 blocker therapy after an episode of peptic ulcer haemorrhage 
should be avoided due to unsatisfactory long-term outcome in terms of ulcer 
recurrence and further ulcer haemorrhage.
Good long-term results can be achieved in the majority of peptic ulcer 
haemorrhage patients by employing definitive operative procedures directed 
to the pathogenesis of peptic ulcer disease.
5. In the surgical treatment of bleeding giant duodenal posterior wall ulcers, 
penetrating into the pancreas, the use of duodenal resection with plasty after 
Helwing, or antrectomy after Herfarth, both combined with vagotomy, yield 
good long-term results.
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SUMMARY IN ESTONIAN
Peptilise haavandi verejooks Eestis: 
epidemioloogia, prognostilised faktorid, ravi ja selle tulemused
Peptilise haavandi verejooks (PHV) on haavandtõve sagedasim tüsistus. Seoses
H. p y lo r i  infektsiooni vähenemisega on haavandtõbi viimaste aastate vältel are­
nenud maades vähenemas. Samal ajal PHV esinemissageduses olulist langust ei 
täheldata (Bloom e t  a l.,  1990; Schwesinger e t  a l.,  2001). Kuigi verejooksu hai­
gete hulgas väheneb nooremate osakaal, tagab PHV esinemissageduse stabiil­
suse verejooksude märkimisväärne sagenemine vanemaealiste hulgas (Bloom e t  
a l.,  1990; Higham e t  a l. ,  2002). Sellise tendentsi põhjuseks peetakse mitte- 
steroidsete põletikuvastaste ravimite (NSAID) üha sagenevat tarvitamist 
(McCarthy, 1991). Patsientide vanuse tõusust tulenevalt on järjest suuremal osal 
PHV patsientidest rasked kaasuvad haigused.
Olemasolevad andmed PHV kohta Eestis on ärevusttekitavad. Eesti Vaba­
riigi Sotsiaalministeeriumi andmeil tõusis PHV esinemissagedus 1993. aasta 40 
juhtult 100 000 elaniku kohta aastas 77 juhuni 2001. aastal. Arenenud maades 
on vastav näitaja 25-65 (Panos and Walt, 1993; Cutler and Mendeloff, 1981; 
van Leerdam  and Tytgat, 2002).
Ravitulemused on viimase kümne-viieteistkümne aasta jooksul paranenud 
ning suremus on paremates keskustes langenud varasemalt 10%-lt 5%-le (Zittel 
e t  a l.,  2000) vaatamata vanematele ja  raskemate kaasuvate haigustega patsien­
tidele.
Tulemuste paranemisel on oluline osa endoskoopilise ravi arengul. Vere­
jooksu endoskoopiline peetamine on muutunud PHV ravivõtete esmavalikuks 
(Lanschot e t  a l., 2002) kombinatsioonis tänapäevase antisekretoorse raviga 
(Cash, 2002). Mitmed randomiseeritud uuringud näitavad, et endoskoopilise 
raviga väheneb PHV haigetel vereülekannete ja  kirurgilise ravi vajadus, langeb 
märkimisväärselt kordus verejooksude arv ning väheneb suremus (Lee and 
Leung, 1997; Gralnek e t  a l., 1998).
PHV kirurgiline ravi osakaal on küll oluliselt vähenenud (Williams e t a l., 
1993; Asaki, 2000), kuid 5-10%  patsientidest vajavad seda siiski (Qvist e t  a l., 
1994; Zittel e t  a l.,  2000). Operatsioon on näidustatud kui (1) on tegemist raske 
jätkuva verejooksuga, mis ei allu algsele intensiivravile, (2) endoskoopilise ja 
medikamentoosse raviga ei õnnestu jätkuvat või korduvat verejooksu kontrolli 
alla saada ja  (3) kui esineb kaasnev teine operatsiooninäidustus, perforatsioon, 
stenoos või maliigse protsessi kahtlus (Stabile and Stamos, 2000). Operatsioo- 
nimeetoditest on viimasel ajal saanud valdavaks mittedefinitiivsed, haavandtõve 
patogeneesi mittemõjutavad meetodid nagu veritseva haavandipõhja üleõmblus 
ning haavandi ekstsisioon. Nende pooldajad väidavad, et operatsioonijärgne
H. p y lo r i  eradikatsioon likvideerib haavandtõve ning selle tüsistuste taastekke 
võimaluse (Ohmann, 2000; Röher e t  a l.,  1996). Samas pole H. p y lo r i  esinem is­
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sagedus PHV haigetel ja  selle roll PHV tekkes üheselt ja  kindlalt määratud 
(Millat et a l., 2000). Ka pole H. pylori eradikatsiooni tulemused kaugeltki 
absoluutsed (Vaira et al., 1997; Maaroos et al., 2001). Lisaks on paljude verit­
sevate haavandite tekkes juhtivaks põhjuseks NSAIDid. Nimetatud asjaolud 
muudavad mittedefinitiivsed operatsioonid kaugtulemuste suhtes ebakindlaks. 
Definitiivseid operatsioone, vagotoomiat ja  maoresektsiooni teevad veel vaid 
mõned keskused, kus vastavad kirurgilised oskused on säilinud. Operatsioon on 
küll keerulisem, kuid tagab parema tulemuse varases operatsioonijärgses 
perioodis, tõstmata seejuures suremuse riski (Poxon et al., 1991; Kubba et al., 
1996), ning annab paremad kaugtulemused kui mittedefinitiivne operatsioon.
Antud uurimistöö eesmärgiks oli uurida PHV epidemioloogiat, ravi ja  selle 
tulemusi kuna Eestis pole seda seni süstemaatiliselt tehtud.
Uurim istöö eesm ärgid
1. Iseloomustada PHV epidemioloogiat Tartu maakonnas, hõlmates esinemis­
sagedust, patsientide vanuselist ja  soolist koosseisu, soodustavaid faktoreid,
H. pylori infektsiooni taset, haavandi asukohta ja  patsientide suremust 
(publikatsioonid I-IV ).
2. Määrata PHV haigete suremuse prognostilised faktorid (publikatsioon IV).
3. Hinnata muutusi PHV ravitaktikas viimastel aastatel. Anda hinnang en- 
doskoopilise ja  kirurgilisele ravi rollile PHV puhul ning nende meetodite 
mõjule ravitulemustele (publikatsioon VII).
4. Uurida konseravtiivselt ja  operatiivselt ravitud PHV haigete kaugtulemusi 
(publikatsioon V).
5. Selgitada Helwingi ja  Herfarthi poolt gigantsete veritsevate duodeenumi 
tagaseina haavandite puhuks väljapakutud operatsioonimeetodite kaugtule­
mused (publikatsioon VI).
Patsiendid ja  uurim ism eetodid
Seitsmes eraldi planeeritud uurimistöös koguti ja  analüüsiti ühtekokku 1270 
PHV haige andmed. Uuringu grupid on osalt kattuvad.
Esimeses, retrospektiivses pilootuuringus võrreldi endoskoopiakabineti 
registreerimiskaartide alusel seedetrakti ülaosa verejooksude põhjuseid ning 
patsientide struktuuri kahel perioodil, 1979-81 (206 patsienti) ja  1989-91 (401 
patsienti).
SA Tartu Ülikooli Kliinikumi arvutiandmebaasi ja  haiguslugude alusel 
tehtud teises, retrospektiivses uuringus analüüsiti haavandtõve tüsistuste, PHV 
ja  peptilise haavandi perforatsiooni esinemissagedust Tartu maakonnas 15-aas- 
tase ajavahemiku vältel (1979-1993).
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Kolmas oli prospektiivne uuring, milles võrreldi seedetrakti ülaosa verejook­
sude epidemioloogiat Tartu maakonnas ja  Kesk-Soome piirkonnas. Analüüsiti 
kõigi 1.8.1992-31.7.1994 ravil viibinud 263 Tartumaa ja  263 Kesk-Soome 
haige andmeid.
Prospektiivselt kogutud andmed 1992-93. aastal ravitud 144 Tartumaa PHV 
haige kohta analüüsiti neljandas, PHV epidemioloogiat ja  suremuse prognos- 
tilisi faktoreid hindavas töös. Prospektiivsetes epidemioloogilistes uuringutes 
oli uuringu piirkond defineeritud —  Tartu maakond (Tartu linn ja  Tartumaa). 
Esinemissagedus arvutati uute juhtudena 100 000 elaniku kohta aastas. Haigeid 
intervjueeriti põhjaliku küsitlusprotokolli alusel, kliinilised andmed saadi 
haiguslugudest. Neljandas uuringus võeti PHV haigetel H. pyloriga infitseeri- 
tuse määramiseks mao limaskesta biopsiad (värviti Giemsa meetodil).
Viiendas, prospektiivses randomiseerimata uuringus võrreldi 1.1.1992- 
30.6.1994 (2,5 a.) ravil viibinud 61 opereeritud ja  102 konservatiivselt ravitud 
PHV haige ravi kaugtulemusi Visicki elukvaliteedi skaala alusel. Visicki elu­
kvaliteedi skaala: Visick I —  väga hea: kaebused puuduvad; Visick II —  hea: 
vähesed, normaalset elu ja  töötamist mittesegavad kaebused; Visick III —  
rahuldav: mõõdukad, teatud määral elutegevust ja  töötamist segavad kaebused; 
Visick IV —  halb: rasked sümptoomid või endoskoopial kindlakstehtud haa- 
vand.
Kuuenda uuringu objektiks olid kuusteist 1984-93. aastal Helwingi ja  Her- 
farthi meetodite järgi opereeritud duodeenumi tagaseina gigantse veritseva haa- 
vandiga patsienti, kellel hinnati ravimeetodi kaugtulemusi Visicki elukvaliteedi 
skaala alusel. Uuritud Helwingi ja  Herfarthi operatsioonimeetodid seisnevad 
järgmises. Helwingi meetodi korral (Figure 1, publ. VI) resetseeritakse duo- 
denumi eessein ja  vabastatakse oraalne tagasein haavandi servast. Haavandit ei 
ekstsideerita. Järgnevalt nihutatakse duodeenumi oraalne ots üle haavandipõhja 
ja  anastomoseeritakse aboraalse otsaga, jättes niimoodi haavandi väljaspoole 
duodeenumi valendikku, s.o. haavand eksterioriseeritakse. Herfarthi meetodi 
korral (Figure 2, publ. VI) tehakse duodenaalhaavandit ekstsideerimata antru- 
mektoomia. Järgnevalt nihutatakse maokönt üle haavandi põhja ja  anastomo­
seeritakse duodeenumiga, eksterioriseerides haavandi. Mõlemal juhul tehakse 
lisaks vagotoomia.
Seitsmendas uuringus võrreldi 1992-93. aastal ravitud 212 PHV haige ja 
1999-2000. aastal ravitud 177 PHV haige andmeid eesmärgiga hinnata endo- 
skoopilise ja  kirurgilise ravi rolli ja  tulemust.
Statistiliseks andmetöötluseks sisestati andmed arvuti andmebaasidesse.
U urim istööst tulenevad järeldused
1. Peptilise haavandi verejooks on kõige sagedasem seedetrakti ülaosa vere­
jooksu põhjus, moodustades Tartu maakonnas, Eestis kõigist verejooksudest 
üle poole. Naishaiged on vanemad, on enne peptilise haavandi verejooksu
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enamusel juhtudest kasutanud NSAIDe (64%) ja  peamiselt on neil tegemist 
verejooksuga maohaavandist, võrreldes meeshaigetega, kes on nooremad, on 
harvem kasutanud NSAIDe (36%) ja  kelle verejooksu põhjuseks on sage­
damini duodenaalhaavand.
Tartu maakonnas on peptilise haavandi verejooksu esinemissagedus ala­
tes 1991. aastast peaaegu kahekordistunud. Peptilise haavandi verejooksu 
esinemissagedus Tartu maakonnas on võrreldes arenenud maade andmetega 
kõrge, seda tänu tunduvalt kõrgemale esinemismäärale nooremaealise 
elanikkonna seas. Vanemaealistel on peptilise haavandi verejooksu esine­
missagedus madalam kui arenenud maades.
H. pylori infektsioon on peptilise haavandi verejooksuga haigetel sage 
(89%).
2. Olulisemad suremust mõjutavad prognostilised faktorid peptilise haavandi 
verejooksu korral on kaasuv südamehaigus, kordusverejooks, vererõhu näit 
hospitaliseerimisel alla 100 mmHg, patsiendi vanus üle 65 aasta ja  hemo­
globiini väärtus hospitaliseerimisel alla 80 g/l.
3. Endoskoopilise injektsioonravi intensiivsem rakendamine peptilise haavandi 
verejooksude korral on oluliselt vähendanud kirurgilise ravi vajadust ning 
haigete suremust.
4. Vahelduvat ravi H 2 blokaatoritega peale peptilise haavandi verejooksu epi­
soodi tuleb vältida, kuna sellel on sageli ebarahuldavad kaugtulemused 
(retsidiivhaavandid, korduvad verejooksud).
Definitiivsed operatsioonimeetodid tagavad peptilise haavandi verejooksu 
korral valdaval enamusel head kaugtulemused.
5. Helwingi ja  Herfarthi operatsioonimeetodite kasutamine gigantsete, pank- 
reasse penetreerunud veritsevate duodeenumi tagaseina haavandite kirurgili­
ses ravis annab head kaugtulemused.
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ENDOSCOPIC FINDINGS IN UPPER 
GASTROINTESTINAL TRACT HEMORRHAGE 
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The incidence o f upper gastrointestinal hemorrhage (UGIH) is 50- 
160 per 100 000 inhabitants [1, 2, 3].
Peptic ulcer, gastritis, esophageal varices and Mallory-Weiss 
syndrome are responsible for 64-80% of UGIH [4, 5, 6].
Though elective ulcer surgery has dramatically declined in the past 
15 years [7, 8], the admission rate [9, 10] and emergency surgery [7, 
11] for peptic ulcer bleeding has not decreased.
Non-steroidal anti-inflammatory drugs (NSAID) are often con­
sidered to be responsible for hemorrhagic gastritis and ulcer formation 
[12, 13]. People using these drugs are put to a higher risk of gastrointes­
tinal bleeding [14, 15]. Consumption of NSAID is increasing in the 
whole world, especially in the elderly [16, 17] and probably due to this 
there has been a major change in the age structure of UGIH. The 
percentage o f the elderly has significantly risen in hemorrhage patients 
[1 ,18].
Mortality rate of UGIH ranges from 3,7 to 11,8% [19, 20].
These data show that UGIH remains a challenging problem for 
surgical departments.
During more than two decades of development and extensive 
spread, endoscopy has shown its exactness and usefulness in diagnosing 
and treating UGIH. It is essential for the accurate diagnosis of the cause 
of hemorrhage and its localisation.
The main causes o f hemorrhage according to esophagogastroduo- 
denoscopy are depicted in Table 1.
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Causes of UGIH according to endoscopy.
Table 1
%
Villar 
et al. 1977
Peetsalu A. 
et al. 1987
Mum W.H. 
et al. 1990
Duodenal ulcer 26,0 24,9 34,6
Gastric ulcer 10,4 27,0 18,7
Gastritis 18,2 15,7
Esophageal varices 15,1 6,3 6,3
Mallory -  Weiss s. 7,8 5,8 5,0
Esophagitis 3,6 9,1
Gastric tumor 3,6 8,1 2,7
Miscellaneous 7,8 5,5 14,1
No diagnose 7,3 6,8 9,5
The aim of our study was to assess the possible alterations of UGIH 
in the light of the epidemiological changes in the world, enhanced 
NSAID consumption and changes in the Estonian society during the last 
years.
PATIENTS AND METHODS
Esophagogastroduodenoscopic investigation of UGIH in Tartu 
University Clinic began in 1978. Since then all patients with UGIH 
(excluding a small number of those with very poor general condition, 
patients operated urgently after admission due to severe bleeding and 
those refusing endoscopy) were examined endoscopically. Majority of 
the investigations were performed within 12 hours after the admission, 
all within 48 hours.
Fiberoptic instruments that have been used are the following: GIF-
ОЗ, TYF-2D, GIF-K, ACMI, PUTSCHOK.
Every result of endoscopy is recorded on a special card.
We analysed all the cards of two separate periods - 1979-81 (I 
period) and 1989-91 (П period) in order to study the cause, sex and age 
distribution of UGIH and changes in these variables.
206 patients (148 male and 58 female) were investigated in I period 
and 401 (273 male and 127 female) in II period.
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In the study of the causes of UGIH all pyloric and prepyloric ulcers 
were classified into the duodenal ulcer group. Erosions, acute ul­
cerations and intramucosal bleeding spots of stomach were classified as 
gastropathy according to Z. Maratka et al. The group "miscellaneous" 
consists of the causes of bleeding with less than 2% occurrence 
(duodenopathy, stomal peptic ulcer, esophageal cancer, gastric heman­
gioma, duodenal tumors, chemical corrosion of esophagus, pancreatic 
cancer infiltrating duodenal wall etc.). In some cases endoscopy didn’t 
reveal a lesion responsible for the bleeding - classified as "no diagnose".
As the study includes all the endoscopic records of UGIH patients, 
not only of those coming from Tartu and Tartu region, but also of other 
parts of southern Estonia, it doesn’t reveal the incidence .
RESULTS
During I period (1979-81) 206 patients and during П period (1989- 
91) 401 patients with UGIH were examined endoscopically.
Figure 1 depicts the causal distribution of UGIH in both periods.
causes
Fig.l. Causes of bleeding according to endoscopy (UD - duodenal ulcer, 
UV -  gastric ulcer, G - gastropathy, M-W - Mallory-Weiss syndrome, 
E -  esophagitis, VE - esophageal varices, TU V - gastric tumor, 
MISC -  miscellaneous, NO DG - no diagnose)
Duodenal ulcer, gastric ulcer and gastropathy are responsible 
respectively for approximately 30, 20 and 10% of all the bleedings. I 
and П period don’t differ significantly in any of the causes of hemor­
rhage. The rate of miscellaneous causes and "no diagnose" group hasn’t 
changed either.
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Figure 2 compares UGIH sex rates.
The overall sex rates indicate a nearly 2:1 relation, with 71,8% 
men and 28,2% women in I period and 68,2% versus 31,8% in П 
period. There is no significant difference between the two periods (Fig. 
2a.).
In the duodenal ulcer hemorrhage group the percentage of male 
patients has decreased from 77,8% to 6S,3% and there is a respective 
increase of female patients from 22,2% to 34,7% (Fig. 2b.). However, 
the change is not statistically significant. There is an analogical situation 
in the gastric ulcer hemorrhage group (Fig. 2c.). In both these groups 
the male to female ratio is approximately 2:1 in П period.
In gastropathy patients the male to female ratio is 3:1 with no 
remarkable change.
Г Ы *  F « m t *
sex
Fig. 2a. Total sex ratio in UGIH patients
Mil* FtmU
sex
Fig. 2b. Sex ratio in duodenal ulcer hemorrhage patients
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Fig. 2c. Sex ratio in gastric ulcer hemorrhage patients
The sex rates of the "no diagnose" group don't differ significantly 
through the two periods. The same can be said about bleeding from 
gastric malignancies, the male: female ratio being 1:1 in П period.
Male patients predominate in Mallory - Weiss tear group. The 
relation 9:1 has not changed during the ten years.
The age structure of the three main causes of UGIH during the two 
periods is represented in Figure 3.
Duodenal ulcer occurrence is relatively equal through the age 
groups in I period. In II period there is a rise in the age group 50-69 
years (42% of all the bleedings) (Fig. 3a.). Comparing the two periods 
shows no significant changes in the occurrence rates of different ages.
29 S9 49 59 69 79
age
Fig. 3a. Age and duodenal ulcer hemorrhage
The incidence of gastric ulcer hemorrhage rises with the age in both 
periods. Patients over 60 years constitute 51% of all the cases in I 
period and 58% in П period (Fig. 3b.).
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Gastropathy as a cause of bleeding prevails in the 40-69 years old 
in both periods, 69% in I period and 74% in П period belong to this 
group.
Collation of the three main causes of UGIH shows that gastric ulcer 
patients are significantly older than those with duodenal ulcer or 
gastropathy.
29 39 4« 59 69 79
age
Fig. 3b. Age and gastric ulcer hemorrhage 
DISCUSSION
The absolute number of UGIH patients examined endoscopically has 
increased twofold in a decade in Tartu University Surgical Clinic. A 
remarkable rise in the incidence of UGIH could be suspected, but this 
research is not a geographically defined area study and so does not 
provide the exact data for incidence changes.
The diagnostic yield of endoscopy was 89,3% in I period and 
92,5% in П period (no significant difference). Most centres report of 
results close to 90% or exceeding it [1, 21, 221. It is known that the 
shorter the time from admission to endoscopy, the bigger the infor­
mation [23].
Certain changes have been noted in the causal distribution of UGIH 
_ Kurata reports of a remarkable increase of the rate of gastric ulcer and 
a decrease of duodenal ulcer in USA 124]. At the same time the overall 
rates of hemorrhage have not changed in the United Kingdom 125] and 
a Finland study shows a decrease of gastric ulcer and increase of 
duodenal ulcer hemorrhage [261. These variations are suspected to be 
related to geographical and life-style determined differences [18]. 
However in most works peptic ulcer is claimed to be the reason of 
UGIH in about 50% of the cases [3, 9, 19].
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Our analysis shows also that duodenal ulcer and gastric ulcer have 
been the main causes of UGIH in southern Estonia through the last 
decade, with no remarkable change. They contribute respectively 30 and 
20 % so all together a half of all the bleedings. These two lesions together 
with gastropathy and esophageal varices (up to 15 % of all cases) seem 
to be predominating in the world. In our study esophageal varices are 
the source of bleeding in less than 5 % of cases.
There is a 7 % decline in the rate of gastric malignancies. That may 
be due to diagnosing of earlier stages of tumors the last years. The rate 
of gastric cancer bleeding is yet somewhat higher than found by others 
[2, 26, 22].
The sex distribution of UGIH patients didn’t change significantly 
neither in the overall rates nor in the rates of the main causes of UGIH. 
Various rates o f male predominance are seen in every cause of UGIH. 
The overall male to female ratio is 2:1.
In peptic ulcer hemorrhage there is a trend, yet not significant, of 
changing sex proportions towards the increase of female rate, especially 
in duodenal ulcer, where the male to female ratio changed from 3,5:1 
to 2:1 in ten years. In gastric ulcer the change is from 2,5:1 to 2:1. 
Works on peptic ulcer show that in uncomplicated cases the ratio is 
similar [18, 25] to the one found by us in II period. A Norwegean study 
shows a reversed male:female ratio - 0,7:1 [27]. Maybe, the character 
of the disease is changing, the social roles of sexes are changing, 
women are consuming more NSAID etc. This may have a certain impact 
on peptic ulcer hemorrhage sex ratio.
In hemorrhagic gastropathy the male to female ratio had an 
unsignificant change - a decrease of male rate by 5 %. Mallory - Weiss 
tear is generally related to previous alcohol consumption, so mostly men 
are in risk here. There is no change in this group in our material with 
a ratio 9:1.
The proportion o f the age groups is changing in the world the last 
years. The percentage of the elderly, admitted due to peptic ulcer or 
gastritis hemorrhage has significantly increased in both sexes [18, 25]. 
This is evidently related to changing patterns of NSAID use. And not 
that the gastrointestinal mucosa of the elderly is more prone to the 
damage caused by NSAID [13], but the elderly are consuming these 
drugs remarkabely more than years ago.
Our study shows that the over 60 years age group has increased by 
5% (from 32% to 37%) in duodenal ulcer and 7% (from 51 % to 58%) 
in gastric ulcer patients during 10 years. However, the change is not
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significant. No change has occurred in gastropathy, where the >60  
patients made up 37% in 1979-81 and 38% in 1989-91. It is evident that 
gastric ulcer hemorrhage occurs relatively more often in the older age 
than duodenal ulcer or gastropathy bleeding.
As a conclusion we can say, that there has been no major change 
in the cause, sex and age distribution of UGIH patients in Tartu 
University Surgical Clinic during the past 10 years, but certain minor 
changes show the similar trends as described in the world literature.
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Kaksteistsõrmiku- 
haavandtõve kulg, 
kirurgilise ravi 
tulemused ja ravi hind
Tõnis Vardja Margot Peetsalu  
Jaan  Soplepm ann Ants P eetsalu
kaksteistsõrm ikuhaavandtõbi, kirurgilise ravi 
tulem used, ravi hind
Kaksteistsõrmikuhaavandtõbi on kroo­
niline haigus, millel on kalduvus retsidi- 
veeruda aastakümnete jooksul ja  seda ka 
pärast medikamentoosset ravi H2—retsep­
torite blokaatoritega (H2RB) (4). Samuti 
on seda haigust põdejail risk verejooksu, 
perforatsiooni ja  püloroduodenaalse ste- 
noosi tekkeks (8).
Nende haigete pikaajaline ravi ja  ravi 
taktika ei ole siiani lõplikult lahendatud, 
sest haiguse kulg on individuaalne ja  seda 
on raske ennustada. Kaksteistsõrmiku- 
haavandtõve laadi on m uutnud ka täna­
päevane ravi H2RB-ga ja  tänapäevane ki­
rurgiline ravi (4,8). Selle haiguse ravis tu ­
levad arvesse järgmised peamised 
võimalused: vahelduv või säilitav ravi 
EfeRB-ga, ravi prootonpumba blokaatori­
tega, Helicobacter pylori kolmikravi ja  ki­
rurgiline ravi (eeskätt elunditsäilitavad 
operatsioonid — vagotoomia ilma või koos 
drenaažoperatsiooniga). Üldjuhul on me- 
dikamentoosne ravi valitud tüsistum ata 
ja  kirurgiline ravi tüsistunud kaksteist- 
sõrmikuhaavandi korral. Selline taktika 
ei ole absoluutne (näiteks kirurgiline ravi 
tüsistuste ennetamiseks). Enam tähele-
Tönis Vardja, Margot Peetsalu, Jaan Soplepmann, 
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panu pööratakse ka ravi majanduslikule 
aspektile, s.t. missugune rav ija  millal tu ­
leb see ühiskonnale odavam (9). Uurimis­
töö eesmärk oli selgitada kaksteistsõrmi- 
kuhaavandtõve laadi ja  kulgu Tartu piir­
konna haigeil, kirurgilise ravi tulemusi ja  
ravi hinda.
Uurim ism aterjal ja  -m etoodika. Nime­
tatud haiguse kuluja tüsistuste tekkimise hin­
damise eesmärgil uurisime retrospektiivselt 
54 meespatsienti, kellel kõigil oli 1979. aastal 
ühes endoskoopiakabinetis esmakordselt dia­
gnoositud kaksteistsõrmikuhaavand. Nende 
haigete jälgimisperiood kestis 10 aastat. Kasu­
tasime Tartu polikliiniku ambulatoorsete 
kaartide andmeid, 16 küsimusest koosneva 
ankeetküsitluse ja ambulatoorse vestluse vas­
tuseid ning patsiendi nõusolekul 1989. aastal 
tehtud panendoskoopia tulemusi.
Peptiliste haavandite verejooksude ja perfo­
ratsioonide esinemist Tartu linnas ja maakon­
nas uurisime Tartu Kliinilises Haiglas ravil 
viibinud haigete haiguslugude alusel kahel pe­
rioodil: aastail 1979—1988 oli 356 peptilise 
haavandi verejooksuga ja 132 haavandi perfo­
ratsiooniga haiget, aastail 1990—1993 olid 
need arvud vastavalt 144 ja 57.
Kirurgilise ravi tulemuste hindamiseks ka­
sutasime 482 kroonilist kaksteistsõrmikuhaa- 
vandtõbe põdeja prospektiivse uuringu and­
meid, kellel oli ajavahemikul 1977—1984 Tar­
tus tehtud elunditsäilitav või elunditsäästev 
operatsioon (vagotoomia ilma või koos dre­
naažoperatsiooniga või vagotoomia koos ant- 
rumektoomiaga). Operatsiooni näidustuseks 
oli 69%—1 kaksteistsõrmikuhaavandi tüsistus 
ja 31%—1 mitteefektiivne medikamentoosne 
ravi. Järeluuringud (spetsiaalne küsimustik, 
vestlus, panendoskoopia, happesekretsiooni 
uuringud) tegjme 418 haigel (87%-l) 5—12 
aastat, keskmiselt 8 aastat pärast operatsioo­
ni. Tulemusi hindasime Visicki skaala järgi: 
Visick I — väga hea: kaebusteta; Visick II — 
hea: kerged, mitteolulised vaevused; Visick III 
— rahuldav: kerged või keskmised vaevused, 
mis põhjustavad enesetunde halvenemise või 
töövõime häire; Visick IV — halb tulemus: ras­
ked vaevused või retsidiivhaavand.
Kaksteistsõrmikuhaavandtõve ravi hinna 
arvutamisel lähtusime EV Sotsiaalministee­
riumi määrusest nr. 5 11. märtsist 1993 ja nr. 
53 5. septembrist 1994 "Ravikindlustuse tervi­
seuuringute ja raviteenuste hinnakiri”. Medi- 
kamentoosse ravi hinna selgitamisel võtsime 
aluseks firma TAMDA pakutava ranitidiini — 
preparaadi Ranisan9i hulgimüügihinna, mille 
järgi 150 mg-se tableti hind on 1,4 krooni. Ki­
rurgilise ravi hinna arvestamiseks hindasime
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aastail 1992—1993 Tartu Ülikooli Kirurgia­
kliinikus plaanilises korras kaksteistsõrmiku- 
haavandtõve tõttu opereeritud (vagotoomia 
koos drenaažoperatsiooniga) 31 haige ravil vii­
bimist. Patsiendid viibisid statsionaaris kokku 
keskmiselt 17 voodipäeva, nendest 6 päeva 
enne ja 11 pärast operatsiooni (4 päeva inten­
siivravi palatis).
Uurimistulemused. 10 aasta jooksul 
õnnestus meil kaksteistsõrmikuhaavand* 
tõve kulgu uurida 54 meespatsiendist 43 
patsiendil. Jälgimisperioodil suri kolm 
haiget: üks kusepõievähki, üks maksa- 
vähki ja  üks teadm ata põhjusel. Andmeid 
ei õnnestunud saada 8 haige kohta. Sel­
gus, et kaksteistsõrmikuhaavand tõbi oli 
tüsistunud 16 juhul (37%-l). 10-1 oli tek­
kinud stenoos (23%-l), kolmel verejooks 
(7%-l) ja  ühel penetratsioon Kahel 
haigel (5%-l) esines üheaegselt kaks tü- 
sistust — stenoos ja  penetratsioon. 27 ju ­
hul (63%—1) tüsistusi ei tekkinud. Jälgi­
misperioodil opereeriti 17 haiget (40%), 
kellest 12-1 oli operatsiooni näidustuseks 
kaksteistsõrmikuhaavandtõve tüsistus ja  
5-1 mitteefektiivne medikamentoosne 
ravi. Kõigil 17 opereeritul oli haavandtõ- 
bi agressiivset tüüpi ja  põhjustas elukva­
liteedi langust (haiguse sage retsidiveeru- 
mine, vajadus kasutada perioodiliselt või 
regulaarselt ravimeid, korduv viibimine 
haiglas medikamentoossel ravil, vajadus 
m uuta töötingimusi või elukutset), mis oli 
sam uti operatsiooni näidustuseks. Ope- 
reerim ata 26 juhust esines neljal samuti 
kaksteistsõrmikuhaavandtõve tüsistus
Joonis. P ep tilise  haa- 
vandi verejooksu ja  per­
foratsiooni esin em is­
sagedus Tartu p iirkon­
nas aastail 1979—1993 
(100 000 in im ese kohta).
(kahel stenoos, kahel verejooks) ja  seits­
mel juhul oli haigus seotud elukvaliteedi 
langusega.
Peptilise haavandi verejooksu ja  perfo­
ratsiooni esinemissageduse analüüs Tar­
tu  linnas ja  maakonnas 100 000 täiskas­
vanu kohta näitas, et mõlema tüsistuse 
esinemissagedus aastail 1979—1990 kõi­
kus suhteliselt vähe (vt. joonis). Verejook­
su puhul oli see 18—28 ja  perforatsiooni 
puhul 4—12 juhtu  aastas. Kaksteistsõr- 
mikuhaavandtõbi moodustas verejooksu- 
juhtudest 55% ja  perforatsioonidest 92%. 
Mõlema tüsistuse esinemissageduse m är­
gatav suurenemine algas 1991. aastal ja  
saavutas 1993. aastaks taseme, mil vere­
jooksu esines 48 ja  perforatsioone 20 juh ­
tu aastas.
482 haige kirurgilise ravi analüüs näi­
tas, et operatsioonijärgne letaalsus oli
0,8% (4 surmajuhtu). Kõigil neljal juhul 
oli haavandtõbi tüsistunud ja  kolmel oli 
operatsioon erakorraline. Operatsiooniga 
seotud tüsistusi esines 42 haigel (8,7%—1), 
neist 30-1 oli kaksteistsõrmikuhaavand- 
tõbi tüsistunud ja  12-1 tüsistum ata. Hilis- 
tulemustest moodustasid väga head ja  
head tulemused 90% (378 418-st), rahul­
davad 3% (12 418-st) ja  halvad 7% (28 
418-st). Kõikide halbade tulem uste põh­
juseks olid retsidiivhaavandid, millest 4 
(14%) olid asümptomaatilised.
Vahelduva medikamentoosse ravi ühe 
ravikuuri hind oli 213 ja  ühe aasta  säili­
tava ravi hind 640 krooni (vt. tabel 1). Ki­
rurgilise ravi hind oli 6181 krooni (vt. ta-
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Tabel 1. Kaks teis tsörm ikuhaavand tõve medi 
kamen toosse ravi hind
Uuring/ravi­
teenus
Vahelduva ravi 
1 kuuri (300 ing 
Ranisan’i 
30 päeva) 
hind (kr.)
Säilitava ravi 
(Ranisan’i 
150 mg päevas) 
1 aasta 
hind (kr.)
Esmane arsti
konsultatsioo n 19.— 19.—
Panendoskoopia 100.— 100.—
Ranisan 84.— 511.—
Korduv arsti
konsultatsioon 10,— 10.—
Hind kokku 213,— 640.—
Tabel 2. K irurgilise ravi hind
Uuring/raviteenus Hind (kr.)
Esmane kirurgi konsultatsioon 19,—
Panendoskoopia 100.—
Mao happesekretsiooni test 20.—
Rindkere röntgenoskoopia 4 о . -
EKG го,—
VI kategooria operatsioon 3200,—
Anesteesia 1000,—
Intensiivravipäevad, 4 päeva d 250.— 1000,—
Kirurgiaosakonna ravipäevad,
6 päeva d 74.— 444.—
Pikaravipäevad, 7 päeva â 44.— 308.—
Operatsioonijärgsed korduvad kirurgi
konsultatsioonid 1., 3., 5. aastal,
3 päeva â 10.— 30,—
Hind kokku 6181.—
bei 2). Kirurgilise ja  medikamentoosse 
ravi hinna võrdlemine näitas, et kirurgi­
lise ravi hind on võrdne 29 vahelduva ra ­
vikuuri või 9,7 aasta  säilitava ravi hinna­
ga-
Arutelu. Kaksteistsõrmikuhaavandtõ­
bi on jätkuvalt probleemiks ka tänapäeval 
(3), sest umbes 10% lääneriikide elanik­
konnast haigestub mingil eluperioodil 
peptilisse haavandtõvesse (4). Haavandi 
retsidiivi tekkimise risk nendel haigetel 
aga on suur: ühe aasta jooksul pärast haa­
vandi paranemist tekib vähemalt üks re t­
sidiiv 80%-l haigetest ja  viie aasta jook­
sul praktiliselt kõigil (8).
54 mehe kaksteistsõrmikuhaavandtõve 
kulu jälgimisel aastail 1979—1988 selgus, 
et kõige sagedam tüsistus oli püloroduo- 
denaalstenoos (27%-l), mille esinemissa­
gedus on suurem kirjanduse andmetel
esinevast 11%-st (8). Samuti viitavad kir­
janduse andmed stenoosijuhtude vähene­
misele, põhjendades seda tänapäevase 
efektiivsema medikamentoosse raviga (7). 
Meie patsientidel aga ei olnud sel perioo­
dil H2RB-ravi kättesaadav, mis võiks se­
letada sellist stenoosijuhtude esinemist.
10 aasta jooksul opereeriti 40% uurituist. 
Operatsiooni põhjuseks oli 70%-l kaks­
teistsõrmikuhaavandtõve tüsistus ja  
30%-l mitteefektiivne medikamentoosne 
ravi. Kõigil opereerituil oli enne operat­
siooni tegemist elukvaliteedi langusega.
Elukvaliteedi hindamist, kuigi see on 
subjektiivne ja  ei ole täpselt s tan ­
dardiseeritud (2), peetakse krooniliste 
haiguste, ravi tulemuste ja  ravi ökonoom­
suse aspektist oluliseks näitajaks (2, 6). 
Opereerimata 27 haigest oli neljal kaks­
teistsõrmikuhaavandtõve tüsistus ja  
seitsmel elukvaliteedi langus. Arvatavas­
ti oleks ka nende puhul arvesse tulnud ki­
rurgiline ravi.
Kirjanduse andmed kinnitavad, et olu­
liselt ei ole muutunud peptilise haavandi 
verejooksude ega perforatsioonide esine­
missagedus, seda vaatam ata H 2RB kasu­
tamisele (7). Andmed on ka nende tüsis­
tuste sagenemise kohta ja  seda eeskätt 
vanematel inimestel (üle 65-aastastel) ja  
mittesteroidsete põletikuvastaste ravimi­
te kasutajatel (3, 4, 5). Tartu piirkonna 
elanike analüüs näitas, et peptilise haa­
vandi verejooksude ja  perforatsioonide 
esinemissagedus püsis suhteliselt stabiil­
sena aastail 1979—1990. 1991. aastast 
alates aga ilmnes mõlema tüsistuse aas­
tase esinemissageduse selge suurenemis- 
tendents. Ka meie andmeil oli verejooks 
sageli (45%—1) seotud mittesteroidsete põ­
letikuvastaste ravimite kasutamisega, 
seda eeskätt vanematel naistel (10).
Kirurgiline ravi (elunditsäilitavad ope­
ratsioonid) on mõjutanud kaksteistsõrm i­
kuhaavandtõve kulgu ja  laadi. Pärast 
suurte kogemustega kirurgide operatsioo­
ne oli retsidiivhaavandeid 10 aasta  kohta 
umbes 10%, samas kui pärast H2RB-ravi
011 retsidiivhaavandite arv 18 kuu järel 
umbes 100% (4). Samuti on pärast k irur­
gilist ravi retsid ii vhaavand parema ise­
loomuga, retsidiveerub harvem ning võib
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olla ka sümptoomideta, on paremini me- 
dikamentidega ravitav ja  võib mitte kor­
duda (1).
Uurimistulemuste alusel olid elundit- 
säästvad operatsioonid ohutud (operat­
sioonijärgne letaalsus oli 0,8%). Keskmi­
selt 8 aasta t pärast operatsiooni moodus­
tasid väga head ja  head tulemused 90%. 
Probleemiks on retsidiivhaavand, kuid 
nende arv, 6,7% kõigist kontrollitud hai­
getest ja  8% endoskopeeritutest, on suhte­
liselt väike. Elukvaliteet aga oli langenud 
40-1 (12-1 Visick III ja  28 retsidiivhaavan- 
diga patsiendil) ehk 10%—1.
A. Sonnebergi andmeil on USA-s kaks­
teistsõrmikuhaavandtõve ravi hinna as­
pektist kõige tasuvam säilitav EfeRB-ravi 
(9), sest kirurgiline ravi (proksimaalne 
vagotoomia) on kallis oma alghinna tõttu 
ja  see m uutub odavamaks, kui vahelduv 
või säilitav ravi on kestnud vastavalt 29 
ja  32 aastat. Saksamaal aga on kirurgili­
ne ravi odavam juhul, kui säilitav ravi on 
kestnud 6 aastat. Arvestades Eestis toi­
muvaid suuri muutusi arstiabis, kajastab 
ravi hind vaid hetkeseisu ja  see võib lähi­
tulevikus oluliselt muutuda. Medikamen- 
toosse ravi hinna arvutamiseks valisime 
H2RB-ravi hinna, sest need ravimid on 
praegu kättesaadavad. Ravi prootonpum- 
ba blokaatoritega on kallis ravimi kõrge 
hinna tõttu ja  Helicobacter pylori kolmik- 
ravi ei ole leidnud laialdast kasutam ist 
puuduliku diagnoosimise ja  mitte alati si­
hipärase ravitaktika tõttu.
Meie tulemused näitavad, et kirurgiline 
ravi on odavam, kui säilitav ravi on kest­
nud 9,7 aastat. Kirurgilise ravi hinda 
oleks meil võimalik vähendada operat­
sioonieelse perioodi lühendamise teel. 
Enam ik operatsioonieelseid uuringuid ja  
vajaduse korral medikamentoosset ravi 
(haavandipiirkonnas lokaalset turset vä­
hendav ja  sellega opereerimist tehniliselt 
kergendav) on võimalik teha ambulatoor­
selt.
Ravimeetodi valik iga kaksteistsõrmi­
kuhaavandtõve põdeja korral on indivi­
duaalne. Nõustume taani kirurgi A. Am- 
drupi öelduga, et haige ei ihalda gastro- 
enteroloogi, kes kunagi ei soovita 
operatsiooni, ega kirurgi, kes soovitab 
seda alati.
Järeldused.
1. Tartus ajavahemikul 1979—1988 
uurituist tüsistus kaksteistsõrmikuhaa- 
vandtõbi 37%—1, sagedam tüsistus oli pü- 
loroduodenaalstenoos. Opereeriti 40% 
haigeist. Nende kõigi puhul oli tegemist 
elukvaliteedi langusega enne operatsioo­
ni.
2. 1990-ndatel aastatel oli Tartu  piir­
konnas elavate inimeste peptiliste haa­
vandite verejooksude ja  perforatsioonide 
esinemissagedus aastas suurenemisten- 
dentsiga võrreldes 1980-ndate aastatega. 
Verejooks on sageli seotud mittesteroidse- 
te põletikuvastaste ravimite kasutam ise­
ga.
3. Elunditsäilitavad operatsioonid 
kaksteistsõrmikuhaavandtõve ravis on 
ohutud ja  heade hilistulemustega, taga­
des 90%-le hea elukvaliteedi.
4. Kirurgilise ravi hind on võrdne 9,7 
aasta säilitava Ü2RB-ravi hinnaga.
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Summary
Natural history, results o f surgery and the  
costs of treatm ent of duodenal u lcer d isease. In
Tartu, during the years 1979—1988 the duodenal 
ulcer disease complicated in 37% of the patients stu­
died. The most frequent complication was pyloro- 
duodenal stenosis. In the 1990s there is a tendency 
towards a rising frequency of peptic ulcer haemor­
rhages and perforations, as compared to the 1980s. 
In 482 organ preserving operations the postopera­
tive lethality was 0,8%, and complications occurred 
in 8,7%. Averagely 8 years after the operation the 
proportion of the excellent and good results was 90%, 
satisfactory — 3%, and poor — 7%. The cost of sur­
gical treatment today is equal to that of 9,7 year 
maintenance treatment.
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ACUTE UPPER GASTROINTESTINAL HAEM ORRHAGE IN  CENTRAL 
FINLA ND PROVINCE, FINLAND, A N D  IN TARTU COUNTY, ESTONIA
J. SOPLEPMANN, M. UDD, A. PEETSALU and A. PALMU
FROM THE SECOND DEPARTMENT OF SURGERY, TARTU UNIVERSITY HOSPITAL, TARTU, ESTONIA, AND THE 
DEPARTMENT OF SURGERY, CENTRAL HOSPITAL OF CENTRAL FINLAND, JYVÄSKYLÄ, FINLAND
ABSTRACT
Background and Aims: A comparative study of the epidemiology of acute upper gastrointestinal haemorrhage 
(UGIH) was carried out in Central Finland province (CF), Finland, and in Tartu county (TO, Estonia.
Patients and M ethods: All patients from CF and TC aged > 15 who were treated in the Central Hospital of 
Central Finland and in Tartu University Hospital for UGIH, entered the prospective study during 1 August 1992
-  31 July 1994. Altogether 298 patients (198 men, 100 women) were treated in CF and 270 patients (159 men, 104 
women) in TC.
Results and Conclusions: The overall incidence of UGIH was 68.3/100,000 adults per year in CF and 98.6 in 
TC. The incidence increased considerably with age: from 3.1 in those aged 2ft-29 to 314.1 in those > 80 in CF, and 
from 13.2 to 299.1 in TC, respectively. Incidence rates were twice as low in younger age groups in CF compared to 
TC, almost equalized in those > 60 and became even higher in those > 80. 63 % of the patients (55 % men, 79 % 
women) in CF and 49 % (35 % men, 70 % women) in TC were > 60. NSAID use before UGIH was equally com­
mon (46 %) in both regions. Peptic ulcer accounted for over 50 % of UGIH cases both in CF and TC. Mortality 
rate was 8.1 % in CF and 9.9 % in TC. The main epidemiological differences between the regions are the lower 
overall incidence of UGIH, due to the lower incidence of haemorrhage in the younger age groups, and the higher 
proportion of the elderly patients in CF compared to TC.
KEY WORDS: EPIDEMIOLOGY; INCIDENCE; MORTALITY; NONSTEROIDAL ANTI-INFLAMMATORY DRUGS; PEPTIC 
ULCER; UPPER GASTROINTESTINAL HAEMORRHAGE
INTRODUCTION
Upper gastrointestinal haemorrhage (UGIH) 
is by no way a single entity, but a number of 
features common for the development, clini­
cal course, principles of diagnosing and treat­
ment and finally also outcome risk factors 
have made it useful to consider different 
causes of bleeding together.
The incidence of UGIH is estimated at 48 
to 150 per 100,000 population per year (1, 2).
Approximately half of UGIH episodes are 
accounted for by duodenal and gastric ulcer. 
Acute gastroduodenal mucosal lesions, 
oesophageal varices, oesophagitis and Mallo­
ry -  Weiss tear are responsible for one-third 
of the episodes (3, 4, 5). Various minor cau­
ses of bleeding have an incidence of about
10 %; in up to 10 % of the patients no lesions 
can be detected by endoscopy (5, 6).
Peptic ulcer (PU) haemorrhage has been re­
ported to rise in the elderly (7, 8). This trend 
could be related to the taking of NSAIDs (9). 
Obviously, PU bleeding, haemorrhagic and 
erosive gastritis are closely related to previ­
ous NSAID use (10, 11, 12, 13). There is evi­
dence that these drugs may play a role in all 
types of gastrointestinal bleeding (14). NSAID 
consumption is increasing, especially in the 
elderly (15,16), while women use these drugs 
more often than men (9, 17).
Mortality rates of 8-10 % for UGIH, that 
have not significantly changed during recent 
decades in most centres seem to be related to 
the increasing proportion of elderly patients 
(18).
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TABLE 1
Socio-economic development and nonsteroidal anti-inflamma- 
tory drug (NSAID) consumption in Finland and Estonia.
Finland Estonia
GNP per capita 1991 
HDI world ranking 1992 
NSAID use 1989 (DDD)
23 930 
16
66.7
3 970 
29 
49.9
GNP = gross national product per capita per year ex­
pressed in USD 
HDI = human development index 
DDD -  defined daily doses per 1 000 inhabitants per day
To evaluate the significance of the problem, 
we performed a prospective study of UGIH 
epidemiology in the province of Central Fin­
land (257,000 inhabitants, 1993) and in Tartu 
county, Estonia (159,000 inhabitants, 1993), as 
no publication has until now dealt with UGIH 
in these regions. The study is valuable in pro­
viding comparable information about UGIH 
in case of kindred nations living on the op­
posite coasts of the Gulf of Finland. There are 
certain differences between the countries that 
could have an impact on the epidemiology of 
UGIH. Finland and Estonia have a similar cul­
tural background but Finland has a six-fold 
higher gross national product per capita and 
a higher socio-economic level of develop­
ment, according to the United Nations "Hu­
man Development Report 1994" (Table 1). Ta­
ble 1 also contains data on NSAID consump­
tion in the two countries, expressed by de­
fined daily dose methodology in 1989 (19,20).
The aim was to study the incidence of 
UGIH, the patient population structure, pos­
sible predisposing factors, causes of haemor­
rhage and mortality in the two regions.
PATIENTS AND METHODS
We assessed data on all cases of patients aged > 15 
years treated for acute UGIH in the Central Hos­
pital of Central Finland, Jyväskylä, Finland, and in 
Tartu University Hospital, Tartu, Estonia, during 
01 August 1992 -  31 July 1994. Acute UGIH was 
defined as melaena and/or haematemesis of < 1 
week duration before admission, or onset of signs 
of bleeding in hospital.
Only patients from the province of Central Fin­
land and from Tartu county were included in the 
study. Altogether 298 patients with haemorrhage 
were treated in Central Finland and 263 patients 
in Tartu county.
The patients were questioned about previous 
UGIH, as well as of smoking habits, alcohol and 
NSAID consumption before the onset of bleeding. 
The final diagnosis was established by endoscopy, 
X-ray technique (one case in Tartu), surgery or au­
topsy. 96.3 % of the patients underwent endosco­
py in the Central Hospital of Central Finland 
where the Pentax videoendoscopy system was 
used, and 95.1 % in Tartu University Hospital, Es­
tonia, where Olympus fiberoptic endoscopes were 
employed. In 6 patients (2.0 %) in Central Finland 
ana in 9 patients (3.4 %) in Tartu no endoscopy, 
operation or autopsy was performed and so the 
causes of UGIH were not established. These pa­
tients were included in the evaluation of incidence, 
patient profile and mortality but excluded from the 
analysis of the causes of haemorrhage.
Prepyloric and pyloric ulcers were considered in 
the duodenal ulcer group, haemorrhagic gastro- 
pathy and gastric mucosal erosions, in the acute 
gastric mucosal lesion group.
Population characteristics for Central Finland 
were obtained from "Population Structure 1993. 
Official Statistics of Finland" published by Statis­
tics Finland, and for Tartu county from "Popula­
tion Age Structure. Counties of Estonia 1990-1991" 
issued by the Viljandi County Statistics Bureau, 
Estonia. Incidence rates were calculated from the 
number of new UGIH cases diagnosed during one 
year and expressed per 100,000 population per 
year.
Statistical analysis of the significance of differ­
ences was performed using the chi-square test. 
Yates' correction was applied to approximate the 
chi-square test where necessary.
RESULTS
There were 298 episodes of UGIH (198 in men 
and 100 in women) in 270 patients in Central 
Finland with 23 patients (8.5 %) admitted 
more than once. In Tartu 243 patients were 
treated on 263 occasions (159 men and 104 
women) with 16 patients (6.6 %) admitted 
more than once.
INCIDENCE
The overall incidence of UGIH per 100,000 
adults per year was 68.3 in Central Finland 
and 98.6 in Tartu county. In Central Finland 
the incidence rate increased 100-fold with age, 
from 3.1 in patients aged 20-29 years to 314.1 
in those > 80 years of age, in Tartu county 23- 
fold, from 13.2 to 299.1, respectively. Inci­
dence rates by sex and age are depicted in Ta­
ble 2.
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TABLE 2
Incidence rate o f upper gastrointestinal haemorrhage by age groups per 100,000 population per year in Central Finland and in
Tartu county.
Age groups
Central Finland Tartu county
Total Males Females Total Males Females
15-19 0 0 0 7.9 16.1 0
20-29 3.1 5.9 0 13.2 26.2 0
30-39 23.1 42.2 2.7 43.6 75.3 13.4
40-49 51.7 85.2 12.8 116.4 196.2 45.1
50-59 77.2 104.1 50.3 150.2 234.0 82.5
60-69 120.4 186.4 65.2 164.1 230.7 122.7
70-79 206.2 351.7 122.5 250.2 282.6 235.7
£80 314.1 361.5 303.7 299.1 451.6 247.9
Total 68.3 92.3 45.4 98.6 133.4 70.3
PATIENT PROFILE
The total male to female ratio was 2:1 in Cen­
tral Finland and 1.5:1 in Tartu, which showed 
no significant difference between the regions.
The mean age of the patients was 64.2 in 
Central Finland and 58.8 in Tartu. In Central 
Finland the proportion of the patients aged
> 60 was 62.7 %, which is significantly higher 
than 49.1 % in Tartu (P = 0.001). In Central 
Finland 79.0 % of the women and 55 % of the 
men were aged > 60, in Tartu 70.2 % and 
35.2 %, respectively. The distribution of age 
groups is depicted in Fig. 2.
CAUSES OF HAEMORRHAGE
A lesion responsible for bleeding was re­
vealed on endoscopy, operation or autopsy in 
90.4 % of the patients in Central Finland and 
in 92.9 % in Tartu. The most frequent cause 
of haemorrhage was PU, accounting for more 
than half of the total number of cases in both 
centres. Duodenal ulcer prevailed in both sex­
es in Central Finland, accounting for 31.3% 
of all cases in women and for 27.0 % of cases 
in men. In Tartu county, gastric ulcer was 
more common in women (30.0 % of all cases) 
and duodenal ulcer in men (38.3 % of all 
cases). In Central Finland, PU haemorrhage 
was followed by oesophageal varices and 
oesophagitis, in Tartu, by acute gastric mu­
cosal lesions and Mallory -  Weiss tear. The 
distribution of the causes of UGIH is presen­
ted in Fig. 1.
PREDISPOSING FACTORS
One-third of the patients in Central Finland 
and one-fourth in Tartu had suffered from 
previous UGIH (Table 3).
46.1 % of the patients in Central Finland 
and 46.8 % in Tartu county had taken NSAIDs 
prior to bleeding. The elderly had used these 
drugs significantly more often than younger 
patients. Women had used NSAIDs signifi­
cantly more frequently than men in Tartu 
county. In Central Finland the difference was 
not significant (Table 3).
Smoking habits showed no difference, but 
the men admitted to the Central Hospital of 
Central Finland had consumed alcohol prior 
to bleeding significantly more often than the 
men admitted in Tartu (Table 3).
MORTALITY
Mortality rate was 8.1 % in Central Finland 
and 9.9 % in Tartu county. Patients > 65 years 
of age accounted for 63 % of the total mor­
tality in Central Finland and for 69 % of the 
total mortality in Tartu county. In Tartu the 
mortality rate was four-fold higher for those
> 65 years of age compared to younger pa­
tients, which was mainly due to the high 
mortality rate (24.1 %) in women aged > 65. 
There were neither sex nor age related differ­
ences in mortality rates in Central Finland 
(Table 4).
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Fig. 1. Causes of upper gastrointestinal haemorrhage in 
Central Finland and in Tartu county.
DU = duodenal ulcer MW = Mallory-Weiss tear
GU = gastric ulcer MAL = malignancies
EV = oesophageal varices OTH = others 
E = oesophagitis NL = no lesion revealed
AGL = acute gastric mucosal lesions
DISCUSSION
The overall incidence of UGIH was 68.3 per 
100,000 adults per year in Central Finland and 
98.6 in Tartu county. The incidence rate seems 
to be relatively low in Central Finland and 
m edium  in Tartu county, considering the 
range of incidence rates from 48 to 150 as re­
ported from elsewhere (1, 2). In both centres 
the incidence showed a substantial increase 
w ith age. Incidence rates in younger age 
groups were considerably lower in Central 
Finland than in Tartu county but became al­
most equal for those > 60 years of age and 
were even higher for those aged > 80. In both 
centres the incidence of UGIH in men com­
pared to women was more than double in all 
age groups except in those > 80 in Central Fin­
land and in those > 70 in Tartu county. A sim­
ilar pattern has been reported in a study from 
the United Kingdom (1).
Several studies report ageing trends in 
UGIH patients during recent decades (18, 21). 
Indeed, the proportion of the elderly was high 
in Central Finland: two-thirds of the patients 
and as many as 79 % of all the women w ith 
haem orrhage were aged > 60 there. The pro ­
portion of tne elderly was significantly lower 
in Tartu. Half of the patients and 70 % of the 
wom en were > 60 years of age there. The dis­
crepancy in the share of the elderly is not the 
result of the different proportion of the eld­
erly in the population of the regions studied. 
According to demographic data, people > 60
<20 20-29 30-39 40-49 50-59 60-69 70-79 >79
Fig. 2. Age distribution of upper gastrointestinal haem­
orrhage patients in Central Finland and in Tartu county.
years of age constitute 19 % of the whole pop­
ulation in Central Finland and 18 % in Tartu 
county.
The above age related differences could be 
associated w ith the more extensive NSAID 
use in Finland (Table 1). It is also possible that 
different Helicobacter pylori infection rates re­
ported recently in both countries have an im­
pact on the incidence and age structure of 
UGIH, because this bacterium is related to the 
developm ent of PU disease. Studies have 
shown an extremely high prevalence, 73- 
87 %, of Helicobacter pylori infection among the 
population of Estonia in three regions; the 
prevalence is as high as 68-83 % even in those 
bom  in 1955-70 (22, 23). In Finland the prev­
alence of Helicobacter pylori related gastritis is 
high (70-80 %) in cohorts bom  at the begin­
ning of the century, lower (40-50 %) in those 
born in the decade following W orld War II 
and still lower (20-35 %) in those bom  in re­
cent decades (24). This discrepancy, presum ­
ably related to differences in the level of 
socioeconomic developm ent betw een the 
countries, may result in the higher prevalence 
of PU disease and subsequently higher haem ­
orrhage rates among the younger population 
in Tartu county, as well as in the predom i­
nance of the elderly in Central Finland. It 
could be expected that in Central Finland PU 
haemorrhage may become less common after 
some decades due to the Helicobacter pylori co­
hort effect, whereas in Tartu county it will 
m aintain the position of the m ost frequent 
cause of UGIH for a longer period.
The main cause of UGIH was PU disease 
both in Central Finland and in Tartu county, 
accounting for more than half of the total 
num ber or cases. On the whole, the rate of 
duodenal ulcer haemorrhage prevailed that of 
gastric ulcer haemorrhage 1.3-fold in both  re-
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TABLE 3
Predisposing factors of upper gastrointestinal haemorrhage patients in Central Finland and in Tartu county.
Predisposing factors Central Finland Tartu county P
Num ber/patients % Num ber/patients %
Previous haemorrhage 105/298 35.2 60/229 26.2 <0.05
once 57/298 19.1 37/229 16.2 NS
more 48/298 16.1 23/229 10.0 NS
Smoking 90/283 31.8 77/229 33.6 NS
men 79/187 42.2 67/139 48.2 NS
women 11/96 11.5 10/90 11.1 NS
Alcohol prior to bleeding 103/281 36.7 46/230 20.0 < 0.001
men 91/185 49.2 38/141 27.0 < 0.001
women 12/96 12.5 8/89 9.0 NS
NSAIDs prior to bleeding 129/280 46.1 108/231 46.8 NS
men 77/182 42.3 53/139* 38.1 NS
women 52/98 53.1 55/92 59.8 NS
NSAIDs in < 65 patients 50/127*» 39.4 59/150+ 39.3 NS
NSAIDs in ä 65 patients 79/153 51.6 49/81 60.5 NS
NSAIDs prior to bleeding 
gastric ulcer 39/58 67.2 28/55 50.9 NS
duodenal ulcer 44/78 56.4 31/72 43.1 NS
acute gastric lesions 6/19 31.6 13/20 65.0 NS
NS = not significant
* P < 0.01 when compared to NSAIDs prior to bleeding in women in Tartu county 
** P < 0.05 when compared to NSAIDs in Ž 65 patients in Central Finland 
+ P < 0.01 when compared to NSAIDs in Ž 65 patients in Tartu county
TABLE 4
M ortality by sex and age of upper gastrointestinal haemorrhage patients in Central Finland and in Tartu county.
Sex/age (years) Mortality P
Central Finland Tartu county
Num ber/patients % Num ber/patients %
Men 15/198 7.6 10/159 6.3 NS
age < 65 7/108 6.5 6/122 4.9 NS
age > 65 8/90 8.9 4/37 10.8 NS
Women 9/100 9.0 16/104 15.4 NS
age < 65 2/30 6.7 2/46* 4.3 NS
age â 65 7/70 10.0 14/58 24.1 = 0.056
Total 24/298 8.1 26/263 9.9 NS
age < 65 9/138 6.5 8/168** 4.8 NS
age Ž 65 15/160 9.4 18/95 18.9 <0.05
NS = not significant
* P < 0.05 when compared to women aged > 65 in Tartu county 
** P < 0.001 when compared to patients aged > 65 in Tartu county
gions. However, gastric ulcer haem orrhage 
was more common in women in Tartu coun­
ty. The distribution of the causes of UGIH is 
similar in both observed regions and is close 
to that reported from other centres (3, 4). 
There is only one major difference between
the two regions: a higher incidence of 
oesophageal disease (oesophagitis and 
oesophageal varices) in Central Finland, the 
reason of which has remained unclear.
The incidence rates of UGIH were notably 
lower for younger wom en than for men in
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both regions but showed a more pronounced 
increase with age and almost equalized in the 
older age groups. This indicates that there ex­
ist also other factors than Helicobacter pylori 
contributing to age and sex related discrep­
ancies. One of these is the circumstance that 
certain causes of haemorrhage are observed 
mostly in younger men (Mallory -  Weiss tear 
that is mostly related to alcohol abuse), 
whereas others are more likely to occur in 
older women (gastric ulcer). It has also been 
found that elderly women consume more 
NSAIDs than men (17), which places them at 
a higher risk of NSAID related lesions, par­
ticularly of gastric ulcer. NSAID use prior to 
haemorrhage was equally frequent in both re­
gions. Nearly half of the patients had received 
NSAIDs, while the elderly had used them sig­
nificantly more often than younger patients. 
The same observation has been made else­
where as well (17).
Compared to duodenal ulcer development, 
gastric ulcer development (25) as well as gas­
tric ulcer bleeding (10) are reported as being 
related more to NSAID use. However, NSAID 
use prior to gastric ulcer haemorrhage was 
slightly but not significantly higher than 
NSAID use prior to duodenal ulcer haemor­
rhage in both regions.
Mortality rates of UGIH are mostly repor­
ted to be around 10 % (26, 27). Several spe­
cialized units have achieved rates as low as 
3.7-4.8 % (5, 28). The mortality rate was 8.1 % 
in Central Finland and 9.9 % in Tartu, with­
out significant differences. However, patients 
aged > 65 had a significant, nearly four-fold 
higher mortality compared to those < 65 of 
age in Tartu county. The reason for this was 
the high, 24.1 % mortality in women aged > 65 
years there. In Central Finland the relative 
risk of mortality was 1.3-fold higher for pa­
tients aged > 65 collated with that of younger 
ones.
It can be concluded that in Central Finland 
the incidence of UGIH is somewhat lower 
than in Tartu county. This is mainly due to 
low rates among the younger population, 
while in the elderly the rates are nearly equal­
ized. While the distribution of the causes of 
UGIH is basically the same and there is no 
difference in sex ratios between the regions, 
the proportion of the elderly is significantly 
higher in Central Finland. These findings 
could partly result from higher NSAID con­
sumption in Finland. The difference in Heli­
cobacter pylori infection rate, a factor connec­
ted with different levels of socio-economic de­
velopment, could also have an impact on the 
described age related discrepancies. Therefore 
further time related epidemiological studies 
in the regions under study would be of inter­
est.
ACKNOWLEDGEMENTS
The study was supported by Grant 35 from 
the Estonian Science Foundation and by a 
scholarship from the Centre for International 
Mobility, Finland. The skilful assistance by 
Mrs. Ülle Kirsimägi is highly appreciated.
REFERENCES
1. Rockall TA, Logan RFA, Devlin HB, Northfield TC: In­
cidence of and mortality from acute upper gastroin­
testinal haemorrhage in the United Kingdom.
Br Med ) 311: 222-226,1995
2. Cutler JA, Mendeloff Al: Upper gastrointestinal bleed­
ing. Nature and magnitude of the problem in the U.S. 
Dig Dis Sei 26: 90-96,1981
3. Wara P: Incidence, diagnosis, and natural course of 
upper gastrointestinal haemorrhage. Prognostic val­
ue of cünical factors and endoscopy.
Scand J Gastroenterol 22 (Suppl 137): 26-27,1987
4. Henriksson AE, Svensson J-O: Upper gastrointestinal 
bleeding with special reference to blood transfusion. 
Eur J Surg 157:193-196,1991
5. Sanderson JD, Taylor RFH, Pugh S, Vicary FR: Special­
ized gastrointestinal units for the management of 
upper gastrointestinal haemorrhage.
Postgrad Med J 66: 654-656,1990
6. Allum WH, Brearley S, Wheatley KE, Dykes PW, Keigh­
ley MRB: Acute haemorrhage from gastric malignan­
cy. Br J Surg 77:19-20,1990
7. Bardhan KD, Cust G, Hinchliffe RFC, Williamson FM, 
Lyon C, Bose K: Changing pattern of admissions and 
operations for duodenal ulcer.
Br ] Surg 76: 230-236,1989
8. Bloom BS, Fendrick AM, Ramsey SD: Changes in pep­
tic ulcer and gastritis/duodenitis in Great Britain, 
1970-1985. J Clin Gastroenterol 12: 100-108,1990
9. McCarthy DM: Acid peptic disease in the elderly. 
Clin Geriatr Med 7: 231-254,1991
10. Wilcox CM, Shalek KA, Cotsonis G: Striking prevalence 
of over-the-counter nonsteroidal anti-inflammatory 
drug use in patients with upper gastrointestinal 
haemorrhage. Arch Intern Med 154: 42-46,1994
11. Rodriguez LAG, Jick H: Risk of upper gastrointestinal 
bleeding and perforation associated with individual 
non-steroidal anti-inflammatory drugs.
Lancet 343: 769-772,1994
12. Holvoet J, Terriere L, Van Нее V, Verbist L, Fierens E, 
Hautekeete ML: Relation of upper gastrointestinal 
bleeding to non-steroidal anti-inflammatory drugs 
and aspirin: a case-control study.
Gut 32: 730-734,1991
13. Chamberlain CE: Acute haemorrhagic gastritis. Gas­
troenterol Clin North Am 22: 843-873,1993
228 J. Scrplepmann, M . Udd, A . Peetsalu and A . Palmu
14. Lanas A, Sekar M C, Hirshowitz BI: Objective evidence 
of aspirin use in both ulcer and nonulcer upper and 
lower gastrointestinal bleeding.
Gastroenterology 103: 862-869,1992
15. Glise H: Epidemiology in peptic ulcer disease. Scand 
J Gastroenterol 25 (Suppl 175): 13-18, 1990
16. Leivonen M , Kivilaakso E: Peptic ulcer bleeding today: 
Risk factors and characteristics of the disease.
Scand J Gastroenterol 26:1013-1019,1991
17. Savage RL, M öller PW , Ballantyne CL, Wells JE: Varia­
tion in the risk of peptic ulcer complications with 
nonsteroidal antiinflammatory drug therapy. 
Arthritis Rheum 36: 84-90,1993
18. Gilbert DA: Epidemiology of upper gastrointestinal 
bleeding. Gastrointest Endosc 36 (Suppl 5): 8-13,1990
19. Finnish Statistics on Medicines 1990. Edited by the 
Finnish Committee on Drug Information and Statis­
tics. Kelan omatarvepaino, Helsinki, Finland, 1991, 
pp. 145-150
20. Kiivet RA, Bergman U, Sjöqvist F: The use of drugs in 
Estonia compared to the Nordic countries.
Eur J Clin Pharmacol 42: 511-515,1992
21. M artio J, Jukka E, Isomäki H: Ulkustauti ja tuleh- 
duskipulääkkeet. Suomen Lääkärilehti 27: 2493-2495, 
1991 (in Finnish)
22. Maaroos H-I: Helicobacter pylori infection in Eston­
ian population: Is it a health problem?
Ann Med 27: 613-616,1995
23. Vorobjova T, Kisand K, Haukanõmm A, Maaroos H-I, 
Wadström T, Uibo R: The prevalence of Helicobacter 
pylori antibodies in a population from southern Es­
tonia. Eur J Gastroenterol Hepatol 6: 529-533,1994
24. Stpponen P, Helske T, Järvinen P, Hyvärinen H, Seppälä 
К, Siurala M: Fall in the prevalence of chronic gastri­
tis over 15 years: analysis of outpatient series in Fin­
land from 1977,1985, and 1992.
Gut 35:1167-1171,1994
25. Langman MJS, Brooks P, Hawkey CJ, Silverstein F, Yeo­
mans N: Non-steroidal anti-inflammatory drug asso­
ciated ulcer: Epidemiology, causation and treatment. 
Eur J Gastroenterol Hepatol 6: 442-449,1991
26. Katschinski B, Logan R, Dames J, Faulkner G, Pearson J, 
Langman M: Prognostic factors in upper gastrointes­
tinal bleeding. Dig Dis Sei 39: 706-712,1994
27. Clason AE; Macleod DAD, Elton RA: Clinical factors 
in the prediction of further haemorrhage or mortal­
ity in acute upper gastrointestinal haemorrhage.
Br J Surg 73: 985-987,1986
28. Holman RAE, Davis M , Gough KR, Garteil P, Britton 
DC, Smith RB: Value of a centralised approach in the 
management of haematemesis and melaena: experi­
ence in a district general hospital.
Gut 31: 504-508,1990
Received: April 3,1997 
Accepted: April 28,1997
Correspondence:
Jaan Soplepmann, M.D.
Tartu University Hospital 
L. Puusepa 8 
EE2400 Tartu, Estonia 
Tel: +37 27 448234 
Fax: +37 27 448205
25

Soplepmann J, Peetsalu A, Peetsalu M, Tein A, Juhola M. 
Peptic ulcer haemorrhage in Tartu County, Estonia: epidemiology and
mortality risk factors. Scandinavian Journal 
o f  Gastroenterology 1997; 32: 1195-1200.
Peptic Ulcer Haemorrhage in Tartu County, Estonia: Epidemiology and 
Mortality Risk Factors
J. SOPLEPMANN, A. PEETSALU, M. PEETSALU, A. TEIN & M. JUHOLA
Second Dept, of Surgery, Tartu University Hospital, Tartu, Estonia, and Dept, of Pathology, Central
Hospital of Central Finland, Jyväskylä, Finland
Soplepmann J, Peetsalu A, Peetsalu M, Tein A, Juhola M. Peptic ulcer haemorrhage in Tartu County, 
Estonia: epidemiology and mortality risk factors. Scand J Gastroenterol 1997;32:1195-1200.
Background: The aim of the study was to assess the epidemiology and mortality risk factors of peptic ulcer 
haemorrhage (PUH) in Tartu County, Estonia. Methods: In a prospective unselected defined area study, 
data for 144 patients aged >15 years with new cases of PUH were analysed during a 2-year period. 
Results: The incidence of PUH was 57 per 100,000 adult population per year, increasing from 12 in 
patients aged 20-29 years to more than 135 in those >70 years. The incidence was 2.3-fold higher for men. 
The incidence of gastric ulcer haemorrhage was 26 (men, 33; women, 20) and that of duodenal ulcer 22 
(men, 39; women, 9). Of the women 72% and of the men 37% were >60 years. Nonsteroidal anti­
inflammatory drugs (NSAIDs) were used by 45% of the patients (64% of women, 36% of men). 
Helicobacter pylori infection was present in 93% of the duodenal ulcer patients and in 81% of the gastric 
ulcer patients. Mortality (8%) was related to age, shock, haemoglobin <80 g/1, cardiac comorbidity, and 
recurrence of haemorrhage. Conclusions: The incidence of PUH is relatively high owing to a high 
incidence among the younger population in Tartu County. Women with PUH are older, have consumed 
more NSAIDs, and have mainly gastric ulcer; men are younger, have consumed less NSAIDs, and are 
prone to duodenal ulcer haemorrhage. H. pylori infection is common in PUH patients. Mortality risk 
factors coincide with those reported by other researchers.
Key words: Epidemiology; haemorrhage; Helicobacter pylori; incidence; mortality; nonsteroidal anti­
inflammatory drugs; peptic ulcer
Jaan Soplepmann, M.D., Second Dept, of Surgery, Tartu University Hospital, Puusepa 8, EE-2400 Tartu, 
Estonia (fax: +372 7448205)
A continuous decrease in hospital admissions (1) and surgery 
(1-3) for peptic ulcer (PU) disease during recent decades has 
been repeatedly reported from different regions. However, 
emergency admissions and surgery for PU complications lack 
such a trend (1,3, 4).
Peptic ulcer haemorrhage (PUH) is estimated to have an 
incidence of 25-58 per 100,000 population per year (5, 6). 
The incidence rates of PUH are significantly higher in the 
elderly, and time trends show a continuous increase in the 
proportion of elderly persons (4).
Recent studies have pointed out the significant role of 
H elicobacter pylori and nonsteroidal anti-inflammatory drugs 
(NSAIDs) in ulcer development. NSAID consumption is 
related to an enhanced risk of ulcer haemorrhage (7, 8). The 
use of NSAIDs is increasing (9), and the elderly are more 
prone to take them owing to diseases of the locomotor system. 
The growing proportion of elderly persons could be a reason 
that the PUH mortality rates have persisted around 8-10% for 
decades. Still, some units have achieved death rates as low as 
3-5.5% (10-12).
The aim of our study was to establish the epidemiology of 
PUH, covering incidence, patient profile, H. pylori infection
rate, predisposing factors, mortality, and mortality risk factors 
in Tartu County, Estonia. No such information has been 
available about the region until now.
PATIENTS AND METHODS
A prospective unselected defined area study of PUH was 
carried out at Tartu University Hospital, Estonia, from 1 
January 1992 to 31 December 1993. Tartu County, with
160,000 inhabitants, served as a defined catchment area, since 
all patients with gastrointestinal haemorrhage from this 
county are treated only in Tartu University Hospital. Thus 
the incidence of PUH estimated by our study group is close to 
the actual rate.
The study included all departments of surgery and internal 
medicine and intensive care units. All patients >15 years of 
age with new cases of PUH during a year were included, 
either presenting with haemorrhage within 10 days of the first 
sign of bleeding or developing it during hospital treatment for 
some other disease.
During the study period a total of 271 new cases of upper
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Table I. Distribution of age groups in the population of Tartu County 
and the incidence of peptic ulcer haemorrhage per 100,000 
population per year
Age group, 
years
Share of 
the whole 
population (%)
Incidence of peptic 
ulcer haemorrhage
Men Women All
15-19 7.4 ___ ___ ___
20-29 16.2 22.5 — 11.5
30-39 13.5 23.7 9.0 16.2
40-49 11.5 150.1 15.4 78.8
50-59 11.6 132.7 43.9 83.6
60-69 10.0 150.9 76.4 105.5
70-79 5.3 209.7 102.4 135.6
>80 3.1 198.5 119.1 139.0
Total 78.5 82.7 36.1 57.1
gastrointestinal haemorrhage were recorded, of which PUH 
accounted for 144 cases (53.1%).
Haemorrhage was defined as haematemesis or melaena, a 
drop in the haemoglobin/haematocrit value, or clinical 
evidence of blood loss. PU as a cause of haemorrhage was 
established at endoscopy (139 cases), at operation (2 cases of 
urgent operation due to clinically active bleeding), or at 
autopsy (3 cases of exsanguination). Endoscopy was per­
formed within 48 h of admission, in most cases (77%) within 
24 h. PU was classified in accordance with location: gastric 
ulcer, prepyloric ulcer (within 0.5 to 3 cm proximal of the 
pyloric ring), pyloric ulcer, and duodenal ulcer. Shock was 
defined as systolic blood pressure <100 mmHg, and rebleed- 
ing as any sign of bleeding recurring within 10 days of 
admission.
All patients capable of adequate communication were 
questioned about their history and symptoms of ulcer disease, 
PUH, and other major diseases, and about smoking, alcohol 
consumption, NSAID use (both aminosalicylic acid (ASA)
and non-ASA), and signs of bleeding. An ulcer was 
considered asymptomatic when there were no complaints 
(epigastric pain or discomfort) typical of PU within 2 weeks 
before the onset of PUH. By NSAID use and alcohol 
consumption is meant the use of these agents within 48 h 
before the first sign of bleeding. Regular NSAID use is the 
daily use of these drugs for more than 1 week. Clinical data, 
results of laboratory analyses, and endoscopy, surgical, and 
autopsy findings were obtained from the case histories.
In 120 PUH cases 2 gastric mucosal biopsy samples were 
taken from the antrum and 2 from the corpus, stained in 
accordance with Giemsa, and investigated microscopically 
for the presence of H. pylori infection.
The evaluation of incidence was based on the publication 
of the Statistical Office of Estonia, ‘Population Age Structure. 
Towns and Counties of Estonia. January 1, 1995’. Incidence 
rates were calculated per 100,000 population per year.
The data were analysed by means of StatView Student for 
the Macintosh. Medians with 95% confidence intervals (Cl) 
were calculated for age. Absolute numbers were compared by 
means of the chi-square test with continuity correction.
RESULTS
Incidence
The incidence of PUH was 57.1 per 100,000 adults per 
year. It was 82.7 for men and 36.1 for women, with a 2.3-fold 
higher relative risk for men. Incidence rate (IR) increased 
considerably with age, from 11.5 in those aged 20-29 years to 
more than 135 in those >70 years (Table I). The incidence of 
gastric ulcer was 25.8 (men, 32.6; women, 20.2), of duodenal 
ulcer 22.2 (men, 38.7; women, 8.7), of prepyloric ulcer 5.5 
(men, 5.2; women, 5.7), and of pyloric ulcer 1.6 (men, 3.5; 
women, 0). The male to female IR ratio was 1.6:1 for gastric 
ulcer and 4.4:1 for duodenal ulcer.
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Tabic II. Predisposing factors of peptic ulcer haemorrhage by sex and age
Predisposing factors
Men Women All
n/patients (%) /i/patients (%) n/patients (%)
NSAID consumption 32/90 (35.6) 30/47* (63.8) 62/137 (45.3)
Age <60 years 19/57 (33.3) 9/14 (64.3) 28/71 (39.4)
Age >60 years 13/33 (39.4) 21/33 (63.6) 34/66 (51.5)
Regular NSAID use 15/90 (16.7) 16/47t (34.0) 31/137 (22.6)
Age <60 years 5/57 (8.8) 5/14 (35.7) 10/71 (14.1)
Age >60 years 10/ЗЗф (30.3) 11/33 (33.3) 21/66§ (31.8)
Alcohol consumption 12/93 (12.9) 2/46 (4.3) 14/139 (10.1)
Smoking 56/94 (59.6) 7/47Ц (14.9) 63/141 (44.7)
* P -  0.003 compared with men. 
t  P = 0.004 compared with men. 
t  P = 0.019 compared with men aged <60 years. 
§ P = 0.023 compared with all aged <60 years.
/* = 0.0001 compared with men.
Patient profile
There were 144 new cases of PUH during the study period, 
with a male to female ratio of 1.9:1 (94 men and 50 women). 
The median age of the patients was 59 (95% Cl, 56-62). The 
median age of male patients was 53.5 (95% Cl, 50-58), and 
that of female patients 66.5 (95% Cl, 63-71). Of the patients 
49.3% were >60 years old, and 72% of the women and 37.2% 
of the men were aged >60 years (P = 0.0001). Age and sex 
distribution is depicted in Fig. 1.
Helicobacter pylori infection
Of the PUH patients, 89.2% (107 of 120) had H. pylori 
infection. It was present in 100% (14 of 14) of prepyloric 
ulcer patients, in 93.5% (43 of 46) of duodenal ulcer patients, 
and in 81.1% (43 of 53) of gastric ulcer patients. The 
differences were not significant.
Predisposing factors  
Of the patients 17.9% (25 of 140) had previously had PUH, 
and 45% (63 of 140) had a previously verified ulcer diagnosis.
Altogether, 45.3% of the patients had used NSAIDs 48 h 
before the onset of bleeding, and half of these had been 
receiving regular NSAID treatment longer than 1 week. Of 
the patients 42.9% (6 of 14) of those with prepyloric ulcer 
versus 13.5% (7 of 52) of those with duodenal ulcer had been 
receiving regular NSAID treatment (P  = 0.038). For gastric
ulcer the percentage was 25.8 (16 of 62) without a significant 
difference from the above-mentioned ulcer locations. Data on 
NSAID use, smoking, and alcohol consumption are depicted 
in Table II.
Causes o f  haemorrhage
Gastric ulcer was the commonest cause of PUH (45.1%), 
followed by duodenal ulcer (38.9%) and others. The 
distribution of causes of haemorrhage differed between the 
sexes (Table Ш). Duodenal ulcer prevailed in men, and 
gastric ulcer in women.
Endoscopy showed active bleeding (Forrest I) in 10.1% (14 
of 139) of the patients, stigmata of recent bleeding (Forrest II) 
in 54.7% (76 of 139), and ulcer without stigmata (Forrest III) 
in 35.2% (49 of 139) of the patients.
Asymptomatic ulcers
In 27.3% (38 of 139) of the patients complaints (pain, 
epigastric discomfort) typical of PU were lacking. Of these, 3 
had active bleeding, 19 had stigmata of recent bleeding, and 
16 had ulcer without stigmata. In patients aged >60 years 
asymptomatic ulcer accounted for 32.8% (22 of 67) and in 
younger patients for 22.2% (16 of 72) of the cases, in regular 
NSAID users for 33.3% (10 of 30) and in nonusers for 27.2% 
(28 of 103) of the cases. Asymptomatic ulcer occurred in 
28.3% (26 of 92) of the men and in 25.5% (12 of 47) of the
Table III. Distribution of the causes of haemorrhage by sex in peptic ulcer haemorrhage patients
Diagnosis Men (%) Women (%) All (%)
Gastric ulcer 37 (39.4) 28 (56) 65 (45.1)
Duodenal ulcer 44 (46.8) 12* (24) 56 (38.9)
Prepyloric ulcer 6 (6.4) 8 (16) 14 (9-7)
Pyloric ulcer 4 (4.2) — 4 (2.8)
Marginal ulcer 2 (2.1) — 2 (1.4)
Others t 1 (1.1) 2 (4) 3 (2.1)
Total 94 (100) 50 (100) 144 (100)
* /* = 0.013 compared with duodenal ulcer in men.
t  Combined ulcers: one patient with prepyloric and gastric ulcer, two patients with prepyloric and duodenal ulcer.
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Table IV. Mortality risk factors in patients with peptic ulcer haemorthage
Risk factors No. of patients n
Mortality
% Chi-square, P
Sex: men/women 94:50 5:7 5.3:14.0 0.140
Age: >65/<65 years 54:90 9:3 16.7:3.3 0.013
Gastric ulcer/duodenal ulcer 65:56 8:3 12.3:5.4 0.313
Previous PUH/no 25:109 1:7 40:6.4 0.994
NSAID use/no 62:75 6:3 9.7:4.0 0.323
Age <65 years, regular NSAID therapy/no 14:73 2:1 14.3:1.4 0.104
Age >65 years, regular NSAID therapy/no 17:33 3:3 17.6:9.1 0.673
Haematemesis/no 63:73 8:2 12.7:2.7 0.059
Shock/no 22:114 7:5 31.8:4.4 0.0002
Pulse rate <10Q/>100 85:47 7:4 8.2:8.5 0.784
Haemoglobin <100 (g/l)/> 100 85:59 9:3 10.6:5.1 0.385
Haemoglobin <80 (g/l)/>80 40:104 7:5 17.5:4.8 0.033
Major cardiac disease/no 21:121 7:3 33.3:2.5 0.0001
Admitted <24/>24 h after PUH 66:71 7:4 10.6:5.6 0.450
Forrest I/Forrest II, III* 14:125 3:6 21.4:4.8 0.068
Recurrent haemorrhage/no 27:117 8:4 29.6:3.4 0.0001
* Forrest I = active bleeding; Forrest П = stigmata of recent bleeding; Forrest III = no stigmata of recent bleeding. PUH = peptic ulcer 
haemorrhage; NSAID = nonsteroidal anti-inflammatory drug.
women. Of the duodenal ulcers 28.3% (15 of 53) and of the 
gastric ulcers 19.0% (12 of 63) were asymptomatic. None of 
these differences proved to be statistically significant.
M ortality and m ortality risk factors
The overall mortality of PUH patients was 8.3%. The 
median age of the patients who died was 66 (95% Cl, 59-73 
years) and that of the patients who survived 57 (95% Cl, 54— 
62 years). Patients aged >65 years accounted for 75% of the 
deaths. The death rate was 4.8 per 100,000 adult population 
per year.
The mortality was significantly related to older age, shock, 
haemoglobin <80 gЛ, severe cardiac comorbidity, and 
recurrence of haemonhage during treatment (Table IV).
DISCUSSION
PU is the commonest cause of gastrointestinal haemorrhage. 
This fact, the latest data on ulcer pathogenesis, and new 
prevention and treatment modalities have aroused increased 
interest in the epidemiology of PUH. Most studies indicate 
that PU is responsible for at least half of all bleeding episodes 
from the upper gastrointestinal tract (13, 14). Our study 
confirms these data, with PUH accounting for 53.1% of all 
haemorrhage cases.
The incidence of PUH was 57.1 per 100,000 adult 
population per year in Tartu County, Estonia. This level can 
be considered high compared with the range of 25-58 per
100,000 per year as estimated by other researchers (5, 6). 
Haemonhage has been found to affect elderly persons 
disproportionately (4). Indeed, IR rose significantly with 
age in our study, being 10-fold higher for patients aged >70 
years (more than 135 per 100,000 per year) than for those 
aged 20-39 years (11.5 per 100,000 per year). Incidence was
higher for men in all age groups. The same age- and sex- 
related differences have been noted in a German (15) and a 
U.S. study (6). In women increase in IR with age was steady, 
whereas in men a sharp sixfold increase in IR appeared in the 
age group 40-49 years as compared with younger patients in 
Tartu County (Table I). In the German study IR showed a 
more uniform growth. Compared with our study, overall IR 
was twice as low for patients aged <50 years, equalized for 
those aged 50-79 years, and was twice as high for those >80 
years. The U.S. study shows a very high incidence (242 per
100,000 per year) in patients more than 65 years of age as 
compared with the respective rate in Tartu County.
Several studies have found that gastric ulcer is a more 
frequent cause of PUH than duodenal ulcer (14, 15), whereas 
others report the contrary (16). In our study gastric ulcer 
haemorrhage had the highest overall incidence, followed by 
duodenal ulcer and prepyloric ulcer. However, in men 
duodenal ulcer incidence was higher, whereas in women 
gastric ulcer prevailed, and the incidence of duodenal ulcer 
was low, close to that of prepyloric ulcer.
The distribution of PUH patients (Fig. 1) shows a 
predominance of younger men and elderly women: 72% of 
the women and 37.2% of the men were aged >60 years. 
Several studies show a high proportion of the elderly among 
PUH patients. In studies from the United Kingdom 81% (12) 
and 74% (16) of the patients were aged >60 years; in an 
Australian study their share was 69% (17). In the Tartu region 
the proportion of patients aged >60 years, 49.3%, was lower 
than in the mentioned studies. This difference can be partly 
explained by the lower proportion of elderly persons in the 
whole population of Estonia. The other possible contributing 
factor is high H. pylori infection rate among the inhabitants of 
Estonia. The role of H. pylori in PU development has recently 
been established. It has been shown that eradication of this
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bacterium reduces ulcer recurrence (18, 19) and bleeding 
relapses (18, 20). It is suggested that H. pylori infection rate 
depends on the socioeconomic level. According to the United 
Nations ‘Human Development Report 1994’, Estonia ranks 
behind developed countries with regard to the level of 
socioeconomic development. This could be the reason why
H. py lo ri infection is commoner in Estonia than in Western 
countries, affecting 73-87% of the population in three regions 
studied (21). Even younger people from cohorts bom in 
1955-70 had infection rates as high as 68—83% (21, 22). 
Comparable data from Western countries show significantly 
lower H. pylori infection rates among those bom in recent 
decades, ranging from 10% to 20% (23). The high H. pylori 
infection rate might result in a high prevalence of PU disease 
and account for the subsequent higher PUH rate among the 
younger population found in our study.
H. py lo ri infection was frequently observed in the gastric 
mucosa of PUH patients. Its presence was slightly higher in 
prepyloric and duodenal ulcer patients than in gastric ulcer 
patients.
The recently reported somewhat lower NSAID consump­
tion among the population of Estonia than in developed 
countries (24) may have an impact on age distribution, as 
these drugs are more often used by the elderly. This could 
explain the lower IR among the elderly compared with other 
countries (6, 15).
NSAID use has been established as carrying enhanced risk 
of PU genesis and of PUH development. Studies show the use 
of these drugs in 34.6% to 89% (12,25) of cases. According to 
our study, 45.3% of the patients had used NSATOs before the 
onset of bleeding. Regular NSAID treatment before PUH was 
significantly more often observed in the elderly. Women used 
these drugs considerably more frequently than men. In case 
patients with PUH, presumably caused by NSAIDs, were 
excluded, the discrepancy between the male to female 
incidence ratio (2.3:1) would be even greater. Could such 
a sex-related difference be caused by other factors like 
stress, smoking, and alcohol consumption? Of the possible 
predisposing factors of ulcer haemorrhage, smoking was 
significantly more frequent in men than in women in our 
study.
NSAIDs seem to be more related to prepyloric and gastric 
ulcers than to duodenal ulcers (7, 9). Our study confirms this 
finding: the proportion of regular NSAID users among 
patients with prepyloric ulcer (42.9%) was slightly higher 
than among gastric ulcer patients (25.8%) and significantly 
higher than among duodenal ulcer patients (13.5%).
In one-fourth of the patients from Tartu County haemor­
rhage developed from asymptomatic ulcers. Asymptomatic 
ulcers present a major problem, as no preventive measures 
can be applied against life-threatening ulcer complications. It 
has been found that in older people ulcer symptoms can be 
vaguely expressed, and NSAID use is often present in such 
cases (26). The presence of ulcer symptoms was not related to 
NSAID use in a previous study (7). According to our study,
ulcer symptoms before bleeding were not related to age, sex, 
diagnosis, or NSAID use.
The mortality rates of PUH vary widely, from 3% (10) to 
16.9% (27). Although not close to the lowest rates, the 8.3% 
mortality in Tartu County is comparable to rates observed in 
most centres. Some authors have reported lower mortality 
rates, relating it to specialized unit management, strict 
protocol (11), aggressive approach (28), and restrictive blood 
transfusion policy (29).
In our patients death was associated with higher age, shock, 
haemoglobin level <80 g/1, major cardiac disease, and 
recurrent bleeding. These risk factors coincide with those 
established by other researchers (12, 16, 17).
To conclude, our study indicates that despite the lower IR 
of PUH in the elderly and owing to the higher IR in the 
younger population, the overall incidence is relatively high in 
our study compared with that reported from elsewhere. These 
differences could be the result of the synchronous interaction 
of different factors. Lower NSAID consumption among the 
Estonian population and higher prevalence of H. pylori 
infection among the young seem to play the key role. 
Unfortunately, no time-related data are currently available 
for the region. Therefore further studies directed to changes in 
epidemiology would be of importance.
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Long-term results of peptic ulcer haemorrhage
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Summary
Ainu. To assess the long-term follow-up results of patients treated 
operatively and conservatively for peptic ulcer haemorrhage (PUH). 
Patients and methods. In a prospective non-randomised study, 163 
PUH patients, of whom 61 had passed definitive operative procedu­
res and 102 had been treated conservatively (intermittent therapy 
with Hj blockers after hospital treatment), were assessed for morta­
lity, causes of death, ulcer recurrence and ulcer haemorrhage two 
years after discharge from hospital.
Results. 18 patients died due to causes unrelated to ulcer complica­
tions.
Excellent and good results were obtained in 40% (34/86) of the 
conservatively treated and 79% (37/47) of the operatively treated 
patients. In 49% (42/86) of conservatively treated patients, recur­
rence of peptic ulcer was diagnosed during follow-up and 14 of 
them re-bled within two years. O f the operatively treated patients 
13% (6/47) suffered from recurrent ulcer and three of them had 
another haemorrhage during follow-up.
Conclusions: Intermittent H2 blocker therapy after hospital treat­
ment for PUH fails to control recurrence of peptic ulcer and ulcer 
haemorrhage. Definitive operations for PUH are efficient in avoi­
ding recurrence of peptic ulcer and its complications in long term.
Key words peptic ulcer haemorrhage, long-term results, operative 
treatment, H2 blockers.
The world-wide tendency o f decline in hospital treat­
ment and surgery (1-3) o f uncomplicated peptic ulcer di­
sease has not been reflected either in the frequency of 
peptic ulcer haemorrhage (PUH) or in the need for sur­
gical intervention due to PUH (1,3,4).
For decades the greatest concern has been reducing 
hospital morbidity and mortality o f PUH patients. Few 
works have emphasised the importance of long-term re­
sults, therefore, we studied the two-year follow-up results 
of the patient treated conservatively and operatively for 
PUH.
Patients and methods
During a period o f 2,5 years (1.01.92 - 30.06.94) a 
prospective non-randomisea study of long-term results of 
peptic ulcer haemorrhage has been carried out at Tartu 
University Hospital, Estonia. Inclusion criteria were age, 
> 15 years, and residence in Tarty county (160,000 inha-
Received September 3, 1999; accepted November 11, 1999
bitants) where Tartu University Hospital is the only ho­
spital serving gastrointestinal haemorrhage patients. Pep­
tic ulcer, as the source of haemorrhage, was established 
endoscopically and a total of 170 patients were treated 
for PUH on 184 occasions.
To investigate the long-term results o f PUH only the 
first occasions o f either conservative or operative treat­
ment during the 2,5-year period were included. Six pa­
tients managed conservatively on the first occasion had 
another haemorrhage requiring operation, they were in­
cluded both in the conservatively and operatively treated 
roups for follow-up. 13 patients, who died during the 
ospital stay were excluded; two o f them had passed 
emergency operation and 11 had been treated conservati­
vely.
There were 163 patients left for analysis, o f whom 61 
had been operated and 102 had been treated conservati­
vely. O f the 102 patients treated conservatively 67 were 
men and 35 were women, their mean age was 58.4 (SE ±
1.66). O f the 61 patients treated operatively 45 were 
men and 16 were women, their mean age was 55.2 (SE ±
1.73). Emergency operations had been undertaken in 21 
patients for persistent or recurrent bleeding. In 40 pa­
tients early elective operation after stabilisation of the 
condition had been carried out. The indications were 
giant and/or penetrating ulcer with a visible vessel or 
adherent clot, previous episodes o f ulcer bleeding, steno­
sis, and need for regular extensive NSAID therapy In all 
cases definitive operations with ulcer removal were 
performed. In gastric ulcers partial gastrectomy was car­
ried out. Praepyloric ulcers were treated with partial ga­
strectomy or truncal vagotomy with antrumectomy. In 
case o f duodenal ulcer, vagotomy (truncal or proximal se­
lective vagotomy) with either antrumectomy or ulcer ex­
cision with pyloroplasty according to Holle were used. 
Conservatively treated patients passed a 4-6-week H 2 
blocker treatment after discharge from hospital and were 
thereafter all on intermittent treatment on demand. No 
Helicobacter pylori eradication was used. Two years after 
hospital treatment data were collected for assessment of  
long-term results.
Data on mortality and causes o f death for the two- 
year follow-up were obtained from the Registry Office o f  
Tartu County Government. Data on recurrence of hae­
morrhage during two years from hospital treatment were 
obtained from statistical database o f  Tartu University
177
28
J .  So p lep m an n  c i al.
Hospital. In a mean time of 17 months (range 12-31 
months) the patients who had neither died nor suffered 
from recurrent haemorrhage passed a follow-up examina­
tion in which their subjective quality of life was assessed 
using a questionnaire. O f these patients 86% (100/116) 
agreed to undergo endoscopic investigation. The results 
were graded according to a modified Visick scale. Visick 
I = excellent: no symptoms; Visick II = good: mild symp­
toms without impact either on the quality of life or abi­
lity to work; Visick III - satisfactory: moderate symptoms 
causing a certain degree o f discomfort or disability; Vi­
sick IV = poor: severe symptoms or recurrent ulcer. Eigh­
teen patients, o f whom rive had passed the follow-up 
examination, died within two years from hospital treat­
ment. Seven o f the conservatively treated patients and 
ten o f the operatively treated patients were lost during 
follow-up (90% follow-up rate).
Chi-square test with continuity correction was used 
for statistical analysis.
Results
During the two-year follow-up period there were no 
deaths related to peptic ulcer haemorrhage. Eleven of the 
conservatively treated and seven o f the operatively treated 
patients died due to different causes: cardiovascular di­
sease (9 cases), malignancies (5 cases), cerebrovascular di­
sease (2 cases), liver failure (1 case) and drowning (1 ca­
se). Recurrence o f ulcer bleeding within two years occur­
red in 16% (14/86) o f the conservatively treated and in 
6% (3/47) o f the operatively treated patients (Table 1). 
There were no ulcer perforations during the follow-up. 
Severe symptoms of peptic ulcer disease and/or recurrent 
ulcer w ithout com plications were observed in 33%  
(28/86) o f the conservatively treated and in 6% (3/47) o f  
the operatively treated patients. Excellent and good re­
sults were obtained in 40% (34/86) o f the conservatively 
treated and in 79% (37/47) o f the operatively treated pa­
tients.
Discussion
The surgeon dealing with peptic ulcer haemorrhage is 
faced with multiple tasks among which the first ones are 
the stabilisation of patient s condition and the reduction 
of the risk of recurrent bleeding in the attempt to dimi­
nish mortality. These tasks, often discussed by resear­
chers, are accomplished with the use o f transfusion, en­
doscopic therapy, medication and definitive or non-defi­
nitive operation. The further goal is to prevent ulcer rela­
pse ana subsequent ulcer complications in long term 
performing medical therapy or definitive operative treat­
ment. However, long-term results of PUH have been ra­
rely assessed in the literature.
In a Hong Kong study (5) the risk of further ulcer 
complication, both haemorrhage and perforation, has 
been found to be as high as 32% over a median follow- 
up period of 36 months. The patients were treated with 
H2 blockers until ulcers healing and received no mainte­
nance therapy thereafter. In a similar study 13% of pa­
tients on intermittent H2 blocker therapy re-bled during 
a mean follow-up of 48 months (6). Tne latter study re­
ports the 6% late complication rate of peptic ulcer in de­
finitively operated patients.
Similarly further haemorrhage occurred in 16% of the 
conservatively treated and in 6% of the operatively trea­
ted patients during the two-year follow-up period in our 
series. However, the difference was not statistically signi­
ficant. Intermittent therapy with H 2 blockers after con­
servative hospital treatment resulted in nearly 50% of re­
currence of ulcer bleeding, ulcer relapse or severe symp­
toms and 40% of excellent and good results. This unsati­
sfactory outcome indicates that intermittent therapy after 
PUH rails to control peptic ulcer disease and funner hae­
morrhage in lone term, and should not be advocated for 
patients. Ranitidine administered in a maintenance regi­
men has revealed the capacity to reduce both duodenal 
ulcer relapse and further ulcer bleeding (7). However, li­
felong maintenance therapy for all ulcer haemorrhage pa­
tients is expensive. The recent advent of drugs for Helico­
Table 1 Long-term results o f treatment o f peptic ulcer haemorrhage patients.
Long-term results Conservatively 
treated patients 
No (%)
Operatively 
treated patients 
No (%)
Chi square
(P)
Visick I* 17 (19.8%) 22 (46.8%) p=0.0021
Visick II 17(19.8%) 15 (31.9%) p=0.1756
Visick III 10(11.6%) 4 (8.5%) p=0.79l5
Visick IV 42 (48.8%) 6(12.8% ) p=0.0001
-  with bleeding 14 (16.3%) 3 (6.4%) p=0.1731
-  without bleeding 28 (32.6%) 3 (6.4%) p=0.0014
Deaths related to ulcer bleeding 0 0
* For Visick grading, see Patients and Methods
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bacter pylori eradication has expanded the possibilities o f 
treating peptic ulcer disease. The first long-term results 
of the use o f these drugs after complications appear to be 
promising (8,9). Some authors claim that definitive ulcer 
surgerv should be avoided in PUH patients (10) and that 
only the undersewing o f bleeding vessel and its branches 
should be performed (11). We are o f the opinion that 
when operative treatment is indicated, definitive proce­
dures with ulcer removal should not be abandoned as 
they provide an immediate and complete control o f the 
bleeding site as well as good long-term results. In our 
study excellent and good long-term results were achieved 
in 80% o f the patients. Definitive operative treatment is 
also a safe procedure. N o hospital deaths resulted from 
early elective operation in our patients. The two patients 
who died has passed emergency operation.
However, although the late prognosis for patients di­
scharged from hospital after treatment due to PUH is 
poor, most deaths cannot be attributed to recurrent ulcer 
bleeding (12,13). In our study 18 patients died within 
two years from hospital treatment due to reasons unrela­
ted toUH. Deaths resulted mainly from cardiovascular 
disease (9/18) and malignancies o f various locations 
(5/18). Among the latter cases, one patient had been dia- 
nosed with praepyloric ulcer during hospital treatment 
ut died of gastric cancer. Obviously, cancer diagnosis 
had been previously missed.
Conclusion
To conclude, in patients with PUH the long-term ef­
fect of treatment should always be considered. Intermit­
tent H 2 blocker therapy is inadequate and should be 
avoided. In the Centres with experience in gastroduode­
nal surgery, definitive operations should not be abando­
ned in the treatment or PUH patients. Good long-term 
results can be achieved applying these procedures direc­
ted to the pathogenesis or ulcer disease.
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ABSTRACT
Background: To assess long-term results of the surgical treatment of giant duo­
denal posterior wall ulcers penetrating into the pancreas, complicated with 
hemorrhage.
Patients and methods: During 1984-1993, 16 patients were operated using 
procedures exteriorizing the giant ulcer base from the duodenal lumen. In 13 
cases duodenal resection with plasty and in 3 cases antrectomy was performed, 
both combined with vagotomy. Long-term results were evaluated clinically and 
endoscopically according to the Visick scale 7-16 years (mean 11 years) after 
operation in 10 patients. Four patients had died from causes unrelated to peptic 
ulcer or operation.
Results: Long-term results were excellent or good in 90% (9/10) of the 
cases. In one patient the long-term result was assessed as satisfactory. Endo­
scopy revealed no cases of ulcer recurrence.
Conclusions: Ulcer base exteriorizing operations, i.e. duodenal resection 
with plasty and antrectomy, combined with vagotomy, yield good long-term re­
sults in the case of giant duodenal posterior wall ulcers penetrating into the 
pancreas, complicated with hemorrhage.
Keywords
Giant duodenal ulcer; penetration; hemorrhage; surgical treatment; long-term 
results
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INTRODUCTION
The incidence of peptic ulcer hemorrhage varies from 25 to 58 cases per 
100, 000 per year [1,2]. In Estonia, the incidence is high, 57 cases per 100 000 
adults per year [3]. The need for the surgical treatment of ulcer hemorrhage has 
significantly decreased mainly owing to the use of endoscopic management 
both elsewhere [4,5] and in Estonia [6].
When bleeding cannot be stopped endoscopically, or when it recurs after 
repeated endoscopic procedures, operative management is indicated.
The aim of the surgical treatment of hemorrhage is to stop bleeding, to re­
move the cause of bleeding, to prevent complications including bleeding recur­
rence, as well as to obtain good long-term outcome. Since 1977, our method of 
choice in duodenal ulcer hemorrhage has been excision of ulcer(s), and form 
and function preserving pyloro- or duodenoplasty after Holle plus vagotomy. 
This has yielded good or excellent long-term results in 86% of cases, with ulcer 
recurrence in 10% of cases on average 8 years after operation [7].
The most complicated phase of the operation is ulcer excision, particularly in 
the case of giant (larger than 2 cm in diameter) duodenal posterior wall ulcers 
penetrating into the pancreas, which are often combined with stenosis. The 
operation is time consuming, with the probability of intraoperative bleeding and 
with the danger of damaging the bile ducts and the pancreas; development of 
postoperative pancreatitis is possible. To avoid these problems, we have since 
1984 introduced duodenal resection with plasty after Helwing et al. [8], com­
bined with vagotomy (DPV) and antrectomy with reconstruction after Herfarth 
et al. [9], combined with vagotomy (AEV). In these methods, giant duodenal 
posterior wall ulcers penetrating into the pancreas are not excised but exteriori­
zed, i.e. the ulcer base is left out of the duodenal lumen.
The aim of this investigation was to assess long-term results in patients 
operated for giant duodenal posterior wall ulcers penetrating into the pancreas, 
complicated with hemorrhage, using the methods of Helwing and Herfarth, 
combined with vagotomy.
PATIENTS AND METHODS
I. Patients
Between 1984 and 1993, 16 patients were operated at the Department of 
Abdominal Surgery of Tartu University Clinics for giant duodenal posterior 
wall ulcer penetrating into the pancreas, complicated with hemorrhage, using 
DPV in 13 cases and AEV in 3 cases. Giant duodenal ulcers were defined as 
ulcers larger than 2 cm in diameter [10]. Patient data were obtained retrospec­
tively from the computer database of the Clinics. The age of the patients at the
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time of operation was 29-74 years (mean 55 years). There were three female 
and thirteen male patients. Endoscopy had been performed in all patients 
preoperatively and the type of hemorrhage was classified according to the For­
rest classification. Four of the patients had persistent bleeding (Forrest I); nine 
had stigmata of recent bleeding: a visible vessel, a clot in the ulcer base (Forrest 
II); three patients lacked stigmata of recent bleeding (Forrest Ш). Stenosis due 
to giant ulcer occurred in 10 patients of 16.
2. Operative methods
2.1. DPV after Helwing
The duodenum is mobilised employing Kocher maneuver. Further, hemipylo- 
rectomy is performed with two semicircular incisions, one above and the other 
below the pylorus (Fig.la). A giant duodenal posterior wall ulcer becomes 
visible (Fig. lb). Current bleeding is stopped by oversewing of the bleeding 
vessel. The proximal part of the duodenum is mobilised from the ulcer and the 
pancreas by severing the duodenum proximal to the ulcer (Fig. lc). In the case 
of stenosis, a circular resection of the stenosed region is performed. Thus two 
separate ends are formed, one on the gastric side and the other on the duodenal 
side. The posterior wall is then sutured in a one-row manner through all layers 
of the posterior wall of the gastric end to the distal edge of the giant ulcer with 
the posterior wall of the duodenal end (Fig. Id). Thus the mobile posterior 
gastric wall is shifted to cover the ulcer base, leaving it out of the duodenal 
lumen, i.e. the ulcer base is exteriorized (Fig. le). Then the anterior wall is 
closed by a two-row suture (Fig. If). Further, vagotomy is carried out.
2.2. AEV after Herfarth
Kocher maneuver is performed to mobilize the duodenum. Further, antrectomy 
is done so that the base of the giant ulcer remains on the pancreas. Current 
bleeding is stopped by oversewing of the bleeding vessel. Then the gastric 
stump is closed leaving an opening for the anastomosis. The posterior wall of 
the opening of the gastric stump is fixed by one-row sutures, involving all 
gastric layers, to the distal edge of the ulcer and the back wall of the duodenum 
(Fig. 2a). In this way the posterior wall of the gastric stump is shifted to cover 
the ulcer base, while the latter is left out of the lumen, i.e. is exteriorized (Fig. 
2b). Then the two-row suturing of the anterior wall will restore the integrity of 
the digestive tract (Fig. 2c). Further, bilateral truncal vagotomy is performed.
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Fig. 1. Duodenal resection with plasty after Helwing. (A) Two semicircular incisions for 
opening o f the duodenum. (B) A giant duodenal posterior wall ulcer is exposed. (C) 
Severing o f the duodenum proximal to the ulcer. (D) The posterior wall is sutured, the 
gastric end to the distal edge of the ulcer. (E) The posterior wall sutures in place. The 
ulcer is exteriorized. (F) The anterior wall is sutured.
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Fig. 2. Antrectomy after Herfarth. (A) Antrectomy has been performed. The posterior 
wall is sutured, the gastric end to the distal edge of the ulcer. (B) Posterior wall sutures 
are completed. The ulcer is exteriorized. (C) The anterior wall is sutured.
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3. Methods of assessment of long-term outcome
The retrospectively selected series of 16 patients was studied prospectively 
thereafter. All the patients were invited for outpatient follow-up between 2000 
and 2001. Long-term results were assessed 7-16 years (mean 11 years) after the 
operation. Nine patients turned up for the follow-up and one more patient 
agreed with a telephone interview. Four patients had died from causes unrelated 
to peptic ulcer or operation during the years that had passed from the operation. 
This was established on the basis of the death certificates obtained from the 
Population Registry. Two patients were lost to follow-up.
On follow-up the results were assessed according to a modified Visick scale 
[11] and an endoscopic investigation was performed. The Visick scale estimates 
were the following:
Visick I -  excellent: no symptoms
Visick II -  good: mild, no disturbing symptoms interfering with normal life or 
work
Visick III -  satisfactory: mild or moderate symptoms causing a certain degree 
of discomfort or disability 
Visick IV -  poor: severe symptoms or recurrent ulcer on endoscopy 
On endoscopic investigation the status of the esophageal, gastric and duodenal 
mucosa was assessed for presence of recurrent ulcer and for the status of the 
anastomosis. Endoscopy was performed by a single experienced endoscopist. 
Informed consent was obtained from each subject before entering the study.
RESULTS
The results of the investigation show that 7-16 years (mean 11 years) after 
operation long-term results were excellent or good in 90% (9/10) of cases 
according to Visick. In one patient the long-term result was assessed as 
satisfactory. Endoscopy revealed no cases of ulcer recurrence. The anastomoses 
after DPV and AEV were sufficiently wide in all cases.
DISCUSSION
Giant duodenal posterior wall ulcers penetrating into the pancreas are often the 
cause of severe hemorrhage, primarily owing to the erosion of a. gastro- 
duodenalis [12]. In such cases the choice of the operative method is compli­
cated, particularly when ulcer hemorrhage is accompanied with stenosis of the 
pyloroduodenal zone.
The results of our investigation demonstrate that in these cases, excellent or 
good long-term results without ulcer recurrence can be obtained in 90% of cases
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with the application of DPV or AEV. An earlier study of 15 patients by 
Helwing et al. [8], yielded good results in all cases 8-24 months after operation. 
Our results confirm good outcome for the first time for a much longer period, 
on average 11 years after operation.
In our opinion, the important determinant accounting for the achievement of 
such good long-term results with the use of Helwing's method is the focus on 
the salvaging resection of the pyloroduodenal region together with form and 
function preserving plasty after H olle's concept [13,14]. Holle's pyloroplasty, 
though not widely used, showed good long-term results in our earlier study [11] 
and has also been recommended recently by other researchers [15]. According 
to Holle's concept, duodenal posterior wall ulcer is excised. This is feasible in 
the case of relatively small ulcers. However, in the case of giant ulcers 
penetrating into the pancreas, there arise technical problems. DPV, which uses 
the exteriorizing of the ulcer base, enables to skip possible hazards and is 
technically simpler compared with ulcer excision. At the same time, stenosis 
from scarring around the ulcer, which, according to our present study is 
frequent, can be simultaneously excised.
Our data show that DPV in the case of a bleeding giant duodenal posterior 
wall ulcer can prevent several postoperative complications that may develop 
with the use of other widely used operative techniques.
Some authors have recommended, in duodenal posterior wall ulcer hemorrhage, 
the oversewing of the bleeding vessel with or without pyloroplasty, combined 
with vagotomy [16, 17]. However, a significant drawback of oversewing is 
occurrence of early recurrent hemorrhage in up to 17-23% of operated patients 
[18,19], with high mortality [19,20].
Bumm and Siewert [21] recommend to combine the oversewing of the 
bleeding vessel in the ulcer base, through duodenotomy, with the extraluminal 
ligation of a. gastroduodenalis, a. gastroepiploica dextra and a. pancreatoduode- 
nalis. Although postoperative mortality in this case has been reported as 3-6%, 
long-term results obtained with this method are not available. Besides, one 
should also take into account that the mere ligation of the bleeding vessel, or the 
oversewing of the ulcer does not eliminate stenosis due to giant ulcer.
As an alternative, Billroth П gastric resection is performed in giant duodenal 
ulcers [18]. However, we consider that Billroth П gastric resection is less 
appropriate than Billroth I type resection because of the possibility of duodenal 
leakage following the atypical closure of the duodenal stump, as well as a 
significantly more frequent occurrence of postgastrectomy syndromes. There­
fore, AEV with Billroth I reconstruction after Herfarth should be recommended, 
where the base of the giant penetrating ulcer is not excised but exteriorized [9], 
together with truncal vagotomy. A similar method has also been suggested by 
Herrington and Davidson [22]. Our earlier study of long-term outcome on aver­
age 8 years after operation shows that truncal vagotomy with antrectomy in 
duodenal ulcer patients yields excellent and good results without ulcer re­
currence in 98% of cases [11].
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Recent studies have shown that H. pylori eradication results in low recurrent 
bleeding in cases of conservatively treated peptic ulcer hemorrhage [23,24]. 
These findings have encouraged some authors to question performance of 
operations with vagotomy in duodenal ulcer hemorrhage [25,26]. Would it be 
right to resort to minimal surgery i.e. to attack only the bleeding vessel without 
vagotomy and to rely on H. pylori eradication? However, as Millat et al. have 
pointed out, the prevalence of H. pylori in bleeding peptic ulcers is not well 
defined and has been assessed to be lower than in uncomplicated ulcers [27]. 
The success of H. pylori treatment has been reported to be 70-80% [28]. 
Besides, development of giant duodenal ulcers has been associated with the use 
of NSAIDs [10], representing one of the main risk factors for peptic ulcer 
bleeding [29]. Moreover, NSAID induced ulcer hemorrhage can develop 
without H. pylori infection. Therefore, we agree with the viewpoint of Stabile 
and Stamos that until now no data support the efficacy of operation for bleeding 
duodenal ulcer that does not include vagotomy [30]. Our good long-term results 
from recent and present studies also serve as an argument for the use of 
vagotomy.
CONCLUSIONS
Ulcer exteriorizing operations with vagotomy yield good long-term results in 
giant duodenal posterior wall ulcers, penetrating into the pancreas, complicated 
with hemorrhage.
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Eesti Arst 2 0 0 2 ; 8 1 (8 ) ; 4 6 8 - 4 7 2
M uutused peptilise h a a v a n d i verejo ok su ra v is
J a a n  S o p lep m a n n 1, M argot P eetsa lu 2, Toom as S illa k iv i2, A ndres Tein2, T o o m as V ä li2, 
A nts P e etsa lu2 -  TÜ Kliinikumi 'hematoloogia-onkoloogia kliinik, kirurgiakliinik
peptiline  haavand, verejooks, endoskoopiline ravi, kirurg iline  ruvt, suremus
P ep tilise  h a a v a n d i v e re jo o k su  ra v ita k t ik a  on v iim aste l aastak ü m n e te l kog u m aa ilm a s  m uutunud - 
k u i v a ra se m a te l aastate l k asu tati ve re jo o k su  e fe k tiiv se k s  p eetam iseks k iru rg ilist rav i, s iis  nüüd on  
jä r je s t  e n a m  k a su tu se l e n d o sk o o p ilin e  m eetodi. See  on  k a a s a  to o n u d  k a  h o sp ita lis e e r im is e  ja  
su re m u se  m õ n in g ase  v ä h e n e m ise . Se lle s  u urin g u s on v õ rre ld u d  k ah e l a ja p e rio o d il, 1 9 9 2 -1 9 9 3  ja  
1 9 9 9 -2 0 0 0 , TÜK k iru rg iak liin ik u s rav il v iib inud  peptilise h a a v a n d i v e re jo o k su g a  h a ig ete  stru ktuu ri, 
r a v it a k t ik a t  ja  -tu lem usi.
Kogu maailmas väheneb peptilise haavan di (PH) 
tõttu hospitaliseeritute hulk ( 1 ). Viimase paarikümne 
aastaga on peptilise haavandi plaanilise kirurgilise 
rav i va ja d u s  vähenenud  mitu ko rda  (1, 2 ). 
Vähenemine on sedavõrd drastiline, et kirjutatakse 
p la a n ilis e s t m a o k iru rg ia s t kui ka d u vas t 
p ro tseduuris t (3). Kontrastiks ee lneva le  po le  
muutunud PH tüsistuste, vere jooksu esinemis­
sagedus ning selle tõttu hospitaliseerimine (1, 2). 
Peptilise haavandi verejooksu (PHV) esinemis­
sagedus m aailmas on 2 5 -5 8  juhtu 100 0 0 0  
inimese kohta aastas (4, 5). Eesti vastav näitaja on 
suur: 5 7  juh tu  100  0 0 0  tä iskasvanu kohta  
aastas (6). Vanemaealiste seas on selle tüsistuse 
esinemissagedus oluliselt suurem ning vanema­
ealiste osakaal kõigist PHV-haigetest on pideva 
kasvutendentsiga. Mitmed autorid on seisukohal, 
et vere jooksuga haigete suremus on viim aste 
aastakümnete jooksul vaatamata diagnostika ja 
ravi tõhustum isele püsinud muutumatuna 10% 
piires (7).
O n teada, et 8 0 -8 5 % -l PHV juhtudest on 
verejooks enne haiglasse saabumist iseeneslikult 
seiskunud. Kirurgilisest vaatevinklist on probleemiks 
jätkuva verejooksuga patsiendid ning need, kellel 
tekib ha ig larav il olles korduv verejooks. Uuringud 
on näidanud, et ainult medikamentoosse raviga ei 
o le võim alik käigusolevat verejooksu seisata ega 
haiglaravi ajal korduvat verejooksu vältida (8). Veel
paarküm m end  a a s ta t ta g a s i o li h a a v a n d i 
vere jooksu ainukeseks efektiivseks peetam is- 
meetodiks operatsioon. Hemostaasi saavutamine 
endoskoopilisel teel on PHV-haigete ravis o lu line 
eda s im in e k . V iim ase l a a s takü m n e l on 
e n d o s k o o p ilin e  rav i (ER) tänu  tõ e n d a tu d  
efektiivsusele muutunud laialdaselt kasutatavaks.
Uuringu eesmärgiks o li iseloomustada PHV 
ravitaktika muutusi ja selle tulemusi Tartu Ü likooli 
K liin iku m i (TUK) k iru rg ia k liin ik u s  v iim a s e l 
aastakümnel.
P atsien d id  ja  m eeto d id
Ajavahemikul 1 .1 .1992-31 .12 .1993 (I periood) 
korraldati TUK kirurgiakliinikus prospektiivne PHV- 
uuring. Uuringusse kaasati kõik PHVga haig laravil 
v iib in u d  212 pa ts ien ti. A rvu ti and m e b a a s is  
fikseeriti nende sugu, vanus, haavandi paiknemine 
ja verejooksu endoskoopiline  tüüp, samuti ka 
p a ts ie n d ile  te o s ta tu d  e n d o s k o o p ilin e  v õ i 
kirurgiline ravi ning lõpe.
A n a lo o g ilis e lt  1 9 9 2 . - 9 3 .  a te h tud  p ro - 
spektiivse  uuringu  p ro to k o ll ig a  te h ti re tro ­
sp e k tiivn e  uuring  a ja va h e m iku l 1 .1 .1 9 9 9  — 
31 .12 .2000  (II periood). Aluseks võeti kõ ig i sel 
a ja l ravil viib inud 177 PHV patsiendi andmed 
endoskoop iakab ine ti uu ringukaartide  a lusel. 
Informatsioon ravi ja selle tulemuste kohta saadi 
haiguslugudest.
Tabel 1. Peptilise haavandi verejooksuga patsientide iseloomustus aastatel 1992-1993(1 periood) |a 1999-2000(11 periood)
1 periood I! periood
Patsiendid (%) Patsiendid (%) P
Patsientide arv 212 177 NS***
mehed 148 (69,8) 135 (76,3) NS
naised 64 (30,2) 42 (23,7)
Keskmine vanus 56 57
mehed 53 54
naised 66 68
> 65aastaseid 71 (33,5) 72 (40,7) NS
mehed 34 (23,0) 46 (34,1) 0,038
naised 37 (57,8) 26 (61.9) NS
Haavandi lokalisatsioon*
DH 113 (53,3) 103 (58,2) NS
MH 97 (45.8) 68 (38,4) NS
JPH 2 (0,9) 6 (3,4) NS
Haavandi lok. mehed
DH 89 (60,1) 86 (63,7) NS
MH 57 (38,5) 44 (32,6) NS
JPH 2(1.4) 5 (3,7) NS
Haavandi lok. naised
DH 24 (37,5) 17 (40,5) 2 NS
MH 40 (62,5) 4(57,1) NS
JPH 0 1 (2,4) NS
Verejooksu tüüp**
Forrest 1 24 (11,7) 30 (16.9) NS
Forrest II 115 (55,8) 97 (54,8) NS
Forrest lill 67 (32,5) 50 (28,2) NS
Informatsioon puudub 6 ( -) 0
* DH - duodenaalhaavand, MH - maohaavand, JPH - jejunum 'i pepliline haavand; 
** Forrest I - haavand jätkuva verejooksuga, Forrest II - haavand hiljutise 
verejooksu tunnustega (veresoone ots, hüüve haavandi põhjas). Forrest III - 
haavand hiljutise verejooksu tunnusteta;
*** NS - erinevus statistiliselt mitteoluline.
Duodeenumi, pülooruse ja prepüloorsed (kuni 
2,5 cm pülooruse rõngast oraalsemale) haavandid 
liig itati pa fogeneetilise mehhanismi sarnasuse 
alusel duodenaalhaavanditeks ning haavandid 
alates 2 ,5  cm pü loo ruses t o ra a lse m a l kuni 
card ia  ni klassifitseeriti m aohaavanditeks (9). 
Eraldi rühma m oodustavad m aoresektsiooni- 
järgsed jejunum \ peptilised haavandid.
Verejooksu endoskoop ilised  tüübid jao ta ti 
Forresti klassifikatsiooni alusel (10): Forrest I -  jät­
kuv verejooks haavandist, Forrest II -  hiljutise 
verejooksu tunnused (nähtav veresoone ots, hüüve 
haavandi põhjas), Forrest III -  haavand hiljutise 
verejooksu tunnusteta.
Endoskoopilise ravina oli mõlemal perioodil 
kasutusel injektsioonteraapia. Esimesel perioodil 
kasutati a in u lt s k le ro te ra a p ia t abso luu tse  
alkoholiga (9 6 °). Teisel perioodil kasutati lisaks
injektsioonteraapiat epinefriin iga (1 : 10 0 0 0 ), 
va ldavalt kombinatsioonis skleroteraapiaga, kuid 
ka iseseisva meetodina.
Kahe perioodi andmed tööde ld i ja võrre ld i 
a rvu tip ro g ra m m i S tatV iew ®  S tudent fo r  the 
Macintosh abil. Absoluutarve võrreldi %2-testi abil. 
Yatesi korrektsiooni kasutati va jadusel %2-testi 
täpsustamiseks. Erinevust peeti statistiliselt oluliseks 
p väärtuse korral alla 0 ,05.
Tu lem u sed
Patsientide struktuuri kajastab tabel 1. PHVga ravile 
sattunutest moodustavad enam kui 2 /3  mehed. 
Meeste ja naiste suhe pole uuritaval ajavahemikul 
oluliselt muutunud (p = 0,154).
Uuritud meeste ja naiste keskmine vanus pole 
7 aasta vä lte l suurenenud. PHVga hosp ita li- 
seeritud naiste keskmine vanus on üle 10 aasta
Tabel 2. Peptilise haavandi verejooksu ravitaktika aastatel 1992-1993(1 periood) ning 1999-2000(11 periood)
1 periood  
ER/Pt* (%)
II periood  
ER /Pt (%)
P
Endoskoopiline ravi
Kõik patsiendid 46/212(21,7) 91/177(51,4) 0,0001
Forrest 1*’ 13/24 (54,2) 25/30 (83,3) 0,042
Forrest II 32/115(27,8) 64/97 (66,0) 0,0001
Forrest III 1/67(1,6) 2/50(4,0) NS***
Kirurgiline ravi 85/212 (40,1) 11/177(6,2) 0,0001
Suremus 14/212 (6,6) 4/177(2,3) 0,042
* ER - endoskoopiliselt ravitud patsientide arv, P t- patsientide üldarv;
** Forrest I - haavand jätkuva verejooksuga, Forrest II - haavand hiljutise 
verejooksu tunnustega (veresoone ots, hüüve haavandi põhjas),
Forrest III - haavand hiljutise verejooksu tunnusteta;
*** NS - erinevus statistiliselt mitteoluline.
suurem kui meestel. 65aastasfe osakaal kõigist PHV- 
patsientidest oli I perioodil 34% ja II perioodil 41 % 
(p = 0,143).
Meestel on ülekaalus verejooks duodenaal- 
haavandist ning naistel maohaavandist. O lulisi 
muutusi veritseva haavandi paiknemises uuritud 
ajavahemikul ei olnud. Verejooksu endoskoopiliste 
tü ü p id e  (Forresti k la s s ifik a ts io o n  a luse l) 
p ro p o r ts io o n is  o lu lis i muutusi ei to im unud  
(p = 0,289).
PHV ra v im e e to d e id  k a ja s ta b  ta b e l 2 . 
O lu lis e lt  enam  kasu ta ti II p e r io o d il e ndos­
ko o p ilise  vere jooksu peetam ise m eetodit PHV 
ravis. Kui 199 2 .-9 3 . a kasutati ERi 22% -l, siis 
1 9 9 9 . - 2 0 0 0 .  a ju b a  51% -l p a ts ie n tid e s t 
(p = 0,0001 ). Verejooksude endoskoopilise ravi 
o sa ka a l kasvas II p e r io o d il m ä rg a ta va lt n ii 
Forresti I kui ka Forresti II tüüpi vere jooksude 
korra l. Forresti I tüüpi verejooksu korral kasutati 
I p e r io o d il ERi 54% -l n ing II p e rio o d il 83%-l 
ju h tu d e s t (p = 0 ,0 4 2 ) ,  F orres ti II tü ü p i 
vere jooksude korra I vastavalt 28%-l ning 66%-l 
juhtudest (p =  0 ,0001  ). ERi kasutamisel tüsistusi 
ei esinenud.
U u ritu d  a ja v a h e m ik u  jo o ksu l vähenes  
m ärk im isväärse lt k iru rg ilise  ravi va jadus. Kui 
1992.-93. a opereeriti 40%  PHV-patsientidest, siis 
1999.-2000. a vaid 6% (p = 0,0001 ). Samal aja­
vahemikul vähenes patsientide suremus 6,6%-lt
2,3%-ni (p = 0,042).
A rutelu
M eie uuringus patsientide vanuselises struktuuris, 
h a a v a n d i pa ikm etes ega  v e re jo o k s u  
e n d o s k o o p ilis te s  tüüp ides (Forrest) uu ritud  
p e r io o d id e l o lu lis i e rinevus i ei o ln u d . See 
võ im aldab meil usaldusväärselt võrre lda kahte 
perioodi ravi taktika ja selle tulemuste osas.
Andm ed nä itavad, et TUK k iru rg iak liin ikus  
kasutati II p e r io o d il ERi p e p tilise  h a a v a n d i 
verejooksu peetamiseks oluliselt sagedamini. Kui 
1992.-93. a teostati seda 22%-! patsientidest, siis 
1999.-2000. a enam kui poolte l ravitutest. ERi 
kasutamise aktiivsus jätkuva verejooksu (Forrest I) 
korral kasvas uuritud ajavahemikul 54%-lt 83%-ni 
ning hiljutise verejooksu tunnuste (Forrest II) korral 
28%-lt 66%-ni.
Uuringud on näidanud, et ilma endoskoopilise 
rav ita  te k ib  lig ik a u d u  p o o lte l p a ts ie n tid e s t 
h a ig la s  v iib im is e  v ä lte l k o rd u s v e re jo o k s . 
Forresti I tüüpi vere jooksuga haigetest jä tkub 
ve re jooks või tekib  ko rdusjooks 88% -l n ing 
Forresti II tüübi korral tekib rets id iiv jooks 43% -l 
juhtudest. Forresti III tüüpi verejooksu korra l on 
see väga harv -  3% (11). Seetõttu tu leb ERi 
kasutada patsientidel, kellel on jätkuv verejooks 
v õ i k o rd u sve re jo o ksu  oh t e n d o s k o o p ilis e l 
u u rin g u l näh ta v  (ve resoone  ots võ i hüüve 
haavandi põhjas). Kui haavandi põhi on puhas, 
s.t puuduvad h ilju tise  ve re jooksu  tunnused, 
peetakse ERi mittenäidustatuks.
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Endoskoopilist injektsioonteraapiat peetakse 
tehn ilise lt suh te lise lt lihtsaks, efektiivseks ja 
ohutuks (12). Kuigi ERi tüsistusena kirjeldatakse ka 
kontrollimatu verejooksu teket ning perforatsiooni, 
esineb neid siiski harva, kuni 0,9%-l (13). M eie 
patsientidel tüsistusi ei esinenud.
PHV-uuringute metaanalüüsile toetudes leidis 
Saeks ka a s tö ö ta ja te g a  1 9 9 0 . aas ta l, et ER 
vähendab oluliselt kordusverejooksude sagedust, 
e ra k o rra lis e  o p e ra ts io o n i v a ja d u s t n ing  
suremust (14). ERi järel tekib kordusjooks kuni 
20%-l PHV-patsientidest (8). Sellisel puhul on 
nä idusta tud ko rduv  ER, m ille  efektiivsus on 
lig ikaudu 75%  (15). K iru rg ilis t ravi peetakse 
näidustatuks vaid juhtudel, kui medikamentoosse 
ravi ja ERiga verejooksu seisata ei õnnestu (16). 
On leitud, et rakendades aktiivselt ERi, va jab  
operatsiooni vaid 5 -6 %  PHV-patsientidest (17). 
Jaapan i kuue keskuse uu rin g u d  on v e e lg i 
paremate tulemustega (12).
M eie uuritud pe riood i vä lte l vähenes TUK 
kirurgiakliinikus PHV ravis k irurg iline aktiivsus 
märkimisväärselt, 40%-lt 6%-ni. Oluliselt vähem oli
vaja teha varajasi plaanilisi operatsioone, mida 
seni oli kasutatud kordusverejooksu suure riskiga 
patsientidel pärast üldseisundi stabiliseerim ist. 
Kuigi varajasi plaanilisi operatsioone soovitatakse 
ka praegu (18), on tänu ERi efektiivsusele nende 
vajadus oluliselt vähenenud. Patsientide suremus 
vähenes ERi sagedam al kasutam isel 6 ,6% -lt 
2,3%-ni. M õned autorid on väitnud, et viimastel 
aastakümnetel pole suremus PHV tõttu vähenenud 
ja see püsib 10% ringis (7). Samas saavutati 
paljudes hästi töötavates keskustes juba 1980ndate 
lõpus suremus alla 5% (19). Kuigi leidub keskusi, 
kus PHV-haigete suremus on 14% (2 0 ), on 
õigustatud seisukoht, et PHV tänapäevane^ravi 
peaks tagama suremuse alla 5% (21 ). Selle üheks 
olulisemaks eelduseks peetakse ERi intensiivsemat 
kasutamist. Seda kinnitavad ka selle töö tulemused.
Jä re ld u s
Endoskoopilise ravi intensiivsema rakendamisega 
on TUK kirurgiakliinikus oluliselt vähenenud peptilise 
haavandi verejooksuga patsientidel kirurgilise ravi 
vajadus ning nende suremus.
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